

AD _____

Award Number: W81XWH-~~€~~ F~~E~~HJJ

TITLE: ~~Ö~~Ö[{]|^@}•~~ä~~^~~Ä~~]|[~~æ~~&~~Ö~~ ~~Ä~~•^ { ~~ä~~ ~~æä~~ } ~~Ä~~ -~~Ö~~~~ä~~^ } &^~~Ö~~~~æ~~^~~ä~~~~Ö~~^~~Ä~~ !~~Ä~~VUÖ

PRINCIPAL INVESTIGATOR: ~~Ö~~~~æ~~^~~Ä~~ @~~Ö~~ ~^

CONTRACTING ORGANIZATION: ~~Ö~~ ^!~~ä~~ ~~ä~~ ~~Ä~~•^ &~~Ö~~~~æ~~ ~~ä~~~~Ä~~ ~ } ~~ä~~~~æä~~ } ~~Ä~~ &~~È~~
~~Ä~~ |~~ä~~ * ~~ä~~ } ~~Ä~~ ~~Ö~~~~Ä~~ ~~Ö~~ ~~Ö~~ ~~Ä~~

REPORT DATE: ~~Ü~~^] ~~ä~~{ ~~ä~~^!~~Ö~~FF

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-09-2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 SEP 2010-31 AUG 2011	
4. TITLE AND SUBTITLE A Comprehensive Approach in Dissemination of Evidence-Based Care for PTSD				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0399	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Farifteh Duffy E-Mail: aporfiri@psych.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) American Psychiatric Foundation, Inc. Arlington, VA 22209				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Abstract on next page.					
15. SUBJECT TERMS Evidence-based care, PTSD, Depressions, Screening and severity monitoring tools, Assessment & treatment recommendations					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 82	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

14. ABSTRACT

The purpose of this study is to pilot test practice improvement approaches for management of PTSD in military behavioral health treatment settings. This project also targets depression and alcohol use problems, which are highly comorbid with PTSD. Key evidence-based assessment and treatment recommendations for the Management of PTSD from the US Departments of Veterans Affairs and Defense (VA/DoD) Clinical Practice Guideline and other major practice guidelines were extracted. The PTSD Checklist-Civilian Version (PCL-C), the 9-item Patient Health Questionnaire (PHQ-9), and AUDIT-C were selected as screening and severity monitoring tools for PTSD, depression, and alcohol use problems, respectively. Performance Improvement in Practice (PIP) tools to inform evidence-based assessment and management for PTSD, depression, substance use problems, and for suicide risk assessment have been published, to provide evidence-based resources to facilitate practice evaluation and identification of potential gaps in care. APIRE staff have met with key clinical staff from select behavioral health MTFs to facilitate management of PTSD, depression, and alcohol use problems in the behavioral health clinics. To achieve this, APIRE has teamed up with the staff of Workflow Division, Office of the Chief Information Officer, Air Force Medical Support Agency, and clinical staff at practice sites to arrive at a practical clinical workflow that is responsive to the needs of the clinicians. The principal charge of the Workflow Division has been to improve AHLTA usability. In APIRE's collaboration with the Workflow Division, AHLTA enhancement also involved integration of PCL-C, PHQ-9 and AUDIT-C into AHLTA to support severity monitoring for PTSD, depression and alcohol use, as a routine part of clinical care.

Table of Contents

	<u>Page</u>
Introduction.....	3
BODY.....	3-5
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusion.....	6
References.....	7-8
Appendices.....	9

A Comprehensive Approach to Disseminate Evidence-Based Care for PTSD

Running Title: PTSD Care Dissemination Project

Introduction

The need for improved treatment of PTSD and depression is underscored by the substantial prevalence of these disorders in the military and general populations. In a recent study of Army soldiers, PTSD rose from 5% before deployment to 13% after deployment to Iraq, and depression increased from 5% to 7%; it is estimated that up to 28% of soldiers returning from Iraq may meet criteria for anxiety or depression (1). A separate study found that 35% of soldiers returning from Iraq receive mental health care in the year following Iraq deployment (2). Despite these data, the RAND Corporation (2008) found that among those returning from Iraq or Afghanistan with PTSD or depression, less than half received any mental health services, and only half of those received minimally adequate care (3). These figures highlight the need for timely and accurate identification, diagnosis, and treatment for affected service members.

In September of 2008, the American Psychiatric Institute for Research and Education (APIRE) received a Department of Defense PTSD Research Program Concept Award to pilot test practice improvement strategies to facilitate evidence-based approaches for the management of PTSD in military behavioral health settings. Because of high rates of comorbidity of PTSD with depression and alcohol use problems, and to parallel current efforts in the Army's RESPECT-MIL program, this project also targets evidence-based care for depression and alcohol use problems. The aims of the PTSD Care Dissemination Project are to:

- 1) systematically identify and disseminate key evidence-based recommendations to support clinical decision-making in the assessment, diagnosis, and treatment of PTSD, depression, and alcohol use problems in military behavioral health settings; 2) select psychometrically-validated and easy-to-use measures for screening and monitoring PTSD, depression, and alcohol use problems; 3) test practice improvement activities to facilitate management of PTSD and depression in military behavioral health settings.

Traditional didactic approaches to continuing education have shown limited success in changing practice (4-5). However, practice collaborative methodology modeled after the Institute for Health Care Improvement (IHI) Breakthrough Series (BTS) allows clinicians to actively plan, test, and implement practice improvements that can significantly improve care delivery efficiency and treatment outcomes (6). The PTSD Care Dissemination Project has adapted the IHI methodology, by specifically promoting Plan-Do-Study-Act (PDSA) approach to testing and implementing improvements for the management of PTSD, depression, and alcohol use in routine clinical practice. Moreover, project participants are provided with Performance in Practice (PIP) tools for the assessment and treatment of PTSD, depression, substance use problems as well as suicide risk assessment as a resource to evaluate their practices' capacity to provide evidence-based care and identify potential gaps in care. Finally, strategies to implement the PCL-C, PHQ-9, and AUDIT-C for routine screening and management of PTSD, depression, and alcohol use problems as a component of clinical workflow are explored.

Body: To meet project objectives, four tasks were outlined in the proposal. Each of the tasks has been described below followed by a brief update on the status of each task.

Task 1: *Extract key recommendations from three major practice guidelines for the treatment of patients with PTSD that are considered professional standards among clinicians; document agreements and discrepancies between the two guidelines; develop quality indicators.*

Status: This task was completed in the first quarter following initiation of the project in 2008. Four major guidelines were reviewed, including the US Departments of Veterans Affairs and Defense (VA/DoD) Clinical Practice Guideline for the Management of PTSD (2004; 7), the American Psychiatric Association practice guideline for the treatment of patients with ASD and PTSD (2004; 8), the National Collaborating Centre for Mental Health PTSD Clinical Guidelines (2005; 9), the APA Guideline Watch (2009; 10), and the Institute of Medicine (IOM) report on Posttraumatic Stress Disorder: Diagnosis and Assessment (2006; 11). Key recommendations for the assessment and treatment of PTSD were extracted and included in a table format (Appendix 1). This table was shared, discussed, and updated based on recommendations from the team of experts assembled under Task 2, and subsequently served as the foundation for developing the Performance in Practice (PIP) tools for PTSD (Appendix 2; 12). The PIP tools for PTSD were published in the Spring 2009 issue of Focus. It is important to note that this publication only includes key recommendations from major guidelines published in the United States in order to complement treatment strategies supported in the US health care systems. The PIP tools for depression were available earlier (Appendix 3; 13), and served as a model for subsequent PTSD PIP tool development. The PIP tools for Alcohol and Substance Use Disorder (SUD) (Appendix 4; 14) and Suicide Risk Assessment (Appendix 5; 15) since been published in the Winter and Spring of 2011, respectively. These PIP tools were specifically targeted given high rates of comorbidity of alcohol and SUD with PTSD and depression, and high risk for suicide among patients suffering from abovementioned disorders.

The PIP tools have multiple applications. First, they provide clinicians with active learning opportunities by translating conceptual information from practice guidelines into practical steps, supporting integration of evidence-based best practices into clinical care. Second, through strategies such as chart reviews and real-time evaluation of new or existing patients, the PIP tools can inform improvement efforts at the clinician-, practice-or systems-level, facilitate detection of potential gaps in evidence-based care, and speed the adoption of evidence-based care into clinical practice. Third, in anticipation of new Maintenance of Certification (MOC) requirements from the American Board of Medical Specialties (ABMS) and the American Board of Psychiatry and Neurology (ABPN) for self-assessment, the PIP tools will provide clinicians with early opportunities for self-assessment and will help prepare them for the coming changes to be implemented in 2014. Fourth, the PIP tools are applicable beyond psychiatry, as they can be used for self-assessment by other provider groups to support improvement activities for care of PTSD, depression, and alcohol use problems, and assessment of suicide risk.

Clinicians in select project MTFs have been provided with PIP tools as a resource to facilitate their evaluation of their practices' capacity to provide evidence-based care and identify potential gaps and targets for quality improvement efforts. Clinicians have been encouraged to employ the Plan-Do-Study-Act approach, promoted by IHI-BTS methodology, to actively plan, test, and implement incremental improvements in their practice. The IHI-BTS methodology has been well studied (6) and previously pilot-tested at APIRE as a part of the National Depression Management Leadership Initiative to enhance depression management in routine psychiatric practices (16).

Task 2: *Convene a team of experts to support following tasks:*

- a. Examine and reconcile discrepant findings from the review in Task 1.*
- b. Identify psychometrically validated and easy-to-use measures for screening, diagnosing, and monitoring PTSD.*
- c. Adapt the Institute for HealthCare Improvement Breakthrough Series (IHI-BTS) model to develop a concentrated CME curriculum for training psychiatrists in evidence-based screening, diagnosing, monitoring and treatment of PTSD, incorporating findings from Tasks 1, 2a and 2b.*

Status: Parts 2a and 2b of this task were completed in the first quarter following initiation of the project in 2008. Experts in the field were identified and invited to join the panel of experts. A series of substantive conference calls preceded a one-day, in-person meeting of the panel, which was convened on November 3, 2008. The panel was charged with completion of Task 2a, to examine and reconcile any discrepancies between major treatment guidelines, and Task 2b, to identify psychometrically validated and easy-to-use measures for screening, diagnosis and monitoring of PTSD. An agenda and list of participants for this meeting are included in Appendix 6.

For Task 2a, the panel reviewed treatment recommendations that had been extracted from the major practice guidelines (Appendix 1). The panel used the 2009 APA Guideline Watch, which was considered to contain the most up-to-date evidence-based recommendations on treatment of PTSD in military populations, to reconcile any potential variations across guidelines.

To complete Task 2b, the panel reviewed Appendix 7 and agreed on the use of the PTSD Checklist-Civilian Version (PCL-C) for screening and monitoring PTSD. Panel also selected the 9-item Patient Health Questionnaire (PHQ-9) for screening and monitoring depression. Since then we have identified AUDIT-C as a suitable screening tool for alcohol use problems. This package of assessment tools are also used in the RESPECT-MIL initiative, thus parallel approaches in measurement-based care will be promoted in both military primary care and behavioral health care settings.

The panel addressed part of Task 2c by providing valuable guidance on potential target settings and participants for this pilot project. They recommended that study efforts should be concentrated in selected DoD military treatment facilities (MTFs) rather than the VA settings. Additionally, the panel encouraged engaging mental health providers from various disciplines rather than psychiatry only.

Finally, the panel strongly encouraged involvement of Dr. Charles Engel, the Principal Investigator for the RESPECT-MIL initiatives, in the PTSD/Depression Care Dissemination Project. We are delighted that Dr. Engel has graciously accepted our invitation and has joined the project as co-investigator.

To date the project research team including Drs. Charles Engel, Henry Chung, David Katzelnick, and Charles Motsinger (as project co-investigators) along with APIRE project staff, have held a number of in-person meetings and conference calls, along with military medical leadership at Psychiatry Clinic at Walter Reed Army Medical Center and the Adult Behavioral Health Clinic at the National Naval Medical Center in order to gain knowledge of behavioral health care and improvement needs in each behavioral health settings. These two sites have since merged into one: the Behavioral Health Center at the Walter Reed National Military Medical Center in Bethesda, MD.

During a full-day in person planning meeting on February 4th, 2011 with clinical leadership at Walter Reed, members of the Workflow Division, and project research team, core principals of chronic disease management, the latest evidence for management of PTSD and other co-occurring conditions (including alcohol and substance use, suicide, and other anxiety and mood disorders), and the IHI Plan-Do-Study-Act approach for implementing quality improvement in clinical setting were reviewed in detail (agenda in Appendix 8). Subsequent to this meeting, plans were made for this project to be implemented as augmentation to current site improvement plans, and in collaboration with the Workflow Division, Office of the Chief Information Officer, Air Force Medical Support Agency. As an approach to system improvement, the Workflow Division routinely conducts clinical workflow analysis and provides system support to improve usability of AHLTA by standardizing documentation of clinical information. The

Workflow Division has an extensive track record in improving quality of documentation via AHLTA by routinizing use of the PHQ-2, PHQ-9 and AUDIT at every visit throughout Air Force primary care clinics. To facilitate integration of evidence-based assessment and management of PTSD, depression, and alcohol use problems, Workflow Division has worked with site clinical leadership at the Walter Reed National Military Medical Center to gain support for the integration of PCL-C, PHQ-9, and AUDIT-C as a routine part of clinical workflow, and upgrading AHLTA to support documentation of these measures during routine clinical visits. An in-person meeting was conducted by the Workflow Division on June 9, 2011 to introduce site clinicians to enhanced AHLTA, to support standardized documentation of PCL-C, PHQ-9 and AUDIT-C. Clinicians were encouraged to share their perspective on how best to improve the system to support their daily clinical needs.

Several presentations of study methods and PIP products have been made in 2010-2011: 1) oral presentation at the American Psychiatric Association Annual Meeting (2011), and 2) oral presentation at the Institute for Psychiatric Services (2011).

Task 3: *Implement a pilot study by recruiting 20 local psychiatrists to attend the CME course (developed in Task 2c); evaluate participants' knowledge concerning PTSD before and after the course.*

Status:

Project is being implemented in the Behavioral Health Center at the Walter Reed National Military Medical Center in Bethesda, MD. All behavioral health clinicians in this site, including psychiatrists, psychologists and social workers are taking part with regard to integration of the PCL-C, PHQ-9 and AUDIT-C as routine component of clinical care. Although a subset of 30 clinicians (10 per disciplines of psychiatry, psychology and social work) will be studied with regard to routine use of these measures.

Task 4: *Conduct a 5-month follow-up study to assess: a) sustainability of the improvement gains achieved following the completion of the course, b) spread within practice to other psychiatric conditions; and c) spread to other clinicians, practices and across specialties (e.g., spread to primary care physicians).*

Status: Practice-based assessment will involve pre- and post- evaluation of health care organization, decision support, clinical information systems, overall patient care, and sustainability with regard to use of PCL-C, PHQ-9 and AUDIT-C as a routine part of clinical care, following implementation of the PTSD Care Dissemination Project, and AHLTA enhancements put into operation by the Workflow Division.

Key Research Accomplishments:

- Extracting key assessment and treatment recommendations for PTSD from four major practice guidelines that are considered professional standards among clinicians (Appendix 1)
- Convening an expert panel meeting to: a) address discrepancies across guidelines (Appendix 1), b) select assessment tools for screening, diagnosis, and severity monitoring for PTSD, depression, and alcohol use problem (i.e., PCL-C, PHQ-9, AUDIT-C), c) inform site selection process (see Task 2)
- Developing PIP tools for PTSD (Appendix 2), based on work accomplished under Task 1 (Appendix 1)
- Subsequently developing PIP tools for alcohol and SUD (Appendix 4), and suicide risk assessments (Appendix 5)
- Forging a productive collaboration with Workflow Division, Office of the Chief Information Officer, Air Force Medical Support Agency to conduct clinical workflow analysis at project sites to arrive at standardized methods in documentation of clinical information and facilitate integration of evidence-

based approaches in the assessment and management of PTSD, depression, and alcohol use in AHLTA.

- Conducting an in-person planning meeting and follow-up site visits with clinical leadership of the Behavioral Health Center at the Walter Reed National Military Medical Center in Bethesda, MD.

Reportable Outcomes

- Published *Performance in Practice: Clinical Tools for the Care of Patients with Posttraumatic Stress Disorder*; Focus; Spring 2009; 7:186-191.
- Published *Performance in Practice Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder*; Winter 2011; 9:31-41.
- Published *Performance in Practice: Clinical Tools for the Care of Patients with Posttraumatic Stress Disorder*; Focus; Spring 2011; 9:171-182.
- Organized a symposium on **Scope, current evidence, and innovative approaches in managing PTSD in the military** and oral presentation at the American Psychiatric Association Annual Meeting (2011)
- Oral presentation at the Institute for Psychiatric Services (2011).

Conclusion

Successful implementation of the PTSD Care Dissemination Project will facilitate integration of psychometrically validated assessment tools, including the PCL-C, PHQ-9, and AUDIT-C as a routine part of clinical care for PTSD, depression, and alcohol use problems. These well-validated tools can support case identification and severity monitoring in order to treat service members to response and remission. To this end, a productive collaboration has been forged with the Workflow Division, Office of the Chief Information Officer, Air Force Medical Support Agency in order to provide system support in AHLTA, to facilitate integration of these tools for routine assessment of patients at every visit at the Behavioral Health Center at the Walter Reed National Military Medical Center. This approach could generate an effective model to support evidence-based approaches in the assessment and management of PTSD, depression and alcohol use problems, creating opportunities for dissemination to other MTFs.

Moreover, the PIP tools for PTSD developed through this grant has the potential to change the way new scientific information is disseminated and adopted in routine practice. Successful implementation of the PIP approach could have immediate impact by lessening existing gaps between evidence-based practice and actual care, and provide preliminary data to inform future development of self-assessment tools for Maintenance of Certification competency requirements, to be launched by 2014. In addition to PTSD, PIP tools for depression, alcohol and SUD, and suicide risk assessment have been published and available as a resource to all clinicians. To this end, this project has the potential to generate workable models for the implementation and dissemination of high impact evidence-based care for PTSD, depression, alcohol use problems and other psychiatric disorders, improving care delivery efficiency and treatment outcomes among suffering service members and their families.

References

1. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL: Combat duty in Iraq and Afghanistan, mental health problems and barriers to care. *N Engl J Med* 2004; 351:13–22
2. [Hoge CW](#), [Auchterlonie JL](#), [Milliken CS](#). Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan [JAMA](#). 2006; 295(9):1023-32
3. Invisible wounds of war: psychological and cognitive injuries, their consequences, and services to assist recovery / Terri Tanielian, Lisa H. Jaycox RAND Center for Military Health Policy Research, Published 2008 by the RAND Corporation
4. Bloom BS: Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. *Int J Technol Assess Health Care*, 2005; 21:380–385.
5. Grimshaw J, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, Vale L: Toward evidence-based quality improvement: evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998. *J Gen Intern Med* 2006; 21(suppl2):S14–S20.
6. Institute for Healthcare Improvement Breakthrough Series College. Boston, Mass, Institute for Healthcare Improvement, 2004
7. Departments of Veterans Affairs and Defense: VA/DoD clinical practice guideline for the management of post-traumatic stress. 2004. http://www.pdhealth.mil/clinicians/vadod_cpg.asp
8. American Psychiatric Association: Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. *Am J Psychiatry* 2004; 161 (11 suppl):1–31.
9. National Collaborating Centre for Mental Health: Post-traumatic stress disorder (PTSD): the management of PTSD in adults and children in primary and secondary care. Clinical Guideline 26. London, National Institute for Clinical Excellence, 2005.
<http://www.nice.org.uk/CG026NICEguideline>
10. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ: Guideline watch (March2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder.
<http://www.psychiatryonline.com/content.aspx?aID=156514>
11. Posttraumatic Stress Disorder: Diagnosis And Assessment Institute of Medicine, National Academies of Sciences, 2006, The National Academies Press 500 Fifth Street, N.W. Washington, DC 20001
12. Duffy F.F.; Craig T.; Moscicki E.K.; West J.C.; Fochtmann L.J.; Performance in Practice: Clinical Tools for the Care of Patients with Posttraumatic Stress disorder; *Focus*; 2009; 7(2):186-191.
13. Fochtmann L.J.; Duffy F.F.; West J.C.; Kunkle R.; Plovnick R.M.; Performance in Practice: Sample Tools for the Care of Patients with Major Depressive Disorder; *Focus*; 2008; 6(1):22-35.
14. Duffy F.F.; West J.C.; Fochtmann L.J.; Willenbring M.L.; Plovnick R.; Kunkle R.; Eld B.; Performance in Practice: Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder; *Focus*; 2011; 9(1):31-41.

15. Duffy F.F.; Moscicki E.K.; Fochtman L.J.; Jacobs D.; Clarke D.E.; Plovnick R.; Kunkle R.; Performance in Practice: Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-Related Behaviors; Focus; 2011; 9(2):171-182.
16. Duffy F.F.; Chung H.; Trivedi M.; Rae D.S., Regier D.A., Katzelnick D.J.; Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? Psychiatric Services; 2008; 59: 1148-1154

Appendix 1
Evidence-Based Guideline Assessment and Treatment Recommendations for PTSD
PTSD/Depression Care Dissemination Project

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
DEFINITION					
<p>Trauma - An extreme traumatic stressor involving direct personal experience...the person's response to the event must involve intense fear, helplessness, horror</p> <p>Acute Stress Reaction (ASR) - ...onset of some signs and symptoms may be simultaneous with the trauma or may follow after an interval of hours or days...symptoms not resolved within 4 days after the event, after ruling out other disorders</p> <p>Acute Stress Disorder (ASD) - clinically significant symptoms >2 days, but <1month after exposure</p> <p>Post Traumatic Stress Disorder (PTSD) - clinically significant symptoms lasting more than 1 month after exposure to a trauma</p> <p>Acute PTSD - clinically significant symptoms lasting >1 month, but <3 months</p> <p>Chronic PTSD - clinically significant symptoms lasting >3 months after exposure to trauma</p> <p>PTSD with delayed onset - clinically significant symptoms at least 6 months after exposure to trauma</p>					
STABILIZATION FOLLOWING AN ACUTE TRAUMA					
In the aftermath of an acute trauma – stabilize patient, provide supportive medical and psychiatric care, and assessment		I			
Assess for availability of basic resources for self care and recovery		I			

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
ASSESSMENT					
<p>After large-scale catastrophes, initial psychiatric assessment includes:</p> <ul style="list-style-type: none"> ✓ differential diagnosis of physical or psychological effects of traumatic event (e.g. anxiety from hemodynamic compromise, hyperventilation, fatigue, etc...) ✓ identification of persons or groups at greatest risk for subsequent psychiatric disorders including ASD or PTSD 		I			
<p>Assess for trauma exposure</p> <ul style="list-style-type: none"> ✓ Recency ✓ Type ✓ Nature ✓ Severity ✓ History 	B	I			
<p>Screen all patients for PTSD (based on DoD/VA guideline recommendations -- suggested initially and then on an annual basis or more if clinically indicated)</p>	B	<p>I</p> <p>Screen for recent or remote trauma exposure</p>	<p>C</p> <p>> For individuals at high risk of developing PTSD (following a major disaster) consideration should be given to the routine use of a brief screening instrument for PTSD at 1 month after the disaster</p>		
<p>Assess for pre-trauma risk factors for ASD/PTSD</p> <ul style="list-style-type: none"> ✓ prior exposure to trauma ✓ adverse childhood ✓ younger age ✓ minority race, ✓ female gender ✓ low socioeconomic or educational status ✓ psychiatric disorders or personality dimensions ✓ cognitive factors 	B	I			

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
Assess for peri-trauma risk factors for ASD/PTSD: ✓ severity of trauma ✓ peri-traumatic dissociation ✓ youth at time of exposure	B				
Assess for post-trauma risk factors for ASD/PTSD ✓ resource loss ✓ lack of social support ✓ ongoing life stressors, bereavement , psychosocial difficulties	B	I			
Assess for ASR, ASD at the time of trauma -- known risk factor for developing PTSD	B	I			
Assess for co-occurring physical or psychiatric disorders (depression, alcohol, other substance, or other anxiety disorders commonly co-occur with PTSD)	B	I			
Assess risk for suicide or harm to others	B	I			
Provide functional Assessment ✓ Global Functional Assessment using GAF or SF-36 ✓ Narrative Functional Assessment to include work/school, relationships, housing, legal, financial, unit/community involvement, and recreation	Insufficient Evidence	I			
Operational Risk: Because re-exposure to trauma exacerbate or trigger PTSD symptoms special consideration must be given when including patients with a history of PTSD symptoms in mission critical operations ✓ Danger to self or others ✓ Risk for family ✓ Ongoing health risk behavior ✓ Medical/psychiatric comorbidities or unstable medical conditions	B				
Additional useful information as a part of assessment include: time of onset, frequency, course, severity, level of distress, and time elapsed since exposure	Rating not available				

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
PSYCHIATRIC MANAGEMENT			C > Chronic disease management models should be considered for the mngmnt of pts w/ chronic PTSD who have not benefited from a number of courses of evidence-based treatment		> A study of collaborative care suggests that care-management in combination with evidence-based psychotherapy and medication Tx may diminish PTSD symptoms in acutely injured trauma survivors
Monitor patients with ASD for development of PTSD	A				
Evaluation and management of physical and psychological health and functional impairment		I			
Availability of resources for self-care and recovery		I			
Coordination of care		I			
Enhance treatment adherence		I			
Providing education regarding ASD/PTSD		I			
TREATMENT -PHARMACOTHERAPY				> Committee found the evidence for all classes of drugs reviewed (i.e. α-	> Emerging evidence for adjunct psychotherapy and d-cycloserine > Prazosin may be more effective than other medications indicated for PTSD (e.g. SSRIs)
Pharmacotherapy may be the first-line intervention for acutely traumatized patients		II	A > Drug tx for PTSD <u>should not be</u> used as a routine first-line treatment for adults (in general use or by mental health specialist) in preference to a trauma-focused psychological therapy		

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
Propranolol may be considered for treatment of immediate post-event stress	B				
Pharmacotherapy for treatment of ASD – Imipramine for hyperarousal/excessive arousal/panic attacks	B				
Other pharmacotherapy for treatment of ASD <ul style="list-style-type: none"> ✓ Benzodiazepines for sleep disturbance/insomnia/hyperarousal/excessive arousal/panic attacks ✓ Chloral hydrate for sleep disturbance/insomnia ✓ Propranolol for hyperarousal/excessive arousal/panic attacks 	C	III			
SSRIs as first line for the treatment of PTSD	A	I	B > Drug tx (paroxetine or mirtazapine for general use, and amitriptyline or phenelzine for initiation by mental health specialists only) should be considered for the treatment of PTSD in adults who expresses a preference <u>not to engage</u> in a trauma-focused psychological tx	> Weight of the scientific evidence is insufficient to determine the efficacy of SSRIs	> Evidence for superiority of SSRIs and SNRIs over placebo for <u>non-combat-related</u> PTSD > SSRIs may no longer be recommended with the same level of confidence for veterans with <u>combat-related PTSD</u> as for patients with non-combat-related PTSD
Second line treatment for PTSD include TCAs and MAOIs	B	II			
Consider a second generation antidepressants (e.g. nefazodone, trazodone, venlafaxine, mirtazapine, bupropion, etc.) for management of PTSD	C	III			
Consider antidepressant trial of 12 weeks before changing therapeutic regimen	B				
Augment management of nightmares and other symptoms of PTSD with prazosin	C			> Potential efficacy for combat-related nightmares and sleep disturbance in veterans	
Consider maintenance treatment, reassess periodically	C				

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
Insufficient evidence in use of following class of drugs for the treatment of PTSD: <ul style="list-style-type: none"> ✓ Mood stabilizers ✓ Atypical antipsychotics ✓ Pharmacotherapy prophylaxis of PTSD 	Insufficient evidence	III		> Potential efficacy for the adjunctive use of risperidone in pts inadequately responsive to other therapy	> Data are encouraging for adjunctive treatment with a 2 nd generation antipsychotic in patients with partial response to an SSRI or SNRI, including for co-occurring psychotic symptoms
Recommend against: <ul style="list-style-type: none"> ✓ Long term use of benzodiazepines to manage core symptoms of PTSD ✓ Use of Benzodiazapine as monotherapy ✓ Typical antipsychotics in the management of PTSD 	Insufficient evidence	III	C > Hypnotic medication for short-term use for sleep disturbance	> Evidence is inadequate to determine the efficacy of benzodiazepines in the tx of PTSD	
TREATMENT -PSYCHOTHERAPY				4 basic compnts of CBT: > Psychoedu. > exposure > cognitive restruct > anxiety mgmnt training	> Support for exposure-based CBTs such as CPT and prolonged exposure therapy when delivered in individual formats
Brief intervention of CBT (4 to 5 sessions) for ASD	A	II			
Cognitive Therapy (CT) is effective with civilian men and women exposed to combat and non-combat trauma	A	II	A > Trauma-focused CBT or EMDR on an individual outpatient basis B > Recommend 8-12 sessions for 90 min		
CT is effective with military and veteran with combat- and non-combat-related PTSD	Insufficient evidence				
CT is effective for women with PTSD associated with sexual assault	A				
Eye Movement Desensitization and Reprocessing (EMDR) is more efficacious for PTSD than control: wait-line, routine care, and active treatment controls	A	II		> Evidence is inadequate to determine the efficacy of EMDR in the tx of PTSD	
EMDR compared to ET and CT show mixed results	B				

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡	NICE 2005§	IOM 2006	APA Guideline Watch
	Final Grade A – D, I	Level of Clinical Confidence I – III	Grade A – C	Recommendation	
Exposure Therapy (ET) is effective in the treatment of PTSD	A	II		> Evidence is sufficient to conclude the efficacy of exposure therapies in the tx of PTSD	
Stress Inoculation Training (SIT) is effective as a treatment for PTSD related to sexual assault	A	II			
Imagery Rehearsal Therapy (IRT) considered for treatment of PTSD (nightmares and sleep disruption in particular)	B	II			
Psychodynamic psychotherapy for the treatment of patient with PTSD/complex PTSD	B	II			
Consider group therapy (not favoring any particular type)	B	III			
Consider Dialectical behavior Therapy for patients with a borderline personality disorder typified by parasuicidal behaviors	B				
Hypnosis may be used to alleviate PTSD symptoms	B	Insufficient evidence			
Psychoeducation	B-C	II			
Case management		II			
Supportive psychotherapy		II			
Psychological debriefing is ineffective and has adverse long term effects	D Ineffective, or may be harmful	Not recommended	A > Debriefing should not be routine practice		

† DoD/VA Quality Rating

Final Grade of Recommendation

- A** A strong recommendation that the intervention is always indicated and acceptable
- B** A recommendation that the intervention may be useful/effective
- C** A recommendation that the intervention may be considered
- D** A recommendation that a procedure may be considered not useful/effective, or may be harmful.
- I** **Insufficient evidence** to recommend for or against – the clinician will use clinical judgment

‡ APA Clinical Confidence Rating

- I** Recommended with substantial clinical confidence.
- II** Recommended with moderate clinical confidence.
- III** May be recommended on the basis of individual circumstances.

§ National Institute for Clinical Excellence Grading Scheme for Levels of Evidence

- A** Evidence obtained from a single randomized controlled trial or a meta-analysis of randomized controlled trials
- B** Evidence obtained from at least one well-designed controlled study without randomization; evidence obtained from at least one other well-designed quasi-experimental study; evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies
- C** Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities

Farifteh F. Duffy, Ph.D.
 Thomas Craig, M.D.
 Eve K. Moscicki, Sc.D., M.P.H.
 Joyce C. West, Ph.D., M.P.P.
 Laura J. Fochtmann, M.D.

Performance in Practice: Clinical Tools to Improve the Care of Patients with Posttraumatic Stress Disorder

Abstract: To facilitate continued clinical competence, the American Board of Medical Specialties and the American Board of Psychiatry and Neurology are implementing multifaceted Maintenance of Certification programs, which include requirements for self-assessments of practice. Because psychiatrists may want to gain experience with self-assessment, two sample performance-in-practice tools are presented that are based on recommendations of the American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder and the US Departments of Veterans Affairs and Defense (VA/DoD) Clinical Practice Guideline for the Management of Post-Traumatic Stress. One of these sample tools provides a traditional chart review approach to assessing care (Appendix A); the other sample tool presents an approach that permits a real-time evaluation of practice (Appendix B). Both tools focus on treatment of posttraumatic stress disorder (PTSD) among adults age 18 or older, and both can be used as a foundation for subsequent performance improvement initiatives with the aim of enhancing outcomes for patients with PTSD.

In current practice, psychiatrists, like other medical professionals, are expected to maintain their specialty expertise in the face of an ever-expanding evidence base. Because a number of studies have demonstrated a gap between recommended evidence-based best practices and actual clinical practice, a variety of strategies have been developed with the aim of improving the quality of clinical care (1–10). Proactive approaches to improving quality of care such as the use of clinical reminders (11–19) and audit and feedback of practice patterns to prac-

tioners (12–14, 19–22) have resulted in some degree of care enhancement in contrast to the limited success in changing clinician behavior via traditional didactic approaches to education (e.g., CME conferences) (11–15, 23–26). It is also likely that a combination of quality improvement strategies will be essential in promoting substantial improvements in patient care and outcomes (13, 20, 21, 26–30).

As part of this effort to bridge the quality gap between evidence-based practices and actual clinical practice, the American Board of Medical Specialties and the American Board of Psychiatry and Neurology are implementing multifaceted Maintenance of Certification (MOC) programs that include requirements for self-assessments of practice through reviewing the care of at least five patients (31). As with the original impetus to create specialty board certification, the MOC programs are intended to enhance quality of patient care in addition to assessing and verifying the competence of medical practitioners over time (32, 33). Although

CME Disclosure

Farifteh F. Duffy, Ph.D., Eve K. Moscicki, Sc.D., M.P.P., and Joyce C. West, American Psychiatric Institute for Research and Education, Arlington, Virginia; Thomas Craig, M.D., Springfield, Virginia; and Laura J. Fochtmann, M.D., Department of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, New York.

All authors report no competing interests.

Address correspondence to Farifteh Duffy, Ph.D., American Psychiatric Institute for Research and Education, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209; e-mail: fduffy@psych.org.

the MOC phase-in schedule will not require completion of a Performance in Practice (PIP) unit until 2014 (31), individual psychiatrists may wish to begin assessing their own practice patterns before that time. To facilitate such self-assessment related to the treatment of posttraumatic stress disorder (PTSD), this article will provide sample PIP tools that are based on recommendations of two major guidelines published in the United States: APA's Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder (PTSD) (34) and the U.S. Department of Veterans Affairs and Defense (VA/DoD) Clinical Practice Guideline for the Management of Post-Traumatic Stress (35), supplemented by the latest evidence in the most recent APA Guideline Watch (36). Other noteworthy practice guidelines for the treatment of PTSD include the Australian guidelines for the treatment of adults with acute stress disorder and PTSD (37) and the National Institute for Clinical Excellence management of PTSD in primary and secondary care (38).

The PIP tools described here have been developed to specifically address care of PTSD among adults age 18 years and older; screening, diagnosis, and treatment of PTSD among patients younger than 18 years of age is beyond the scope of this article. A similar set of self-assessment tools for the treatment of depression among adults was published earlier (39), guided by recommendations from the APA Practice Guideline for the Treatment of Patients with Major Depressive Disorder (40).

Evidence-based practice guidelines and quality indicators (41, 42) provide an important foundation for assessing quality of treatment. For a number of reasons, however, the realities of routine clinical practice may temper the development and assessment of a clinically appropriate treatment plan for a specific patient. First, as described previously (39), evidence-based practice guidelines and quality indicators are often derived from data based on randomized controlled trials (RCTs). Because patients in efficacy trials and even those in effectiveness trials must meet stringent enrollment criteria, they often differ in important ways from patients seen in routine clinical practice (43). For example, patients in RCTs are less likely to be suicidal, have co-occurring psychiatric and medical conditions that may interfere with treatment, or be as severely ill as patients in routine clinical practice. Such differences may need to be taken into account when a physician is formulating the best treatment plan for an individual patient.

In addition, when quality indicators are used to compare individual physicians' practice patterns, differences in patient characteristics and illness se-

verity between practices may lead to false conclusions about differences in quality of care. In such circumstances, case mix adjustment is important to address confounding and permit accurate comparison of quality indicator results (44, 45). Also, inadequate attention to factors such as case mix adjustments may lead to unintended consequences such as excluding more severely ill or less adherent patients from practices in an attempt to improve performance on specific quality indicators. Finally, for patients who have complex conditions or are receiving simultaneous treatments for multiple disorders, composite measures of overall treatment quality may yield more accurate appraisals than measurement of single quality indicators (46–48).

Although the above caveats need to be taken into consideration, use of retrospective quality indicators can be beneficial for individual physicians who wish to assess their own patterns of practice. If a physician's self-assessment identifies aspects of care that frequently differ from key quality indicators, further examination of practice patterns would be helpful. Through such self-assessment, the physician may determine that deviations from the quality indicators are justified, or he or she may acquire new knowledge and modify his or her practice to improve quality. It is this sort of self-assessment and performance improvement efforts that the MOC PIP program is designed to foster.

INDICATORS FOR THE EVIDENCE-BASED RECOGNITION AND TREATMENT OF PTSD

The evidence underlying the development of indicators for quality assessment/improvement is generally derived from three sources: 1) experimental studies (e.g., RCTs); 2) epidemiologic or observational studies; and 3) expert consensus. For ASD and PTSD, recent clinical practice guidelines have examined these sources of evidence and have been published in the United States by APA (APA Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder) (34) and the VA/DoD (Clinical Practice Guideline for the Management of Post-Traumatic Stress) (35). The clinical indicators in Appendixes A and B are largely derived from these guidelines supplemented with information from a recent Guideline Watch that updates APA practice guidelines (36) and focuses on recent evidence for pharmacological and psychotherapeutic treatment for PTSD. Appendix C highlights key assessment and treatment recommendations derived from the aforementioned guidelines (34–36).

INDICATORS FOR SCREENING, ASSESSMENT, AND EVALUATION OF PTSD

The need for screening and diagnosis of PTSD in psychiatric practice is underscored by the substantial prevalence of PTSD in both the general population and in high-risk populations, especially after exposure to specific traumatic events. For example, recent epidemiologic studies using DSM-III-R and DSM-IV criteria have found the lifetime prevalence of PTSD to range from 6.4% to 9.2% (49–51). In addition, women generally have a higher risk of PTSD than men, controlling for type of trauma (51). These findings support the importance of quality indicators focused on screening for PTSD in the general population using structured instruments such as the PTSD Checklist-Civilian Version (PCL-C) (52). In recent studies of military service members deployed to Iraq and Afghanistan, PTSD prevalence rates of 5.0%–19.9% have been found, varying based on strict or broad definition of PTSD using the PCL, deployment location, and pre-post deployment status (53). In addition, several reports have suggested that routine screening for PTSD can identify subsyndromal PTSD with significant disability at least as frequently as PTSD that meets the full diagnostic criteria (48, 54, 55).

In addition to routine screening for PTSD in general civilian and military populations, evidence has suggested the need for intensive screening and diagnostic efforts intended for populations with a history of exposure to trauma. For example, elevated rates of lifetime and current prevalence of PTSD have been reported for populations exposed to terrorist attacks [e.g., 12.6% PTSD prevalence among residents of lower Manhattan after the 9/11 attacks (56) and 31% PTSD prevalence among survivors of the Oklahoma City bombing 1 year later (57)], natural disasters such as hurricanes [22.5% PTSD prevalence after Hurricane Katrina (58)] and earthquakes [24.2% PTSD prevalence 9 months after an earthquake in China (59)], and medically traumatic events such as burns [28.6% PTSD prevalence at 1 year (60)], cancer surgery [11.2%–16.3% 6-month PTSD prevalence after surgery (61)], acute coronary syndrome [12.2% PTSD prevalence at 1 year (62)], and hospitalization for traumatic injury [20.7% PTSD prevalence at 1 year (63)]. An additional consideration is the need for longitudinal screening of trauma survivors because the onset of PTSD symptoms may be delayed for 6 months or more in a substantial number of individuals. More specifically, a systematic review found that “studies consistently showed that delayed-onset PTSD in the absence of any prior

symptoms was rare, whereas delayed onsets that represented exacerbations or reactivations of prior symptoms on average accounted for 38.2% and 15.3%, respectively, of military and civilian cases of PTSD” (64).

Finally, ongoing screening is essential in identifying PTSD in patients being evaluated or seeking treatment for other psychiatric conditions such as psychosis (65–67). Also, a substantial proportion of patients with mood and other anxiety disorders also have PTSD. For example, it has been estimated that 7%–40% of patients with bipolar disorder also meet the criteria for PTSD (68). In addition, the National Comorbidity Survey found the rate of affective disorders to be 4 times higher among respondents with PTSD than among those without PTSD (e.g., 47.9%–48.5% for major depressive episode in subjects with PTSD versus 11.7%–18.8% for those without PTSD) (49). Similarly, rates of anxiety disorders other than PTSD were twice as high or more among those with PTSD (e.g., 7.3%–31.4% for a variety of specific anxiety disorders) than among those without PTSD (e.g., 1.9%–14.5% for the same range of disorders) (68). Finally the same study reported alcohol abuse/dependence to be up to twice as high among those with PTSD (e.g., 51.9% for men and 27.9% for women) compared to individuals without PTSD (e.g., 34.4% for men and 13.5% for women) (49).

TREATMENT INDICATORS

Indicators for assessing the quality of treatment should ideally be derived from experimental treatment trials, preferably RCTs. However, in the absence of such trials, clinicians must rely on clinical experience augmented by data from observational and retrospective studies and expert consensus. Evidence-based practice guidelines provide clinicians with a valuable clinical resource by compiling and processing the most recent scientific knowledge and expert consensus for the treatment and management of selected disorders. Well-established practice guidelines such as those developed by APA and the VA/DoD, that have been referenced here, use a rigorous standardized process for searching the literature, data extraction, and synthesis (35, 69). For ease of use, recommendations are then graded based on the level of supporting evidence. For example, Appendix C includes the level of clinical confidence/grade for each of the recommendations based on the VA/DoD and APA practice guidelines, and the definition associated with each level/grade.

PHARMACOTHERAPY

The APA and VA/DoD guidelines uniformly recommend the initiation of serotonin-specific reuptake inhibitor antidepressants (SSRIs) as first-line treatment for PTSD (34, 35). However, the recent Guideline Watch (36) and Institute of Medicine report (70), although still supporting use of SSRIs for PTSD among civilians, have found less RCT evidence to support these medications for the treatment of combat-related trauma. There is also less RCT evidence supporting the use of other antidepressants (tricyclic antidepressants, monoamine oxidase inhibitors, and non-SSRI second-generation antidepressants) (36). Expert consensus plus observational studies suggest consideration of an antidepressant trial of at least 12 weeks at adequate doses before the therapeutic regimen is changed and consideration of long-term antidepressant maintenance treatment as clinically indicated. In terms of other potential treatment strategies, there is growing evidence to support the use of prazosin specifically for treatment of PTSD-associated nightmares (71). In addition, recent data suggest that adjunctive treatment with a second-generation antipsychotic agent may be helpful in patients with a partial response to an SSRI or other second-generation antidepressant. However, first-generation antipsychotics should not be used in the management of PTSD. Current evidence also recommends against long-term use of benzodiazepines to manage core PTSD symptoms or as monotherapy, especially given the potential for misuse/abuse and the lack of strong evidence of efficacy. There is, as yet, insufficient evidence to recommend the use of anticonvulsants or primary pharmacotherapeutic prophylaxis of PTSD.

PSYCHOTHERAPY

There is strong RCT evidence supporting the use of exposure-based therapies including exposure-based cognitive behavioral therapy, cognitive processing therapy, prolonged exposure therapy, and brief exposure therapy for civilians with PTSD exposed to trauma (both civilian and wartime) and for women with PTSD associated with sexual assault (34–36). Current recommendations suggest use of trauma-focused cognitive behavior therapy as a first-line treatment for PTSD (36), which is typically delivered on an individual basis for 8–12 sessions of 90 minutes each (38). Exposure-based therapies, however, are not indicated and should be used with caution for “patients living in dangerous situations (e.g., domestic violence) or for patients with current suicidal ideation, substance abuse not

in stable remission, comorbid psychosis, or health problems that preclude exposure to intense physiological arousal” (35).

RCT evidence has suggested that eye movement desensitization and reprocessing treatment may be efficacious for PTSD (36). There is also some RCT evidence supporting the use of stress inoculation therapy for PTSD related to sexual assault (36). Imagery Rehearsal Therapy may be considered for treating nightmares and sleep disruption associated with PTSD. There is strong evidence against the use of psychological debriefing as it may have long-term adverse consequences and has not shown any apparent benefit.

ACKNOWLEDGMENT

This work was funded in part by the Department of Defense Concept Award Grant #W81XWH-08-1-0399 and the American Psychiatric Foundation Barriers to Care Grant.

DISCLOSURE OF OFF-LABEL USE OF MEDICATION

Medications discussed in this manuscript derived from the APA and the VA/DoD practice guidelines may not have an indication from the U.S. Food and Drug Administration (FDA) for the treatment of PTSD. To date sertraline and paroxetine are the only medications approved by the FDA to treat PTSD. Decisions about off-label use should be guided by the evidence provided in the APA or the VA/DoD practice guidelines, other scientific literature, and clinical experience. Medications which have not received FDA approval for any indication are not included in this manuscript.

REFERENCES

1. Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC, National Academy Press, 2001
2. Institute of Medicine: Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC, National Academies Press, 2006
3. Colenda CC, Wagenaar DB, Mickus M, Marcus SC, Tanielian T, Pincus HA: Comparing clinical practice with guideline recommendations for the treatment of depression in geriatric patients: findings from the APA practice research network. *Am J Geriatr Psychiatry* 2003; 11:448–457
4. West JC, Duffy FF, Wilk JE, Rae DS, Narrow WE, Pincus HA, Regier DA: Patterns and quality of treatment for patients with major depressive disorder in routine psychiatric practice. *Focus* 2005; 3:43–50
5. Wilk JE, West JC, Narrow WE, Marcus S, Rubio-Stipec M, Rae DS, Pincus HA, Regier DA: Comorbidity patterns in routine psychiatric practice: is there evidence of under-detection and under-diagnosis? *Compr Psychiatry* 2006; 47:258–264
6. Pincus HA, Page AE, Druss B, Appelbaum PS, Gottlieb G, England MJ: Can psychiatry cross the quality chasm? Improving the quality of health care for mental and substance use conditions. *Am J Psychiatry* 2007; 164: 712–719
7. Rost K, Dickinson LM, Fortney J, Westfall J, Hermann RC: Clinical improvement associated with conformance to HEDIS-based depression care. *Ment Health Serv Res* 2005; 7:103–112
8. Cochrane LJ, Olson CA, Murray S, Dupuis M, Tooman T, Hayes S: Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. *J Contin Educ Health Prof* 2007; 27:94–102
9. Chen RS, Rosenheck R: Using a computerized patient database to evaluate guideline adherence and measure patterns of care for major depression. *J Behav Health Serv Res* 2001; 28:466–474
10. Cabana MD, Rushton JL, Rush AJ: Implementing practice guidelines for depression: applying a new framework to an old problem. *Gen Hosp Psychiatry* 2002; 24:35–42
11. Davis D: Does CME work? An analysis of the effect of educational activities on physician performance or health care outcomes. *Int J Psychiatry Med* 1998; 28:21–39

12. Bloom BS: Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. *Int J Technol Assess Health Care* 2005; 21:380-385
13. Chaillet N, Dubé E, Dugas M, Audibert F, Tourigny C, Fraser WD, Dumont A: Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. *Obstet Gynecol* 2006; 108:1234-1245
14. Grimshaw J, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, Vale L: Toward evidence-based quality improvement: evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966-1998. *J Gen Intern Med* 2006; 21(suppl 2): S14-S20
15. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, Harvey E, Oxman A, O'Brien MA: Changing provider behavior: an overview of systematic reviews of interventions. *Med Care* 2001; 39(8 suppl 2):II2-II45
16. Balas EA, Weingarten S, Garb CT, Blumenthal D, Boren SA, Brown GD: Improving preventive care by prompting physicians. *Arch Intern Med* 2000; 160:301-308
17. Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, Magid DJ, Simon SR, Soumerai SB: Improved therapeutic monitoring with several interventions: a randomized trial. *Arch Intern Med* 2006; 166:1848-1854
18. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ: Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med* 2005; 352:969-977
19. Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A, Jr, Ofman JJ: Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. *BMJ* 2002; 325:925
20. Arnold SR, Straus SE: Interventions to improve antibiotic prescribing practices in ambulatory care. *Cochrane Database Syst Rev* 2005; 4:CD003539
21. Bradley EH, Holmboe ES, Mattern JA, Roumanis SA, Radford MJ, Krumholz HM: Data feedback efforts in quality improvement: lessons learned from US hospitals. *Qual Saf Health Care* 2004; 13:26-31
22. Paukert JL, Chumley-Jones HS, Littlefield JH: Do peer chart audits improve residents' performance in providing preventive care? *Acad Med* 2003; 78(10 suppl):S39-S41
23. Sohn W, Ismail AI, Tellez M: Efficacy of educational interventions targeting primary care providers' behaviors: an overview of published systematic reviews. *J Public Health Dent* 2004; 64:164-172
24. Grol R: Changing physicians' competence and performance: finding the balance between the individual and the organization. *J Contin Educ Health Prof* 2002; 22:244-251
25. Oxman TE: Effective educational techniques for primary care providers: application to the management of psychiatric disorders. *Int J Psychiatry Med* 1998; 28:3-9
26. Green LA, Wyszevski L, Lowery JC, Kowalski CP, Krein SL: An observational study of the effectiveness of practice guideline implementation strategies examined according to physicians' cognitive styles. *Implement Sci* 2007; 2:41
27. Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, Wallston KA, Dittus RS, Alvarez V, Cobb J, Speroff T: Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. *Ann Intern Med* 2006; 145:165-175
28. Hysong SJ, Best RG, Pugh JA: Clinical practice guideline implementation strategy patterns in Veterans Affairs primary care clinics. *Health Serv Res* 2007; 42:84-103
29. Dykes PC, Acevedo K, Boldrighini J, Boucher C, Frumento K, Gray P, Hall D, Smith L, Swallow A, Yarkoni A, Bakken S: Clinical practice guideline adherence before and after implementation of the HEARTFELT (HEART Failure Effectiveness & Leadership Team) intervention. *J Cardiovasc Nurs* 2005; 20:306-314
30. Greene RA, Beckman H, Chamberlain J, Partridge G, Miller M, Burden D, Kerr J: Increasing adherence to a community-based guideline for acute sinusitis through education, physician profiling, and financial incentives. *Am J Manag Care* 2004; 10:670-678
31. American Board of Psychiatry and Neurology: Maintenance of certification for psychiatry. 2007. http://www.abpn.com/moc_psychiatry.htm
32. Institute of Medicine: Health Professions Education: a Bridge to Quality. Washington, DC, National Academies Press, 2003
33. Miller SH: American Board of Medical Specialties and repositioning for excellence in lifelong learning: maintenance of certification. *J Contin Educ Health Prof* 2005; 25:151-156
34. American Psychiatric Association: Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. *Am J Psychiatry* 2004; 161(11 suppl):1-31
35. Departments of Veterans Affairs and Defense: VA/DoD clinical practice guideline for the management of post-traumatic stress. 2004. http://www.pdhealth.mil/clinicians/va-dod_cpg.asp
36. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ: Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <http://www.psychiatryonline.com/content.aspx?aID=156514>
37. Forbes D, Creamer M, Phelps A, Bryant R, McFarlane A, Devilly GJ, Matthews L, Raphael B, Doran C, Merlino T, Newton S: Australian guidelines for the treatment of adults with acute stress disorder and post-traumatic stress disorder. *Aust N Z J Psychiatry*. 2007; 41:637-648
38. National Collaborating Centre for Mental Health: Post-traumatic stress disorder (PTSD): the management of PTSD in adults and children in primary and secondary care. Clinical Guideline 26. London, National Institute for Clinical Excellence, 2005. <http://www.nice.org.uk/CG026NICEguideline>
39. Fochtmann LJ, Duffy FF, West JC, Kunkle R, Plovnick RM: Performance in practice: sample tools for the care of patients with major depressive disorder. *Focus* 2008; 6:22-35
40. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). *Am J Psychiatry* 2000; 157(4 suppl):1-45
41. Eddy D: Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis. *Health Aff (Millwood)* 2007; 26:w500-w515
42. Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ: Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for non-adherence. *J Clin Psychiatry* 2002; 63:727-732
43. Zarin DA, Young JL, West JC: Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. *Soc Psychiatry Psychiatr Epidemiol* 2005; 40:27-35
44. Hofer TP, Hayward RA, Greenfield S, Wagner EH, Kaplan SH, Manning WG: The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. *JAMA* 1999; 281: 2098-2105
45. Greenfield S, Kaplan SH, Kahn R, Ninomiya J, Griffith JL: Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. *Ann Intern Med* 2002; 136:111-121
46. Parkerton PH, Smith DG, Belin TR, Feldbau GA: Physician performance assessment: nonequivalence of primary care measures. *Med Care* 2003; 41:1034-1047
47. Lipner RS, Weng W, Arnold GK, Duffy FD, Lynn LA, Holmboe ES: A three-part model for measuring diabetes care in physician practice. *Acad Med* 2007; 82(10 suppl):S48-S52
48. Nietert PJ, Wessell AM, Jenkins RG, Feifer C, Nemeth LS, Ornstein SM: Using a summary measure for multiple quality indicators in primary care: the Summary QQuality InDex (SQUID). *Implement Sci* 2007; 2:11
49. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* 1995; 52:1048-1060
50. Elhai JD, Grubaugh AL, Kashdan TB, Frueh BC: Empirical examination of a proposed refinement to DSM-IV posttraumatic stress disorder symptom criteria using the National Comorbidity Survey Replication data. *J Clin Psychiatry* 2008; 69:597-602
51. Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis G, Andreski P: Trauma and posttraumatic stress disorder in the community: the 1996 Detroit area survey of trauma. *Arch Gen Psychiatry* 1998; 55:626-632
52. Norris FH, Hamblen JL: Standardized self-assessment measures of civilian trauma and PTSD, Assessing Psychological Trauma and PTSD: A Practitioner's Handbook, 2nd ed. Edited by Wilson J, Keane T. New York, Guilford, 2003. http://www.ncptsd.va.gov/ncmain/ncdocs/assmnts/ptsd_checklist_pcl.html
53. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL: Combat duty in Iraq and Afghanistan, mental health problems and barriers to care. *N Engl J Med* 2004; 351:13-22
54. Schnyder U, Moergeli H, Klaghofer R, Buddeberg C: Incidence and prediction of posttraumatic stress disorder symptoms in severely injured accident victims. *Am J Psychiatry* 2001; 158:594-599
55. Silva RR, Alpert M, Munoz DM, Singh S, Matzner F, Dummit S: Stress and vulnerability to posttraumatic stress disorder in children and adolescents. *Am J Psychiatry* 2000; 157:1229-1235
56. DiGrande L, Perrin MA, Thorpe LE, Thalji L, Murphy J, Wu D, Farfel M, Brackbill RM: Posttraumatic stress symptoms, PTSD, and risk factors among lower Manhattan residents after the Sept 11, 2001 terrorist attacks. *J Trauma Stress* 2008; 21:264-273
57. North CS, Pfefferbaum B, Tivis L, Kawasaki A, Reddy C, Spitznagel EL: The course of posttraumatic stress disorder in a follow-up study of survivors of the Oklahoma City bombing. *Ann Clin Psychiatry* 2004; 16:209-215

APPENDICES A AND B: PERFORMANCE IN PRACTICE SAMPLE TOOLS

Appendices A and B provide sample PIP tools, each of which is designed to be relevant across clinical settings (e.g., inpatient, outpatient), straightforward to complete, and usable in a pen-and-paper format to aid adoption. Although the MOC program requires review of at least 5 patients as part of each PIP unit, it is important to note that larger samples will provide more accurate estimates of quality within a practice.

Appendix A provides a retrospective chart review PIP tool that assesses the care given to patients with PTSD. Although Appendix A is designed as a self-assessment tool, these forms could also be used for retrospective peer-review initiatives. As with other retrospective chart review tools, some questions on the form relate to the initial assessment and treatment of the patients whereas others relate to subsequent care. In general, treatment options for newly diagnosed patients who are being treated for the first time should judiciously follow the first-line evidence-based treatment recommendations. On occasion, however, there may be appropriate clinical reasons for deviation from recommended care including: patient's prior response or reaction to a similar class of pharmacologic agents, differential diagnoses, psychiatric or medical co-occurring conditions, and patient preferences.

Appendix B provides a prospective review form. It is intended to provide a cross-sectional assessment that could be completed immediately following a patient's visit. As currently formatted, Appendix B is designed to be folded in half to allow real-time feedback based upon answers to the initial practice-based questions. This approach is more typical of clinical decision support systems that provide real-time feedback on the concordance between guideline recommendations and the individual patient's care. Such feedback provides the opportunity to adjust the treatment plan of an individual patient to improve patient-specific outcomes. In the future, the same data recording and feedback steps could be implemented via a web-based or electronic record system enhancing integration into clinical workflow. Data from this form could also be used in aggregate to plan and implement broader quality improvement initiatives. For example, if self-assessment using the sample tools

suggests that signs and symptoms of PTSD are inconsistently assessed, consistent use of more formal rating scales such as the PTSD Checklist (PCL) (35, 52) could be considered.

Each of the sample tools attempts to highlight aspects of care that have significant public health implications (e.g., suicide, substance use disorders) or for which gaps in guideline adherence are common. Appendix C includes evidence-based recommendations derived from the APA (34, 36) and the VA/DoD (35) practice guidelines and summarizes specific aspects of care that are measured by these sample PIP tools. Quality improvement suggestions that arise from completion of these sample tools are intended to be within the control of individual psychiatrists rather than dependent upon other health care system resources.

After using one of the sample PIP tools to assess the pattern of care given to a group of 5 or more patients with PTSD, the psychiatrist should determine whether specific aspects of care need to be improved. For example, if the presence or absence of co-occurring psychiatric disorders has not been assessed or if these disorders are present but not addressed in the treatment plan, then a possible area for improvement would involve greater consideration of co-occurring psychiatric disorders, which are common in patients with PTSD.

These sample PIP tools can also serve as a foundation for more elaborate approaches to improving psychiatric practice as part of the MOC program. If systems are developed so that practice-related data can be entered electronically (either as part of an electronic health record or as an independent web-based application), algorithms can suggest areas for possible improvement using specific, measurable, achievable, relevant and time-limited objectives. Such electronic systems could also provide links to journal or textbook materials, clinical practice guidelines, patient educational materials, drug-drug interaction checking, evidence-based tool kits or other clinical materials. In addition, future work will focus on developing more standardized approaches to integrating patient and peer feedback with personal performance review, developing and implementing programs of performance improvements and reassessment of performance and patient outcomes.

Appendix A: Retrospective Chart Review Performance in Practice Tool for the Care of Patients with Posttraumatic Stress Disorder (PTSD)

The purpose of this clinical tool is to complement the physician's clinical judgment with a visual aid highlighting key evidence-based recommendations for the assessment and treatment of PTSD and to provide an opportunity to evaluate potential reasons for deviation from recommended care.

Instructions: Choose the last 5 patients you treated with a diagnosis of PTSD. If the answer for a given item is "Yes," or "Not Applicable," place a check mark in the appropriate box; if the answer to the question is "No" or "Unknown," leave the box unchecked. After reviewing the charts of all 5 patients, complete the final column.

Scoring: Any rows for which the total is less than 5 reflect clinical areas for the physician to examine whether clinical or other circumstances explain why clinical practices are not consistent with recommended care, or whether changes in practice can strengthen the provision of evidence-based care.

I. ASSESSMENT for PTSD	Patient					
	#1	#2	#3	#4	#5	
Check box if new patient initiating treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	# of new patients
Did the initial evaluation assess:						Number of patients with check mark in row?
a. Exposure to trauma (see Appendix C: recommendation II.1)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
b. Signs/symptoms of PTSD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
c. PTSD type: Acute, Chronic, PTSD w/ delayed onset	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
d. Risk factors for PTSD (see Appendix C: recommendation II.3 to 5)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
e. Traumatic brain injury	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
f. Suicidal ideation/plans/intentions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
g. Suicidal behavior/attempts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
h. Non-suicidal self-injurious behaviors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
i. Nicotine use/abuse/dependence	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
j. Alcohol use/abuse/dependence	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
k. Other substance use/abuse/dependence	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
l. Presence of other co-occurring psychiatric disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
m. Presence of general medical conditions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
n. Functional impairment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
o. Prior history of hospitalization	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
p. Patient's prior response to treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
q. Availability or lack of social support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
II. TREATMENT / MANAGEMENT of PTSD						
Does the treatment plan currently include, refer, or consider the following treatment management approaches for PTSD?						
Check if any one of the "a" or "b" psychotherapeutic interventions are provided						
a. Exposure-based psychotherapeutic first-line interventions for PTSD (e.g. Exposure-based Cognitive Behavioral Therapy, Cognitive Processing Therapy, Prolonged Exposure Therapy, Brief Exposure Therapy (4 to 5 sessions))	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
OR						
b. Other psychotherapeutic interventions considered for PTSD (e.g., Stress Inoculation Therapy, Eye Movement Desensitization and Reprocessing, Imagery Rehearsal Therapy)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
c. Appropriate psychopharmacologic intervention for PTSD (e.g., SSRIs, SNRIs, TCAs, MAOIs)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
e. Ongoing follow-up and monitoring (e.g. at least one follow-up every 3 months)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
f. Patient/family education about illness/treatments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
g. Treatment for co-occurring substance use disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5
h. Treatment for other co-occurring psychiatric disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD)

This “real-time” PIP tool is intended to be a prospective cross-sectional assessment that could be completed immediately following a patient visit. As currently formatted, the tool is designed to be folded in half to allow real-time feedback based upon answers to initial practice based questions.

To establish a diagnosis of PTSD (refer to DSM-IV-TR for the diagnostic criteria), a thorough assessment of the patient's current and prior exposure to traumatic event(s) is required. The patient's response to the traumatic event at the time of trauma must involve intense fear, helplessness, or horror (Criterion A) and involve persistent re-experiencing (one or more symptoms in Criterion B); persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness (three or more symptoms in Criterion C), and persistent symptoms of increased arousal (two or more symptoms in Criterion D). There need to be associated change in functioning and the duration of disturbance of one month or more.

Patient's Sociodemographic Characteristics				The treatment plan should consider factors such as age, sex, ethnicity, culture and religious/spiritual beliefs, which may require a modified treatment approach.
Age: _____				
Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female				
Racial/ethnic background	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unknown <input type="checkbox"/>	
Highest level of education	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Marital status	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Assessment of risk factors should include: <i>Pre-trauma Risk Factors for ASD/PTSD</i> : prior exposure to trauma, adverse childhood experiences, younger age, minority race, female gender, low socioeconomic or educational status, psychiatric disorders or personality dimensions, cognitive factors.
Employment status	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Assess the following:				
Assess for PTSD Specific pre-, peri-, and post-trauma events	Yes	No	Unknown	
Most recent trauma types (motor vehicle crashes, violence, combat-related, sexual-related, other)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Severity of trauma (mild, moderate, severe)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Peri-trauma Risk Factors for ASD/PTSD</i> including: severity of trauma, peri-traumatic dissociation, young age at the time of exposure, and acute stress reaction.
Recency of exposure to trauma (time elapsed since exposure)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Level of distress at the time of trauma/peri-traumatic dissociation (mild/moderate/severe)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
History of trauma exposure (i.e., type, severity, frequency, adverse childhood experiences)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Post-trauma Risk Factors for ASD/PTSD</i> including: resource loss, lack of social support, ongoing life stressors, bereavement, psychosocial difficulties.
Since exposure to most recent trauma, is patient experiencing any of the following?	Yes	No	Unknown	If associated symptoms of PTSD are not routinely assessed (as indicated by multiple unknown symptoms of PTSD), consider using a standardized tool for assessing and recording PTSD symptoms such as the 17-item PTSD Check List (PCL) (52) or the Clinician Administered PTSD Scale (CAPS) (72).
Nightmares about the experience/ thinking about it when patient did not want to	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Patient tries hard not to think about the trauma or goes out of his/her way to avoid situations that remind them of it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Patient is constantly on guard, watchful, easily startled	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Patient feels numb or detached from others, activities, or their surroundings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD) (p. 2 of 6)

Current PTSD Diagnosis	Acute <input type="checkbox"/>	Chronic <input type="checkbox"/>	Delayed Onset <input type="checkbox"/>	If the patient has clinically significant symptoms of PTSD consider initiating treatment. If the patient is currently receiving treatment, depending on the duration of treatment and persistence of symptoms a change in the treatment plan may be indicated. Consideration may be given to changing a medication dose, modifying or adding a medication, or revising the primary diagnosis.
Is the patient experiencing clinically significant distress or impairment in social, occupational, or other important areas of functioning that is a change from their pre-trauma level of functioning?	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unknown <input type="checkbox"/>	
Length of time in treatment with psychiatrist or other clinicians for current PTSD: _____ months				
Co-Occurring Psychiatric Conditions	Current	Past	Unknown	Co-occurring psychiatric disorders are common in patients with PTSD and need to be considered when planning care.
Other Anxiety Disorder(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Depressive Disorder(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Tobacco use abuse/dependence contributes to significant morbidity and mortality among smokers, yet can be treated effectively.
Bipolar Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Psychotic Disorder(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Nicotine Dependence	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Alcohol Use Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other Substance Use Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Adjustment Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Somatoform Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Sleep Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Personality Disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Use of alcohol or other substances can be problematic among patients with PTSD and can influence treatment response and suicide risk even in the absence of substance use disorder.
Other psychiatric concerns:	Current	Past	Unknown	
Impaired cognition	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Smoking/Nicotine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Alcohol use problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other substance use problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Sleep problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	N/A	
If the patient has current or past co-occurring psychiatric disorders, are these being addressed in the treatment plan?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
If the patient uses tobacco, has he/she been encouraged to quit?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD) (p. 3 of 6)

Presence of traumatic brain injury (TBI):	Current <input type="checkbox"/>	Past <input type="checkbox"/>	Unknown <input type="checkbox"/>	Assessment of TBI should include, but not be limited to, the following: history, symptoms, neurological exam, neuro-cognitive function, and psychological function.	
If TBI present, rate the severity	Mild <input type="checkbox"/>	Moderate <input type="checkbox"/>	Severe <input type="checkbox"/>		Unknown <input type="checkbox"/>
Suicidal/Self Injurious Behaviors	Yes	No	Unknown		Mild TBI = loss of consciousness 0 to 30 min, alteration of consciousness/mental state up to 24 hours, amnesia 0-1 day. Moderate TBI = loss of consciousness >30 min and <24 hours, alteration of consciousness/mental state >24 hours, amnesia >1 day and <7 days Severe TBI = loss of consciousness >24 hours, alteration of consciousness/mental state >24 hours, amnesia >7 days
Has patient had suicidal ideation or behavior in the past 90 days?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
<i>If Yes:</i>					
Mild/intermittent ideation:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Severe/persistent ideation:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Made a suicide plan:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Self-injurious behavior <i>without intention</i> to die (e.g. cutting behavior)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Self-injurious behavior <i>with intention</i> to die (e.g. suicide attempt)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Number of previous suicide attempts (enter 0 if no previous history)	_____ # attempts				
Does patient have history of violent or aggressive behaviors toward others?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		A history of hospitalization, prior suicide attempts or other self-harming behaviors is relevant in estimating suicide risk.
Was patient ever hospitalized for the treatment of a psychiatric disorder?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Does this patient have a family history of mental illness?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		The presence or absence of aggressive behaviors can also be important to risk assessment.

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD) (p. 4 of 6)

Axis III—General Medical Conditions (including side effects of meds):	Yes	No	Unknown	
Trauma-related injury	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<p>For many patients with PTSD, the trigger traumatic event may also result in physical injury (eg., motor vehicle crashes, violence), consequently the patient's health status should be a particular focus of care. When present, general medical conditions and their treatments can exacerbate existing symptoms or require adjustments in medication doses.</p> <p>Medications prescribed for psychiatric disorders can interact with those for general medical conditions and can produce side effects in various organ systems.</p>
Problems with pain	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hypertension	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Cardiovascular disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Asthma/COPD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Renal disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hepatic disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Infectious diseases (e.g., HIV, Hepatitis C)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Thyroid disease	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Seizure disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Sleep apnea	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Obesity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
If the patient has current general medical conditions, has contact been made with the patient's primary care physician?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<i>If obesity is present:</i>				<p>Weight gain is common with psychiatric medications and obesity contributes to morbidity and mortality.</p> <p>Sleep apnea can be an unrecognized complication of obesity that can be exacerbated by sedating medications.</p>
Is the patient's weight being monitored?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Have nutrition/exercise been discussed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Axis IV—and other psychosocial and environmental problems	Yes	No	Unknown	<p>Psychosocial rehabilitation services are effective in improving quality of life. Consider psychosocial rehabilitation services including: health education, skills training, supported housing, family skills training, social skills training, supportive employment intervention, vocational counseling, occupational/recreational therapy, peer support group</p>
Lack of social support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Housing problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Economic problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Occupational/school problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Marital problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other relationship problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Problem with access to healthcare services	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Problems related to interaction with the legal system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Ongoing life stressors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other psychosocial problems	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD) (p. 5 of 6)

Pharmacologic treatments provided (by psychiatrist or other clinicians):	Dose	Route
Current psychiatric medication(s):		
SSRIs:		
SNRIs:		
TCAs:		
MAOIs:		
Other (Specify: _____)		
Current non-psychiatric medication(s):		
<i>In reviewing the patient's list of psychiatric medications:</i>		
Has the potential for drug-drug interactions been assessed?	Yes <input type="checkbox"/>	No <input type="checkbox"/>
Is each medication essential?	Yes <input type="checkbox"/>	No <input type="checkbox"/>

SSRIs are considered the first-line psychopharmacologic intervention. However, SSRIs are no longer recommended with the same level of confidence for combat-related PTSD as for non-combat-related PTSD. (36)

There are recommendations against: long term use of benzodiazepines to manage core PTSD symptoms; use of benzodiazepines as monotherapy; and use of first generation antipsychotics for the management of PTSD. (34, 35)

Knowledge of medications that patients are receiving for treatment of non-psychiatric disorders is important in assessing potential drug-drug interactions and interpreting reported side effects of treatment. Such information can also alert the clinician to the presence of general medical conditions that may not have been reported by the patient (e.g., hypertension, hyperlipidemias) or to side effects of treatment that may require changes in medications or medication doses.

With the fragmentation of health care, medications that were intended to be tapered may have been continued inadvertently. Continued use of non-essential medications increases costs as well as side effects and drug-drug interactions. Also consider if any of the medications require blood level monitoring or other follow-up laboratory testing. If the patient has residual symptoms, assess the adequacy of the medication dose and determine if changes in medication or dose are indicated.

Appendix B: Sample “Real-Time” Performance-in-Practice (PIP) Tool for Patients with Posttraumatic Stress Disorder (PTSD) (p. 6 of 6)

Psychosocial treatments provided (by psychiatrist or other clinicians):	Current	Past	Unknown	
Exposure-based Cognitive Behavioral Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Exposure-based therapies (e.g. exposure-based cognitive behavioral therapy, cognitive processing therapy, prolonged exposure therapy, brief exposure therapy) are considered first-line evidence-based psychotherapeutic interventions. However, exposure therapies are not indicated and should be used with caution for “patients living in dangerous situations (e.g. domestic violence) or for patients with current suicidal ideation, substance abuse not in stable remission, comorbid psychosis, or health problems that preclude exposure to intense physiological arousal.” (35)
Cognitive Processing Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Prolonged Exposure Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Brief Exposure Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Stress Inoculation Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Imagery Rehearsal Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Eye Movement Desensitization and Reprocessing	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	There is strong evidence against the use of psychological debriefing as it may have long term adverse consequences without any apparent benefits. (34, 35)
Treatment for nicotine problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Treatment for alcohol problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Treatment for other substance use problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Treatment for sleep problem	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Case Management or Care Management	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Self-management approaches	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Patient/family psychoeducation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<i>In reviewing the psychosocial treatment approaches that are being used:</i>				
Does the treatment approach adequately target core symptoms: Yes <input type="checkbox"/> No <input type="checkbox"/>				
Are modifications needed to address residual symptoms? Yes <input type="checkbox"/> No <input type="checkbox"/>				
Estimated degree of adherence to treatment: <input type="checkbox"/> Good <input type="checkbox"/> Fair <input type="checkbox"/> Poor <input type="checkbox"/> Unknown				Difficulty adhering to treatment is a common cause of inadequate response. Treatment of PTSD can be enhanced by assessing adherence and discussing barriers to adherence such as costs, concerns about medication use, complexity and side effects of medication regimens and obstacles to keeping appointments (e.g., transportation, childcare, schedule constraints).
Estimated magnitude of treatment-related side effects: <input type="checkbox"/> Mild <input type="checkbox"/> Moderate <input type="checkbox"/> Severe <input type="checkbox"/> Unknown				
Side effects experienced: _____				
Is additional education or discussion of the treatment plan needed to enhance the patient's understanding and adherence?	Yes <input type="checkbox"/>	No <input type="checkbox"/>		Common side effects of antidepressant medications include sleep-related effects (i.e., sedation, insomnia), gastrointestinal effects (e.g., diarrhea, constipation, nausea), restlessness/anxiety, sexual dysfunction, headache, and anticholinergic effects. Effects on cardiac conduction can be a particular problem with tricyclic antidepressants. For all antidepressants, the FDA has issued warnings that the potential for increased suicidal thoughts or behaviors with antidepressant therapy in individuals under the age of 25 must be balanced against the benefits of treatment.
Based on the severity of the patient's PTSD, is patient receiving evidence-based psychopharmacological and/or psychosocial treatments that are recommended by the practice guidelines?	<input type="checkbox"/>	<input type="checkbox"/>		
Were patient/family preferences taken into consideration in the development of treatment plan?	<input type="checkbox"/>	<input type="checkbox"/>		
Are any changes in the treatment plan likely as a result of using these PIP tools?	<input type="checkbox"/>	<input type="checkbox"/>		

Appendix C: Evidence-Based Assessment and Treatment Recommendations for Posttraumatic Stress Disorder

I. Definition

Trauma: An extreme traumatic stressor involving direct personal experience . . . the person's response to the event must involve intense fear, helplessness, horror

Acute Stress Reaction (ASR): . . . onset of some signs and symptoms may be simultaneous with the trauma or may follow after an interval of hours or days . . . symptoms not resolved within 4 days after the event, after ruling out other disorders

Acute Stress Disorder (ASD): clinically significant symptoms >2 days, but <1 month after exposure

Post Traumatic Stress Disorder (PTSD): clinically significant symptoms lasting more than 1 month after exposure to a trauma

Acute PTSD: clinically significant symptoms lasting >1 month, but <3 months

Chronic PTSD: clinically significant symptoms lasting >3 months after exposure to trauma

PTSD with delayed onset: clinically significant symptoms at least 6 months after exposure to trauma|| (35)

II. Assessment

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004† (35)	APA Guideline 2004‡ (34)
	Final Grade	Level of Clinical Confidence
1. Assess for trauma exposure including: time of onset, recency (time elapsed since exposure), type, nature, severity, history, frequency, course, and level of distress.	B	I
2. Screen patients for PTSD (screen for recent or remote trauma exposure. In military populations the VA/DoD guidelines recommend initial screening followed by screening annually or more if clinically indicated).	B	I
3. Assess for pre-trauma risk factors for ASD/PTSD including: prior exposure to trauma, adverse childhood, younger age, minority race, female gender, low socioeconomic or educational status, psychiatric disorders or personality dimensions, cognitive factors.	B	I
4. Assess for peri-trauma risk factors for ASD/PTSD including: severity of trauma, peri-traumatic dissociation, youth at time of exposure	B	I
5. Assess for post-trauma risk factors for ASD/PTSD including: resource loss, lack of social support, ongoing life stressors, bereavement, psychosocial difficulties	B	I
6. Assess for co-occurring physical or psychiatric disorders (depression, alcohol, other substance, other anxiety disorders, TBI, commonly co-occur with PTSD)	B	I
7. Assess risk for suicide or harm to others	B	I
8. Assess for functional impairment		I

Appendix C: Evidence-Based Assessment and Treatment Recommendations for Posttraumatic Stress Disorder (p. 2 of 3)

III. Treatment/Management:

Based on the 2009 APA Guideline Watch, best evidence from recent studies bolsters support for exposure-based psychotherapies but also pharmacological interventions in many circumstances. (36)

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡
	Final Grade	Level of Clinical Confidence
A. Pharmacotherapy		
1. Pharmacotherapy may be the first-line intervention for acutely traumatized patients		II
2. SSRIs as first-line for the treatment of PTSD Based on most recent evidence outlined in the 2009 APA Guideline Watch for PTSD: a. "Evidence for superiority of SSRIs and SNRIs over placebo for <i>non-combat-related</i> PTSD . . . Evidence of efficacy most convincing for the SSRIs, across all symptom clusters and for co-occurring depression and disability." b. "SSRIs may be no longer recommended with the same level of confidence for veterans with <i>combat-related PTSD</i> as for patients with non-combat-related PTSD." (36)	A	I
3. Second-line treatment for PTSD include TCAs and MAOIs	B	II
4. Consider antidepressant trial of 12 weeks before changing the therapeutic regimen	B	
5. Propranolol may be considered for treatment of immediate post-event stress	B	
6. Consider augmentation with prazosin for the management of nightmares and other symptoms of PTSD (36)	C	
7. Pharmacotherapy for treatment for ASD—Impiramine for hyperarousal/excessive arousal/panic attacks	B	
8. Other pharmacotherapy for treatment of ASD a. Benzodiazepines for sleep disturbance/insomnia/hyperarousal/excessive arousal/panic attacks b. Chloral hydrate for sleep disturbance/insomnia c. Propranolol for hyperarousal/excessive arousal/panic attacks	C	III
9. Consider maintenance treatment, reassess periodically	C	
10. Insufficient but increasing evidence in use of atypical antipsychotics for the treatment of PTSD <i>Based on the most recent evidence outline in the 2009 APA Guideline Watch for PTSD, "data are encouraging for adjunctive treatment with a 2nd generation antipsychotic in patients with partial response to an SSRI or SNRI, including for co-occurring psychotic symptoms."</i> (36)	Insufficient evidence	III
11. Recommend against: a. Long term use of benzodiazepines to manage core symptoms of PTSD b. Use of benzodiazepine as monotherapy c. First generation antipsychotics in the management of PTSD	Insufficient evidence	III

Appendix C: Evidence-Based Assessment and Treatment Recommendations for Posttraumatic Stress Disorder (p. 3 of 3)

Key Evidence-Based Guideline Recommendations	DoD/VA Guideline 2004†	APA Guideline 2004‡
	Final Grade	Level of Clinical Confidence
B. Psychotherapy:		
Based on most recent evidence outline in the 2009 APA Guideline Watch for PTSD, support for “exposure-based CBTs such as CPT and prolonged exposure therapy when delivered in individual formats” (36)		
1. Cognitive Behavioral Therapy (CBT) is an effective treatment for core symptoms of acute and chronic PTSD		I
2. Brief intervention of CBT (4 to 5 sessions) for ASD	A	II
3. Cognitive Therapy (CT) is effective with civilian men and women exposed to combat and non-combat trauma	A	II
4. CT is effective with military and veteran with combat- and non-combat-related PTSD	Insufficient evidence	
5 CT is effective for women with PTSD associated with sexual assault	A	
6. Exposure Therapy (ET) has shown to be effective in the treatment of PTSD	A	II
7. Exposure therapy may not be indicated and should be used with caution for individuals with following conditions: “living in dangerous situations (e.g. domestic violence), current suicidal ideation, substance abuse not in stable remission, comorbid-psychosis, or health problems that preclude exposure to intense physiological arousal.” (35)	Ineffective, or may be harmful	
8. Eye Movement Desensitization and Reprocessing (EMDR) has shown to be effective in the treatment of PTSD	A	II
9. Stress Inoculation Training (SIT) is effective as a treatment for PTSD related to sexual assault	A	II
10. Imagery Rehearsal Therapy (IRT) considered for treatment of PTSD (nightmares and sleep disruption in particular)	B	II
11. Psychodynamic psychotherapy for the treatment of patient with PTSD/complex PTSD	B	II
12. Hypnosis may be used to alleviate PTSD symptoms	B	Insufficient evidence
13. Psychological debriefing is ineffective and has adverse long term effects	Ineffective, or may be harmful	Not recommended
C. Psychosocial Rehabilitation Services		
1. Psychosocial rehabilitation services to include health education, skills training, supported housing, family skills training, social skills training, supportive employment, vocational counseling, occupational/recreational therapy, peer support group should be considered		

† DoD/VA Quality Rating:

Reference: Post-traumatic Stress Disorder VA/DoD Clinical Practice Guidelines: <http://www.ncptsd.va.gov/ncmain/doclist.jsp>

Final Grade of Recommendation

A A strong recommendation that the intervention is always indicated and acceptable

B A recommendation that the intervention may be useful/effective

C A recommendation that the intervention may be considered

May be considered not useful/effective, or may be harmful

Insufficient evidence to recommend for or against—the clinician will use clinical judgment

‡ APA Clinical Confidence Rating:

Reference: The American Psychiatric Association Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Post-traumatic Stress Disorder:

http://www.psych.org/psych_pract/treatg/pg/ASD_PTSD_05-15-06.pdf

I Recommended with substantial clinical confidence.

II Recommended with moderate clinical confidence.

III May be recommended on the basis of individual circumstances.

§ APA Guideline Watch (January 2009)—Reference #36

**Sample "Real-Time" Performance in Practice Tool
for Patients with Posttraumatic Stress Disorder (PTSD)**
Survey Form and CME Certification Begin date April 2009,
End date December 31, 2011.

To earn CME credit for this *Survey Program*, psychiatrists should use the **Sample Real Time Performance in Practice Tool** (Appendix B) as indicated. After using the performance in practice tool for at least 5 patients, participants should fully complete this survey and send it by mail to APACME 1000 Wilson Boulevard, Suite 1825 Rosslyn VA 22209, or fax to 703 907 7849, or send by email to educme@psych.org.

Objective: After completion of this activity psychiatrists will have the foundation for subsequent performance improvement initiatives aimed at enhancing outcomes for patients with PTSD.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. APA designates this educational activity for a maximum of 5 AMA PRA Category 1 credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

		1	2	3	4	5	
1. Overall, I am satisfied with the usefulness of this PIP tool (Appendix B) in assessing my practice patterns.	Strongly disagree	0	0	0	0	0	Strongly agree
2. This PIP tool was difficult for me to use.	Strongly disagree	0	0	0	0	0	Strongly agree
3. The questions and information on this PIP tool were worded clearly.	Strongly disagree	0	0	0	0	0	Strongly agree
4. The organization of information on this PIP tool was clear.	Strongly disagree	0	0	0	0	0	Strongly agree
5. I was able to complete this PIP tool rapidly.	Strongly disagree	0	0	0	0	0	Strongly agree
6. Completing this PIP tool had no effect on my knowledge about treating patients with PTSD.	Strongly disagree	0	0	0	0	0	Strongly agree
7. By completing this PIP tool, I have identified at least one way in which I can improve my care of patients.	Strongly disagree	0	0	0	0	0	Strongly agree
8. Completing this PIP tool has helped me to verify that I am providing appropriate care to my patients.	Strongly disagree	0	0	0	0	0	Strongly agree
9. Completing this PIP tool was a good use of my time.	Strongly disagree	0	0	0	0	0	Strongly agree
10. Reviewing my patterns of practice is a good use of my time.	Strongly disagree	0	0	0	0	0	Strongly agree

List the most helpful aspects of this PIP tool (Appendix B):

- 1.
- 2.
- 3.

List the least helpful aspects of this PIP tool (Appendix B):

- 1.
- 2.
- 3.

How do you plan to use the information gained from this self-assessment in your practice?

How might we improve upon this PIP tool in the future?

Additional comments:

Please evaluate the effectiveness of this CME activity.

1. Achievement of educational objectives: YES _____ NO _____
 2. Material was presented without bias: YES _____ NO _____
- American Psychiatric Association CME**
1000 Wilson Blvd., Suite 1825 Arlington, VA 22209-3901
Telephone: (703) 907-8637, Fax: (703) 907-7849
To earn credit, complete and send this page.
Retain a copy of this form for your records.

Number of hours you spent on this activity _____
(understanding & using the tool; completing the survey up to 5 hrs)

Date _____

APA Member: Yes _____ No _____

Member number _____

Last name First name Middle initial Degree

Mailing address

City State Zip code Country

Fax number

E-mail address: _____

I would like to receive my certificate by:

Fax _____ E-mail _____

Laura J. Fochtmann, M.D.
 Farifteh F. Duffy, Ph.D.
 Joyce C. West, Ph.D., M.P.P.
 Robert Kunkle, M.A.
 Robert M. Plovnick, M.D., M.S.

Performance in Practice: Sample Tools for the Care of Patients with Major Depressive Disorder

Abstract: To facilitate continued clinical competence, the American Board of Medical Specialties and the American Board of Psychiatry and Neurology are implementing multi-faceted Maintenance of Certification programs, which include requirements for self-assessments of practice. Because psychiatrists may want to gain experience with self-assessment, two sample performance-in-practice tools are presented that are based on recommendations of the American Psychiatric Association's Practice Guideline for the Treatment of Patients with Major Depressive Disorder. One of these sample tools provides a traditional chart review approach to assessing care; the other sample tool presents a novel approach to real-time evaluation of practice. Both tools can be used as a foundation for subsequent performance improvement initiatives that are aimed at enhancing outcomes for patients with major depressive disorder.

Psychiatrists, like other medical professionals, are confronted by a need to maintain specialty specific knowledge despite an explosion in the amount of new information and the ongoing demands of clinical practice. Given these challenges, it is not surprising that researchers have consistently found gaps between actual care and recommended best-practices (1–10). In attempting to enhance the quality of delivered care, a number of approaches have been tried with varying degrees of success. Didactic approaches, including dissemination of written educational materials or practice guidelines, produce limited behavioral change (11–19). Em-

bedding of patient-specific reminders into routine care can lead to benefits in specific quality measures (11, 13–16, 20–23) but these improvements may be narrow in scope, limited to the period of intervention or unassociated with improved patient outcomes (24–27). Receiving feedback after self or peer-review of practice patterns may also produce some enhancements in care (13–15, 23, 28–30). Given the limited effects of the above approaches when implemented alone, the diverse practice styles of physicians and the multiplicity of contexts in which care is delivered, a combination of quality improvement approaches may be needed to improve patient outcomes (14, 19, 28, 29, 31–34).

With these factors in mind, the American Board of Medical Specialties and the American Board of Psychiatry and Neurology are implementing multi-faceted Maintenance of Certification (MOC) Programs that include requirements for self-assessments of practice through reviewing the care of at least 5 patients (35). As with the original impetus to create specialty board certification, the MOC programs are intended to enhance quality of patient care in addition to assessing and verifying the competence of medical practitioners over time (36, 37). Although the MOC phase-in schedule will not require completion of a Performance in Practice (PIP) unit until 2014 (35), individuals may wish to begin assessing their own practice patterns before

CME Disclosure

Laura J. Fochtmann, M.D., Professor, Department of Psychiatry and Behavioral Science and Department of Pharmacological Sciences, State University of New York at Stony Brook, and Practice Guidelines Medical Editor, American Psychiatric Association

Robert Kunkle, M.A., and Robert M. Plovnick, M.D., M.S., Department of Quality Improvement and Psychiatric Services, American Psychiatric Association, 1000 Wilson Blvd., Ste. 1825, Arlington, VA 22209-3901

Farifteh F. Duffy, Ph.D., and Joyce C. West, Ph.D., M.P.P., American Psychiatric Institute for Research and Education, 1000 Wilson Blvd, Suite 1825, Arlington, Virginia, 22209

No relevant financial relationships to disclose.

Address correspondence to: Laura J. Fochtmann, M.D., Department of Psychiatry and Behavioral Science, Stony Brook University School of Medicine, HSC-T10, Stony Brook, NY 11794-8101, E-mail: laura.fochtmann@stonybrook.edu

Table 1. Aspects of Major Depressive Disorder Treatment Addressed by Sample Performance-In-Practice Tools

Recommendation	Source of Recommendation ¹	Performance Tool ²
Identify signs and symptoms of depression	MDD PG	A, B, PCPI
Assess suicidal ideation, plans and intent	MDD PG; SB PG	A, B, PCPI
Identify past or current symptoms of mania or hypomania	MDD PG; BP PG	A, B
Identify past and current substance use disorders, including nicotine, alcohol and other substances	MDD PG; SUD PG; SB PG	A, B
Identify other past and current co-occurring psychiatric disorders	MDD PG	A, B
Identify past and current general medical conditions	MDD PG	A, B
Use treatments that are concordant with practice guideline recommendations (see Appendix A).	MDD PG	A, B, PCPI
Integrate treatment of any substance use disorders or other co-occurring psychiatric disorders with treatment for MDD	MDD PG; SUD PG; SB PG	A, B
Provide education to patients/families about depression and its treatment	MDD PG	A, B
Consider factors such as age, sex, ethnicity, cultural or religious beliefs in planning treatment	MDD PG	B
Assess the patient's level of functioning in social, occupational and other important realms	MDD PG	B
Determine whether cognitive impairment is present	MDD PG	B
Determine whether aggressive behavior is present	SB PG	B
Determine whether suicide attempts or other self-harming behaviors are present	MDD PG; SB PG	B
Determine the degree of adherence to treatment	MDD PG	B
Determine if side effects of treatment are present and, if so, which ones	MDD PG	B

¹ Source of Recommendation: MDD PG = Practice Guideline for the Treatment of Patients with Major Depressive Disorder (38); SUD PG = Practice Guideline for the Treatment of Patients with Substance Use Disorders (61); BP PG = Practice Guideline for the Treatment of Patients with Bipolar Disorder (42); SB PG = Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors (62)

² Performance Tool: A = Sample retrospective PIP tool of Appendix A; B = Sample prospective PIP tool of Appendix B; PCPI = Major depressive disorder measures of the American Medical Association Physician Consortium for Performance Improvement (63)

that time. To facilitate such self-assessment related to the treatment of depression, this paper will discuss several approaches to reviewing one's clinical practice and will provide sample PIP tools that are based on recommendations of the American Psychiatric Association's Practice Guideline for the Treatment of Patients with Major Depressive Disorder (38).

Traditionally, most quality improvement programs have focused on retrospective assessments of practice at the level of organizations or departments (39). The Healthcare Effectiveness Data and Information Set (HEDIS) measures of the National Committee for Quality Assurance (NCQA) (40) are a commonly used group of quality indicators that measure health organization performance.

When used under such circumstances, quality indicators are typically expressed as a percentage that reflects the extent of adherence to a particular indicator. For example, in the quality of care measures for bipolar disorder (41) derived from the American Psychiatric Association's 2002 Practice Guideline for the Treatment of Patients with Bipolar Disorder (42), one of the indicators is that "Patients in an acute depressive episode of bipolar disorder who are treated with antidepressants, [are] also receiving an antimanic agent such as valproate or lithium." In this example, to calculate the percentage of patients for whom the indicator is fulfilled, the numerator will be the "Number of patients in an acute depressive episode of bipolar disorder, who are receiving an antidepressant, and who are also receiving an

anti-manic agent such as valproate or lithium.” and the denominator will be the “Number of patients in an acute depressive episode of bipolar disorder who are receiving an antidepressant” (41).

As in the above example, most quality indicators are derived from evidence-based practice guidelines, which are intended to apply to typical patients in a population rather than being universally applicable to all patients with a particular disorder (43, 44). In addition, practice guideline recommendations are mainly informed by data from randomized controlled trials. Patients in such trials may have significant differences from those seen in routine clinical practice (45), including clinical presentation, preference for treatment, response to treatment, and presence of co-occurring psychiatric and general medical conditions (43, 46, 47). These differences may result in treatment decisions for individual patients that are clinically appropriate but not concordant with practice guideline recommendations.

When quality indicators are used to compare individual physicians’ practice patterns, quality measures can be influenced by practice size, patients’ sociodemographic factors and illness severity as well as other practice-level and patient-level factors. For example, when small groups of patients are receiving care from an individual physician, a small shift in the number of individuals receiving a recommended intervention could lead to large shifts in the resulting rates of concordance with evidence-based care. Without appropriate application of case-mix adjustments, across-practice comparisons may result in erroneous conclusions about the quality of care being delivered (48, 49). For patients with complex conditions or multiple disorders receiving simultaneous treatment, composite measures of overall treatment quality may yield more accurate appraisals than measurement of single quality indicators (50–52).

With the above caveats, however, use of retrospective quality indicators can be beneficial for individual physicians who wish to assess their own patterns of practice. If a physician’s self-assessment identified aspects of care that frequently differed from key quality indicators, further examination of practice patterns would be helpful. Through self-assessment, the physician may determine that deviations from the quality indicators are justified, or he may acquire new knowledge and modify practice to improve quality. It is this sort of self-assessment and performance improvement efforts that the MOC PIP program is designed to foster.

Appendices A and B provide sample PIP tools, each of which is designed to be relevant across clinical settings (e.g., inpatient, outpatient), straight-

forward to complete and usable in a pen-and-paper format to aid adoption. Although the MOC program requires review of at least 5 patients as part of each PIP unit, it is important to note that larger samples will provide more accurate estimates of quality within a practice. Appendix A provides a sample retrospective chart review PIP tool that assesses the care given to patients with major depressive disorder. Although it is designed as a self-assessment tool, this form could also be used for retrospective peer-review initiatives. As with other retrospective chart review tools, some questions on the form relate to the initial assessment and treatment of the patient whereas other questions relate to subsequent care. Appendix B provides a prospective review form that is intended to be a cross-sectional assessment and could be completed immediately following a patient visit. As currently formatted, Appendix B is designed to be folded in half to allow real-time feedback based upon answers to the initial practice-based questions. This approach is more typical of clinical decision support systems that provide real-time feedback on the concordance between guideline recommendations and the individual patient’s care. In the future, the same data recording and feedback steps could be implemented via a web-based or electronic record system enhancing integration into clinical workflow (53). This will make it more likely that psychiatrists will see the feedback as interactive, targeted to their needs and clinically relevant. Rather than relying on more global changes in practice patterns to enhance individual patients’ care, such feedback also provides the opportunity to adjust the treatment plan of an individual patient to improve patient-specific outcomes (54–56). However, data from this form could also be used in aggregate to plan and implement broader quality improvement initiatives. For example, if self-assessment using the sample tools suggests that signs and symptoms of depression are inconsistently assessed, consistent use of more formal rating scales such as the PHQ-9 (57–59) could be considered.

Each of the sample tools attempts to highlight aspects of care that have significant public health implications (e.g., suicide, obesity, use of tobacco and other substances) or for which gaps in guideline adherence are common. Examples include underdetection and undertreatment of co-occurring substance use disorders (5) and the relatively low concordance with practice guideline recommendations for use of psychosocial therapies and for treatment of psychotic features with MDD (4). Table 1 summarizes specific aspects of care that are measured by these sample PIP tools. Quality improvement suggestions that arise from completion of these sample

tools are intended to be within the control of individual psychiatrists rather than dependent upon other health care system resources.

After using one of the sample PIP tools to assess the pattern of care given to a group of 5 or more patients with major depressive disorder, the psychiatrist should determine whether specific aspects of care need to be improved. For example, if the presence or absence of co-occurring psychiatric disorders has not been assessed or if these disorders are present but not addressed in the treatment plan, then a possible area for improvement would involve greater consideration of co-occurring psychiatric disorders, which are common in patients with MDD.

These sample PIP tools can also serve as a foundation for more elaborate approaches to improving psychiatric practice as part of the MOC program. If systems are developed so that practice-related data can be entered electronically (either as part of an electronic health record or as an independent web-based application), algorithms can suggest areas for possible improvement using specific, measurable, achievable, relevant and time-limited objectives (60). Such electronic systems could also provide links to journal or textbook materials, clinical practice guidelines, patient educational materials, drug-drug interaction checking, evidence based tool kits or other clinical materials. In addition, future work will focus on developing more standardized approaches to integrating patient and peer feedback with personal performance review, developing and implementing programs of performance improvements and reassessment of performance and patient outcomes.

REFERENCES

1. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, D.C: National Academy Press; 2001.
2. Institute of Medicine. Improving the quality of health care for mental and substance-use conditions. Washington, DC: National Academies Press; 2006.
3. Colenda CC, Wagenaar DB, Mickus M, Marcus SC, Tanielian T, Pincus HA. Comparing clinical practice with guideline recommendations for the treatment of depression in geriatric patients: findings from the APA practice research network. *Am J Geriatr Psychiatry* 2003 Jul; 11(4):448–57.
4. West JC, Duffy FF, Wilk JE, Rae DS, Narrow WE, Pincus HA, et al. Patterns and quality of treatment for patients with major depressive disorder in routine psychiatric practice. *Focus* 2005; 3(1):43–50.
5. Wilk JE, West JC, Narrow WE, Marcus S, Rubio-Stipec M, Rae DS, et al. Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis? *Compr Psychiatry* 2006 Jul; 47(4): 258–64.
6. Pincus HA, Page AE, Druss B, Appelbaum PS, Gottlieb G, England MJ. Can psychiatry cross the quality chasm? Improving the quality of health care for mental and substance use conditions. *Am J Psychiatry* 2007 May; 164(5):712–9.
7. Rost K, Dickinson LM, Fortney J, Westfall J, Hermann RC. Clinical improvement associated with conformance to HEDIS-based depression care. *Ment Health Serv Res* 2005 Jun; 7(2):103–12.
8. Cochrane LJ, Olson CA, Murray S, Dupuis M, Tooman T, Hayes S. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. *J Contin Educ Health Prof* 2007; 27(2):94–102.
9. Chen RS, Rosenheck R. Using a computerized patient database to evaluate guideline adherence and measure patterns of care for major depression. *J Behav Health Serv Res* 2001 Nov; 28(4):466–74.
10. Cabana MD, Rushton JL, Rush AJ. Implementing practice guidelines for depression: applying a new framework to an old problem. *Gen Hosp Psychiatry* 2002 Jan; 24(1):35–42.
11. Davis D. Does CME work? An analysis of the effect of educational activities on physician performance or health care outcomes. *Int J Psychiatry Med* 1998; 28(1):21–39.
12. Sohn W, Ismail AI, Tellez M. Efficacy of educational interventions targeting primary care providers' practice behaviors: an overview of published systematic reviews. *J Public Health Dent* 2004; 64(3):164–72.
13. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. *Int J Technol Assess Health Care* 2005; 21(3):380–5.
14. Chaillet N, Dube E, Dugas M, Audibert F, Tourigny C, Fraser WD, et al. Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. *Obstet Gynecol* 2006 Nov; 108(5):1234–45.
15. Grimshaw J, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, et al. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998. *J Gen Intern Med* 2006 Feb; 21 Suppl 2:S14–S20.
16. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, et al. Changing provider behavior: an overview of systematic reviews of interventions. *Med Care* 2001 Aug; 39(8 Suppl 2):12–45.
17. Grol R. Changing physicians' competence and performance: finding the balance between the individual and the organization. *J Contin Educ Health Prof* 2002; 22(4):244–51.
18. Oxman TE. Effective educational techniques for primary care providers: application to the management of psychiatric disorders. *Int J Psychiatry Med* 1998; 28(1):3–9.
19. Green LA, Wyszewianski L, Lowery JC, Kowalski CP, Krein SL. An observational study of the effectiveness of practice guideline implementation strategies examined according to physicians' cognitive styles. *Implement Sci* 2007 Dec 1; 2(1):41.
20. Balas EA, Weingarten S, Garb CT, Blumenthal D, Boren SA, Brown GD. Improving preventive care by prompting physicians. *Arch Intern Med* 2000 Feb 14; 160(3):301–8.
21. Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, et al. Improved therapeutic monitoring with several interventions: a randomized trial. *Arch Intern Med* 2006 Sep 25; 166(17):1848–54.
22. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med* 2005 Mar 10; 352(10):969–77.
23. Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A, Jr., et al. Interventions used in disease management programmes for patients with chronic illness—which ones work? Meta-analysis of published reports. *BMJ* 2002 Oct 26; 325(7370):925.
24. O'Connor PJ, Crain AL, Rush WA, Sperl-Hillen JM, Gutenkauf JJ, Duncan JE. Impact of an electronic medical record on diabetes quality of care. *Ann Fam Med* 2005 Jul; 3(4):300–6.
25. Rollman BL, Hanusa BH, Lowe HJ, Gilbert T, Kapoor WN, Schulberg HC. A randomized trial using computerized decision support to improve treatment of major depression in primary care. *J Gen Intern Med* 2002 Jul; 17(7):493–503.
26. Sequist TD, Gandhi TK, Karson AS, Fiskio JM, Bugbee D, Sperling M, et al. A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease. *J Am Med Inform Assoc* 2005 Jul; 12(4):431–7.
27. Tierney WM, Overhage JM, Murray MD, Harris LE, Zhou XH, Eckert GJ, et al. Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. *Health Serv Res* 2005 Apr; 40(2):477–97.
28. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. *Cochrane Database Syst Rev* 2005; (4): CD003539.
29. Bradley EH, Holmboe ES, Mattern JA, Roumanis SA, Radford MJ, Krumholz HM. Data feedback efforts in quality improvement: lessons learned from US hospitals. *Qual Saf Health Care* 2004 Feb; 13(1):26–31.
30. Paukert JL, Chumley-Jones HS, Littlefield JH. Do peer chart audits improve residents' performance in providing preventive care? *Acad Med* 2003 Oct; 78(10 Suppl):S39–S41.
31. Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. *Ann Intern Med* 2006 Aug 1; 145(3):165–75.

32. Hyson SJ, Best RG, Pugh JA. Clinical practice guideline implementation strategy patterns in Veterans Affairs primary care clinics. *Health Serv Res* 2007 Feb; 42(1 Pt 1):84–103.
33. Dykes PC, Acevedo K, Boldrighini J, Boucher C, Frumento K, Gray P, et al. Clinical practice guideline adherence before and after implementation of the HEARTFELT (HEART Failure Effectiveness & Leadership Team) intervention. *J Cardiovasc Nurs* 2005 Sep; 20(5):306–14.
34. Greene RA, Beckman H, Chamberlain J, Partridge G, Miller M, Burden D, et al. Increasing adherence to a community-based guideline for acute sinusitis through education, physician profiling, and financial incentives. *Am J Manag Care* 2004 Oct; 10(10):670–8.
35. American Board of Psychiatry and Neurology. Maintenance of Certification for Psychiatry. 2007. Accessed on 11-23-0007. Available from: URL:http://www.abpn.com/moc_psychiatry.htm
36. Institute of Medicine. Health professions education: A bridge to quality. Washington, D.C: National Academies Press; 2003.
37. Miller SH. American Board of Medical Specialties and repositioning for excellence in lifelong learning: maintenance of certification. *J Contin Educ Health Prof* 2005; 25(3):151–6.
38. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). *Am J Psychiatry* 2000 Apr; 157(4 Suppl):1–45.
39. Hermann RC. Improving mental healthcare: A guide to measurement-based quality improvement. Washington, DC: American Psychiatric Pub; 2005.
40. National Committee for Quality Assurance. HEDIS and quality measurement. National Committee for Quality Assurance 2007. Accessed on 12-30-2007. Available from: URL: <http://web.ncqa.org/tabid/59/Default.aspx>
41. Duffy FF, Narrow W, West JC, Fochtmann LJ, Kahn DA, Suppes T, et al. Quality of care measures for the treatment of bipolar disorder. *Psychiatr Q* 2005; 76(3):213–30.
42. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). *Am J Psychiatry* 2002 Apr; 159(4 Suppl):1–50.
43. American Psychiatric Association. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Arlington, Va: American Psychiatric Association; 2006.
44. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. *Postgrad Med* 2000 Apr; Spec No:1–104.
45. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. *Soc Psychiatry Psychiatr Epidemiol* 2005 Jan; 40(1):27–35.
46. Eddy D. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis. *Health Aff (Millwood)* 2007 Jul; 26(4):w500–w515.
47. Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. *J Clin Psychiatry* 2002 Aug; 63(8):727–32.
48. Hofer TP, Hayward RA, Greenfield S, Wagner EH, Kaplan SH, Manning WG. The unreliability of individual physician “report cards” for assessing the costs and quality of care of a chronic disease. *JAMA* 1999 Jun; 281(22):2098–105.
49. Greenfield S, Kaplan SH, Kahn R, Ninomiya J, Griffith JL. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. *Ann Intern Med* 2002 Jan 15; 136(2):111–21.
50. Parkerton PH, Smith DG, Belin TR, Feldbau GA. Physician performance assessment: nonequivalence of primary care measures. *Med Care* 2003 Sep; 41(9):1034–47.
51. Lipner RS, Weng W, Arnold GK, Duffy FD, Lynn LA, Holmboe ES. A three-part model for measuring diabetes care in physician practice. *Acad Med* 2007 Oct; 82(10 Suppl):S48–S52.
52. Nietert PJ, Wessell AM, Jenkins RG, Feifer C, Nemeth LS, Ornstein SM. Using a summary measure for multiple quality indicators in primary care: the Summary QQuality InDex (SQUID). *Implement Sci* 2007; 2:11.
53. Rollman BL, Gilbert T, Lowe HJ, Kapoor WN, Schulberg HC. The electronic medical record: its role in disseminating depression guidelines in primary care practice. *Int J Psychiatry Med* 1999; 29(3):267–86.
54. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. *Drug Alcohol Depend* 2007 May; 88 Suppl 2:S61–S71.
55. Hepner KA, Rowe M, Rost K, Hickey SC, Sherbourne CD, Ford DE, et al. The effect of adherence to practice guidelines on depression outcomes. *Ann Intern Med* 2007 Sep 4; 147(5):320–9.
56. Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, Crismon ML, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. *Psychol Med* 2005 Dec; 35(12):1695–706.
57. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001 Sep; 16(9):606–13.
58. Lowe B, Kroenke K, Herzog W, Grafe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). *J Affect Disord* 2004 Jul; 81(1):61–6.
59. Lowe B, Schenkel I, Carney-Doebbeling C, Gobel C. Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment. *Psychosomatics* 2006 Jan; 47(1):62–7.
60. MacDonald G, Starr G, Schooley M, Yee SL, Klimowski K, Turner K. Introduction to program evaluation for comprehensive tobacco control programs. Centers for Disease Control and Prevention 2001 Accessed on 12-17-2007. Available from: URL: http://www.cdc.gov/tobacco/tobacco_control_programs/surveillance_evaluation/evaluation_manual/00_pdfs/Evaluation.pdf
61. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, second edition. *Am J Psychiatry* 2007 Apr; 164(4 Suppl):5–123.
62. American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. *Am J Psychiatry* 2003 Nov; 160(11 Suppl):1–60.
63. American Medical Association Physician Consortium for Performance Improvement. AMA (CQI) Major depressive disorder. American Medical Association Physician Consortium for Performance Improvement Accessed on 12-17-2007. Available from: URL: <http://www.ama-assn.org/ama/pub/category/16494.html>

NOTES

Appendix A. Sample Retrospective Chart Review Performance-in-Practice Tool for the Care of Patients with Major Depressive Disorder

Instructions: Choose 5 patients with a primary diagnosis of major depressive disorder. If the answer to a given question is “Yes”, place a check mark in the appropriate box. If the answer to the question is “No” or “Unknown”, leave the box unchecked. After reviewing the charts of all 5 patients, complete the final column to determine the relative proportion of patients to whom the recommendation was followed. Any rows for which the total is <2 may be a useful focus for quality improvement efforts.

Guideline recommendation being reviewed	Patient					Number of patients with checkmark in row?
	#1	#2	#3	#4	#5	
Did the initial evaluation assess:						
Signs/symptoms of major depression:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Suicidal ideation/plans/intent	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Substance use/abuse/dependence						
Nicotine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Alcohol	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Other substances	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Presence/absence of general medical conditions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Presence/absence of other co-occurring psychiatric disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
History of hypomanic or manic episodes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Referring to the chart on the reverse side, was treatment concordant with guideline recommendations:						
During the initial acute phase of treatment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
At the time of the chart review (if the treatment plan differs from that in the initial phase of treatment)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Has the treatment plan addressed:						
Patient education about illness/treatments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/5
Co-occurring substance use disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/__ (# applicable)
Other co-occurring psychiatric disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_/__ (# applicable)

Appendix A. (continued) Recommendations for APA Practice Guideline Concordant Treatment of Major Depressive Disorder

Acute Phase of Treatment (focused on inducing symptom remission)

Clinical presentation	Guideline treatment will include:
Mild MDD (minor functional impairment, few symptoms beyond those required for diagnosis)	Antidepressant therapy alone OR Psychotherapy alone ¹ OR Combined treatment with psychotherapy ¹ and antidepressant medication ² (if preferred by patient)
Moderate MDD (greater degree of functional impairment, some symptoms beyond those required for diagnosis)	Antidepressant therapy alone OR Psychotherapy alone ¹ OR Combined treatment with psychotherapy ¹ and antidepressant medication ² OR Electroconvulsive therapy (if preferred by the patient and depression is chronic)
Severe MDD (marked interference with social or occupational function; several symptoms in excess of those required for diagnosis)	Antidepressant therapy alone OR Combined treatment with psychotherapy ¹ and antidepressant medication ² OR Electroconvulsive therapy (if preferred by the patient, if the patient has responded preferentially to ECT in the past or if rapid treatment response is essential)
MDD with psychotic features	Combined treatment with an antidepressant and an antipsychotic medication OR Electroconvulsive therapy
MDD with catatonic features	Benzodiazepines OR Electroconvulsive therapy

Continuation Phase of Treatment (focused on preserving symptom remission over the 16 to 20 weeks after the acute phase of treatment)

If acute phase treatment included:	Guideline concordant treatment will include:
Psychotherapy	Continued psychotherapy
Antidepressant medication	Antidepressant medication of a comparable dose to that used for acute treatment
Electroconvulsive therapy (ECT)	Pharmacotherapy or psychotherapy; continuation ECT is an acceptable alternative if pharmacotherapy or psychotherapy have not preserved remission in past

Maintenance Phase of Treatment (focused on protecting against recurrence of major depressive episodes)

If treatment to prevent depressive recurrence is indicated ³ and acute treatment included:	Guideline concordant treatment will include:
Psychotherapy	Continued psychotherapy, with a decrease in visit frequency generally occurring if cognitive behavioral therapy or interpersonal therapy are used
Antidepressant medication	Antidepressant medication, generally at a comparable dose to that used for acute treatment
Electroconvulsive therapy (ECT)	Pharmacotherapy or psychotherapy; maintenance ECT may be considered if pharmacotherapy or psychotherapy have not preserved remission in past

¹ The presence of significant psychosocial stressors, intrapsychic conflict, interpersonal difficulties, co-occurring personality disorders or poor adherence with treatment may add to the rationale for treating with psychotherapy.

² In patients who have experienced only partial response to adequate trials of medications or psychotherapy alone, combination treatment may be considered.

³ Indications for maintenance phase treatment are based upon risk of recurrence (including consideration of number of prior episodes; presence of co-occurring conditions; residual symptoms between episodes), severity of episodes (including consideration of suicidal ideas and behaviors; psychotic features; severe functional impairments), side effects experienced during continuation therapy, or patient preferences.

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression

This “real time” PIP tool is intended to be a prospective cross-sectional assessment that could be completed immediately following a patient visit. As currently formatted, the tool is designed to be folded in half to allow real-time feedback based upon answers to initial practice based questions. Up to 5 hours additional CME credit can be earned through use of the PIP tool and completion of the survey.

Patient Characteristics: Age: <input type="text"/> Sex: <input type="text"/>		<p>To establish a diagnosis of depression, at least 5 of these symptoms need to be experienced nearly every day over a two week period (with one of the symptoms being either depressed mood or loss of interest or pleasure). However, other symptom assessment intervals may be appropriate when monitoring the presence or absence of symptoms over time.</p> <p>If associated symptoms of depression are not routinely assessed (as indicated by multiple boxes on the left that are checked as unassessed or unknown), consider using a standardized tool for assessing and recording depressive symptoms such as the PHQ-9.</p>		
Estimated duration of depressive illness:				
Length of time in treatment for current depressive episode:				
Which of the following is the patient experiencing?				
	Yes	No	Unknown	<p>When patients are experiencing thoughts of suicide, self-harm or of being better off dead, more detailed questioning is crucial. The presence of suicide plans or intent indicates a significant increase in suicide risk. An intention to use a highly lethal suicide method (e.g., guns, hanging, jumping) will also confer an increase in suicide risk. When a suicide method is identified, the accessibility of the method is an additional part of the inquiry.</p>
Little interest or pleasure in doing things?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Feeling down, depressed, or hopeless?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Trouble falling or staying asleep, or sleeping too much?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Feeling tired or having little energy?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Poor appetite or overeating?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Negative feelings about self?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Trouble concentration?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Psychomotor retardation or agitation?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Thoughts of suicide, self-harm, or being better off dead?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<p>The presence of clinically significant distress or functional impairment is one of the criteria used in making a diagnosis of depression. In addition to being a primary focus of patients and their families, functional impairment is a major determinant of illness related disability and should be routinely assessed.</p> <p>Distress and impairment are equally important to assess in examining response to treatment. If clinically significant distress or functional impairment are present, consider whether a change in treatment plan is indicated. Depending on the duration of treatment and persistence of symptoms, consideration may be given to changing a medication dose, modifying or adding a psychosocial treatment, changing or adding a medication, or revising the primary diagnosis.</p>
If the patient has thoughts of suicide, self-harm or being better off dead, was there a specific inquiry into:				
Suicide plans	Yes	<input type="checkbox"/>	No <input type="checkbox"/>	
Suicide intent	Yes	<input type="checkbox"/>	No <input type="checkbox"/>	
Suicide methods	Yes	<input type="checkbox"/>	No <input type="checkbox"/>	
Is the patient experiencing clinically significant distress or impairment in social, occupational, or other important areas of functioning that is a change from their baseline level of function?	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unknown <input type="checkbox"/>	

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression (p. 2 of 6)

Current Depressive Diagnosis:				In establishing a diagnosis of depression, it is essential to determine whether the patient has had multiple depressive episodes or only a single episode of depression as this will have implications for treatment planning. It is also important to identify other co-occurring psychiatric disorders as part of the initial assessment. Such disorders are common in depressed patients and need to be considered in planning care.
Other Psychiatric Diagnoses:				
Anxiety disorder(s):	Current	Past	Unknown	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Nicotine dependence	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Alcohol use disorder:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other substance use disorder:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Personality disorder:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other psychiatric issues:				
Psychosis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	The presence of psychotic symptoms in a depressed patient will generally necessitate treatment with an antipsychotic and an antidepressant medication or with ECT.
Impaired cognition	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Cognitive impairment may be associated with depression, medication side effects or other underlying causes. It can also influence adherence with treatment and patient safety.
Problematic use of alcohol or other substances (not meeting criteria for a substance use disorder diagnosis)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Use of alcohol or other substances can be problematic in depressed patients and can influence treatment response and suicide risk even in the absence of a substance use disorder.
Additional psychiatric history:	Yes	No	Unknown	A history of hospitalization, suicide attempts or other self-harming behaviors is relevant in estimating suicide risk. The presence or absence of aggressive behaviors can also be important to risk assessment.
Hospitalizations	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Suicide attempts	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other self-harming behaviors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Aggressive behavior	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Mania/Hypomania	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	If not specifically assessed, manic or hypomanic episodes may not be reported. The treatment of a depressive episode may need to be modified if Bipolar I or Bipolar II disorder is identified, as use of an antidepressant in bipolar patients may be associated with occurrence of hypomanic or manic episodes.
				If any of the aspects of psychiatric diagnosis, symptoms or history on this page are not routinely assessed, increasing rates of assessment may be a useful goal for performance improvement.

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression (p. 3 of 6)

General Medical Conditions (including side effects of meds):	Yes	No	Unknown	
Hypertension	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<p>When present, general medical conditions and their treatments can contribute to depressive symptoms or require adjustments in medication doses. Medications prescribed for psychiatric disorders can interact with those for general medical conditions and can produce side effects in various organ systems (e.g., renal or thyroid difficulties with lithium, seizures with clozapine and other psychotropic medications, glucose dysregulation and hyperlipidemia with second generation antipsychotic medications). In addition, individuals with psychiatric illnesses may be at increased risk of acquiring general medical conditions (e.g., HIV and Hepatitis C acquired through intravenous substance use, cardiovascular and respiratory conditions through smoking). Weight gain is common with psychiatric medications and obesity contributes to morbidity and mortality. Sleep apnea can be an unrecognized complication of obesity that can be exacerbated by sedating medications.</p> <p>If general medical conditions and medication related side effects are not being routinely identified, this may be a useful focus of performance improvement efforts</p>
Cardiovascular disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Asthma/COPD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Renal disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hepatic disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Infectious diseases (e.g., HIV, Hepatitis C)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Thyroid disease	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Seizure disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Sleep apnea	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Obesity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Diabetes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hyperlipidemia	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
If obesity is present, is the patient's weight being monitored?				
<p style="text-align: center;">Yes <input type="checkbox"/> No <input type="checkbox"/></p>				<p>Given the rise in obesity as a public health problem and the common occurrence of weight gain with psychotropic medications, monitoring of weight and recommendations about weight control strategies are increasingly relevant elements of treatment planning.</p>
<p style="text-align: center;">have nutrition and exercise been discussed?</p> <p style="text-align: center;">Yes <input type="checkbox"/> No <input type="checkbox"/></p>				
If the patient has current general medical conditions, has contact been made with the patient's primary care physician?				
<p style="text-align: center;">Yes <input type="checkbox"/> No <input type="checkbox"/></p>				<p>Collaborating with other clinicians is an important part of psychiatric management. When a patient has a current general medical condition, communication with the patient's primary care physician may be indicated.</p>
Current non-psychiatric medication(s)	Dose	Frequency	Route	<p>Knowledge of medications that patients are receiving for treatment of non-psychiatric disorders is important in looking for potential drug-drug interactions and interpreting reported side effects of treatment. Such information can also alert the clinician to the presence of general medical conditions that may not have been reported by the patient (e.g., hypertension, hyperlipidemias) or to side effects of treatment that may require changes in medications or medication doses.</p>

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression (p. 4 of 6)

Current psychiatric medication(s)	Dose	Frequency	Route	<p>Knowledge of medications that patients are receiving for treatment of psychiatric disorders is important in assessing the patient's response to treatment and interpreting reported side effects of treatment. In reviewing the list of the patient's current medications, infrequently administered medications (e.g., long-acting injectable antipsychotic medications) should not be overlooked. If the patient has residual symptoms, assess the adequacy of the medication dose and determine if changes in medication, medication dose or concomitant psychosocial therapy are indicated.</p>																
<p>Has the potential for drug-drug interactions been assessed for the patient's current medication regimen?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <input type="checkbox"/></p>				<p>Many psychotropic medications are metabolized through the cytochrome P450 and uridine 5'-diphosphate glucuronosyl-transferase enzyme systems, have high degrees of binding to plasma proteins or act on the P-glycoprotein transporter in the gastrointestinal tract. Consequently, there are many opportunities for clinically relevant drug-drug interactions to occur when patients are receiving psychotropic medications. If identification of potential drug-drug interactions is not routinely done, this may be a useful focus for performance improvement.</p>																
<p>If any of the patient's medications require laboratory monitoring (e.g., medication blood levels, evaluation of side effects), has this been performed?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <input type="checkbox"/></p>				<p>Specific medications may also require blood level monitoring or other follow-up laboratory testing to assess for the presence of side effects. If such monitoring is indicated but sometimes overlooked, this may also be a useful focus for performance improvement initiatives.</p>																
<p>Is each medication essential?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>				<p>Continued use of non-essential medications increases costs as well as side effects and drug-drug interactions. With the fragmentation of health care, medications that were intended to be tapered may have been continued inadvertently. As a result, patients may be taking multiple medications of the same class without evidence in the literature that this improves outcomes. Regular review of patients' medication regimens may help determine which medications are essential (and should not be stopped) and which may be able to be tapered and discontinued.</p>																
<p>Other somatic treatment approaches:</p> <table border="1"> <thead> <tr> <th></th> <th>Current</th> <th>Past</th> <th>Unknown</th> </tr> </thead> <tbody> <tr> <td>Electroconvulsive therapy</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Vagal nerve stimulation therapy</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Other:</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>					Current	Past	Unknown	Electroconvulsive therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Vagal nerve stimulation therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Other:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<p>The current and past use of other somatic treatment approaches is relevant to treatment planning as well as to assessment of therapeutic responses and treatment-related side effects. Inquiring about past experiences with these treatments is sometimes overlooked as part of the evaluation of patients with depression.</p>
	Current	Past	Unknown																	
Electroconvulsive therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	
Vagal nerve stimulation therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	
Other:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																	

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression (p. 5 of 6)

Psychosocial treatments used (by psychiatrist or other clinicians):	Current	Past	Unknown	
Psychodynamic psychotherapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<p>The current and past use of psychosocial treatment approaches is relevant to treatment planning as well as to assessment of therapeutic responses. Inquiring about past experiences with these treatments is sometimes overlooked as part of the evaluation of patients with depression. If the past and current use of psychosocial treatments is not routinely assessed, this may be a useful focus for performance improvement. If psychosocial treatments are being provided by other clinicians, it will be crucial to collaborate with these clinicians in the care of the patient.</p>
Cognitive psychotherapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Behavioral psychotherapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Interpersonal psychotherapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Supportive psychotherapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Education about illness or treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Medication management	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Self-management approaches	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other:				
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
In reviewing the psychosocial treatment approaches that are being used:	<p>If psychosocial treatment approaches are infrequently utilized as part of the treatment of depressed patients, this might prompt a review of typical treatment planning approaches. If the psychosocial treatments being employed do not adequately address core symptoms or residual symptoms, modifications in the patient's plan of treatment may be indicated depending upon factors such as the type and duration of treatment.</p>			
Does the treatment approach adequately target core symptoms? Yes <input type="checkbox"/> No <input type="checkbox"/>				
Are modifications needed to address residual symptoms? Yes <input type="checkbox"/> No <input type="checkbox"/>				
Estimated degree of adherence to treatment: Good <input type="checkbox"/> Fair <input type="checkbox"/> Poor <input type="checkbox"/> Unknown <input type="checkbox"/>	<p>Difficulty adhering to treatment is a common cause of inadequate response. Treatment of depression can be enhanced by assessing adherence, providing additional education to patients and their involved family members and discussing barriers to adherence such as costs, concerns about medication use, complexity and side effects of medication regimens and obstacles to keeping appointments (e.g., transportation, childcare, schedule constraints).</p>			
Is additional education or discussion of the treatment plan needed to enhance the patient's understanding and adherence? Yes <input type="checkbox"/> No <input type="checkbox"/>				
Estimated magnitude of treatment-related side effects: Severe <input type="checkbox"/> Moderate <input type="checkbox"/> Mild <input type="checkbox"/> Unknown <input type="checkbox"/>	<p>Assessment of side effects of treatment is crucial in all patients and could be a focus for performance improvement if not routinely determined. Although side effects are less commonly considered in patients receiving psychosocial treatments, intensive insight oriented treatments or exposure therapies may be associated with increases in anxiety for some patients. With antidepressant medication, common side effects include sleep-related effects (i.e., sedation, insomnia), gastrointestinal effects (e.g., diarrhea, constipation, nausea), restlessness/anxiety, sexual dysfunction, headache, and anticholinergic effects. Effects on cardiac conduction can be a particular problem with tricyclic antidepressants. For all antidepressants, the FDA has issued warnings that the potential for increased suicidal thoughts or behaviors with antidepressant therapy in individuals under the age of 25 must be balanced against the benefits of treatment.</p>			
Side effects experienced:				

Appendix B. Sample “Real-Time” Performance-in-Practice Tool for Patients with Depression (p. 6 of 6)

<p>Based upon the severity of the patient's depressive disorder, is the overall treatment approach concordant with that recommended practice guideline on the preceding page?</p>	<p>Although care is often noted to diverge from guideline based recommendations, other evidence suggests that providing guideline-concordant care is likely to improve patient outcomes. However, these data are based upon populations of patients and the samples in randomized trials (on which guidelines are typically based) have different characteristics than patients seen in actual practice. If a patient's plan of treatment does diverge from that recommended in the practice guideline, it is useful to consider the patient-specific factors relevant to the treatment plan as well as the rationale for the current plan of care. If patients' treatment plans infrequently follow guideline recommendations, this might serve as a focus for performance improvement.</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p> <p>What patient specific factors (if any) have led to modifications in the approach to treating the patient's depression compared to that recommended by the practice guideline?</p>	
<p>If the patient has current or past co-occurring psychiatric disorders, are these being addressed in the treatment plan?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <input type="checkbox"/></p>	<p>Co-occurring psychiatric disorders are common in depressed patients and need to be considered in planning care. Including treatment for each disorder in the treatment plan is likely to improve outcomes for each disorder. Substance use disorders, in particular, are often underrecognized and undertreated, despite the fact that integrated treatment is effective. Performance improvement efforts might be focused on increasing the rates of treatment for all co-occurring disorders or may focus on specific disorders with high rates of occurrence in individuals with depression (e.g., smoking cessation in individuals with nicotine dependence).</p>
<p>Has the treatment plan considered factors such as age, sex, ethnicity, culture, and religious/spiritual beliefs that may require a modified treatment approach?</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <input type="checkbox"/></p>	<p>In individualizing the patient's plan of treatment, factors such as age, sex, ethnicity, culture and religious/spiritual beliefs are essential yet are often overlooked. If such factors are unassessed or infrequently incorporated into treatment planning, this might serve as a focus for performance improvement.</p>
	<p>Are any changes in this patient's treatment plan likely as a result of this review process?</p>
	<p>Are any performance improvement initiatives or further reviews of practice planned as a result of this review process?</p>

Sample "Real-Time" Performance in Practice Tool for Patients with Depression

Survey Form and CME Certification Begin date February 2008,
End date February 2010.

To earn CME credit for this *Survey Program*, psychiatrists should use the **Sample Real Time Performance in Practice Tool** as indicated. After using the performance in practice tool, participants should fully complete this survey and send it by mail to APACME 1000 Wilson Boulevard, Suite 1825 Rosslyn VA 22209, or fax to 703 907 7849, or send by email to educme@psych.org.

Objective: After completion of this activity psychiatrists will have the foundation for subsequent performance improvement initiatives aimed at enhancing outcomes for patients with major depressive disorder.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. APA designates this educational activity for a maximum of 5 AMA PRA Category 1 credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

		1	2	3	4	5	
1. Overall, I am satisfied with the usefulness of this PIP tool in assessing my practice patterns.	Strongly disagree	0	0	0	0	0	Strongly agree
2. This PIP tool was difficult for me to use.	Strongly disagree	0	0	0	0	0	Strongly agree
3. The questions and information on this PIP tool were worded clearly.	Strongly disagree	0	0	0	0	0	Strongly agree
4. The organization of information on this PIP tool was clear.	Strongly disagree	0	0	0	0	0	Strongly agree
5. I was able to complete this PIP tool rapidly.	Strongly disagree	0	0	0	0	0	Strongly agree
6. Completing this PIP tool had no effect on my knowledge about treating patients with depression.	Strongly disagree	0	0	0	0	0	Strongly agree
7. By completing this PIP tool, I have identified at least one way in which I can improve my care of patients.	Strongly disagree	0	0	0	0	0	Strongly agree
8. Completing this PIP tool has helped me to verify that I am providing appropriate care to my patients.	Strongly disagree	0	0	0	0	0	Strongly agree
9. Completing this PIP tool was a good use of my time.	Strongly disagree	0	0	0	0	0	Strongly agree
10. Reviewing my patterns of practice is a good use of my time.	Strongly disagree	0	0	0	0	0	Strongly agree

List the most helpful aspects of this PIP tool:

- 1.
- 2.
- 3.

List the least helpful aspects of this PIP tool:

- 1.
- 2.
- 3.

How do you plan to use the information gained from this self-assessment in your practice?

How might we improve upon this PIP tool in the future?

Additional comments:

Please evaluate the effectiveness of this CME activity by answering the following questions.

1. Achievement of educational objectives: YES _____ NO _____
2. Material was presented without bias: YES _____ NO _____

American Psychiatric Association CME

1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Telephone: (703) 907-8637, Fax: (703) 907-7849
To earn credit, complete and send this page.
Retain a copy of this form for your records.

Number of hours you spent on this activity _____
(understanding & using the tool and completing the survey up to 5 hours)

Date _____

APA Member: Yes _____ No _____

Member number _____

Last name First name Middle initial Degree

Mailing address

City State Zip code Country

Fax number

E-mail address: _____

I would like to receive my certificate by:

Fax _____ E-mail _____

Farifteh F. Duffy, Ph.D.
 Joyce C. West, Ph.D., M.P.P.
 Laura J. Fochtman, M.D.
 Mark L. Willenbring, M.D.
 Robert Plovnick, M.D., M.S.
 Robert Kunkle, M.A.
 Beatrice Eld, B.S.

Performance in Practice: Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder

Abstract: The American Board of Medical Specialties (ABMS) and the American Board of Psychiatry and Neurology (ABPN) are implementing multifaceted *Maintenance of Certification* (MOC) requirements to enhance quality of patient care and assess and verify the competence of physicians over time (ABPN 2009). Beginning in 2013, for those applying for 2014 MOC examinations, the practice assessment component (Part 4 of MOC) will require physicians to compare their care for five or more patients with “. . . published best practices, practice guidelines or peer-based standards of care and develop a plan to improve effectiveness and efficiency of his or her clinical activities” (ABPN 2009). To this end, the *Performance in Practice Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder* that are presented here provide psychiatrists with the opportunity to gain experience with practice assessment, in preparation for the new ABMS and ABPN MOC requirements. Because the evidence-based quality indicators included in the tools presented here are considered core components in the care of patients with substance use problems or disorders, use of these tools can serve as a foundation in developing a systematic approach to practice improvement for the assessment and treatment of patients with substance use disorders.

Alcohol, tobacco, and other substance use disorders are among the most common medical problems in patients presenting in primary care and specialty mental health settings. In the United States, it is estimated that one in seven adults will have an alcohol or other substance use disorder over the course of his or her lifetime (1). Alcohol and nicotine disorders are most prevalent. Nearly one-third of U.S. adults drink enough to cause or place them at risk of adverse consequences (2), whereas 28% of the population aged 12 or older use tobacco products and 9% have used illicit drugs in the past month (3). Individuals with substance use disorders have very high rates of morbidity, mortality, and functional impairment, as well as significantly higher medical costs associated with their disproportionate use of health care resources (4–8). Alcohol and tobacco use are two of the nation’s lead-

ing causes of death from modifiable factors (8, 9). Moreover, substance use disorders are common comorbidities among individuals with mood, anxiety,

CME Disclosure

Farifteh F. Duffy, Ph.D., and Joyce C. West, Ph.D., M.P.P., American Psychiatric Institute for Research and Education, Arlington, VA

Laura J. Fochtman, M.D., Department of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, NY

Mark L. Willenbring, M.D., St. Paul, MN

Robert Plovnick, M.D., M.S., Robert Kunkle, M.A., and Beatrice Eld, B.S., American Psychiatric Association, Arlington, VA

All authors report no competing interests.

Address correspondence to Farifteh Duffy, Ph.D., American Psychiatric Institute for Research and Education, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209. E-mail: fduffy@psych.org.

and other mental disorders (5). Longitudinal studies suggest that individuals with these diagnoses are at an increased risk for the later onset of nicotine, alcohol, and illicit drug dependence (10).

Despite the availability of effective treatments and preventative interventions (11–18), only a minority of patients receive care of any type, and there is generally a 10-year gap between the onset of these disorders and first treatment, according to studies of treatment access in the United States (8, 19–21). Systematic assessments of the quality of general medical and specialty mental health care in the United States indicate that patients with substance use problems and disorders receive the poorest overall quality of care compared with that for individuals with other conditions (22). A major national study of care quality in primary care practices found that only 11% of patients with alcohol dependence received what the study described as indicators of quality care, including assessment of alcohol dependence among binge drinkers and treatment referral for individuals with a diagnosis of alcohol dependence (22).

Among psychiatric patients treated in routine practice settings in the United States, approximately one-quarter were identified by their treating psychiatrist as having a current substance use disorder (23); however, the majority of these patients were not reported to be receiving current treatment for these conditions. For example, 91% of patients identified as having nicotine dependence were not receiving any smoking cessation treatments (24). Similarly, nearly 7 of 10 patients with identified alcohol dependence and 6 of 10 patients with other identified substance use disorders were not receiving treatment for these disorders from their psychiatrist or any other clinician. Although medications to treat other mental health conditions are commonly used by psychiatrists, medications to treat substance use disorders are rarely used in routine psychiatric practice settings (25). These findings underscore the fact that clinical assessment and treatment of substance use and related disorders represents a tremendous opportunity to improve clinical practice in an area of medicine associated with high morbidity and mortality (4–8).

The American Board of Medical Specialties (ABMS) and the American Board of Psychiatry and Neurology (ABPN) are now moving to implement multifaceted *Maintenance of Certification* (MOC) requirements to enhance quality of patient care and assess and verify the competence of physicians over time (26). Beginning in 2013, for those applying for 2014 MOC examinations,

a practice assessment component of maintenance of certification will require physicians to compare their care for five or more patients with “. . . published best practices, practice guidelines or peer-based standards of care and develop a plan to improve effectiveness and efficiency of his or her clinical activities” (26). Because the assessment and treatment of substance use disorders reflects a clinical area of great opportunity to improve clinical practices and ameliorate the immense burden of disease and suffering associated with these conditions, these *Performance in Practice: Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder* were developed to meet the new ABMS and ABPN MOC requirements.

These performance in practice (PIP) tools were developed by first identifying evidence-based assessment and treatment recommendations from the following sources: the American Psychiatric Association’s (APA’s) “Practice Guideline for the Treatment of Patients with Substance Use Disorders” (2006) (11); APA’s “Guideline Watch: Practice Guideline for the Treatment of Patients with Substance Use Disorders” (2007) (12); the Veteran’s Administration (VA)/Department of Defense (DoD) “Clinical Practice Guideline: Management of Substance Use Disorder (SUD)” (2009) (13); U.S. Department of Health and Human Services “Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update” (2008) (14) and Varenicline criteria for prescribing (updated February 2010) (15); the National Institute on Alcohol Abuse and Alcoholism (NIAAA): A Clinician’s Guide (2005) (16); the NIAAA Prescribing Medications for Alcohol Dependence (2008) (17); the National Institute for Health and Clinical Excellence, NICE Clinical Guideline: Drug Misuse—Opioid Detoxification (2007) (18); and APA’s *Practice Guideline for Psychiatric Evaluation of Adults* (2006) (27). These evidence-based guidelines were developed through systematic medical literature reviews and critical evaluation of the scientific research by experts in the assessment and treatment of substance use disorders. Consequently, the physician PIP Tools presented here are based on the best available current medical research and evidence-based recommendations for the assessment and treatment of substance use disorders.

These *Performance in Practice: Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorder* are specifically intended to do the following:

1. Provide simple assessment tools for physicians to examine the care provided to systematically selected adult patients to assess whether the clinician's current patient assessment and treatment practices for alcohol, tobacco, opiate and other substance use disorders are consistent with the latest evidence-based recommendations.
2. Offer valuable clinical resources (including easily accessible sources for brief screening, assessment, and treatment interventions) and key evidence-based recommendations for clinicians to use if they identify areas in which additional knowledge or modifications to clinical practices may help improve clinical assessment and treatment practices.
3. Provide a brief, practical, easy-to-use tool that in the future may be used to meet the new ABMS and ABPN maintenance of certification requirements for assessments of clinical practice with the aim of enhancing the quality of patient care.

The Performance in Practice: Physician Practice Assessment Tools for the Screening, Assessment, and Treatment of Adults with Substance Use Disorders presented in Appendices 1 and 2 are designed to facilitate retrospective chart review and allow physicians to evaluate their capacity to provide screening and comprehensive assessment and to allow physicians to evaluate their provision of evidence-based treatments for patients with selected substance use disorders. To this end, the PIP tools include three sections related to 1) screening of all patients for use of tobacco, alcohol, and other substances. 2) review of the core components of a comprehensive clinical evaluation for those whose screening results are positive, and 3) provision of treatment for nicotine, alcohol, and opioid use disorders for clinicians who wish to assess their practice alongside current evidence-based treatment recommendations. Each of the sections attempts to highlight aspects of care that have significant public health implications or for which gaps in guideline adherence are common (e.g., screening all patients for use of tobacco, alcohol, and other substances). The last column of the tools provides guideline-supported recommendations and clinical resources to assist in practice improvement efforts. Quality improvement opportunities that arise from using the tools can generally be managed by individual psychiatrists and applied as a part of their routine practice, rather than by relying on other health care system resources.

The PIP clinical tools have been designed to be relevant across clinical settings (e.g., inpatient and outpatient), straightforward to complete, and us-

able in a pen-and-paper format to aid adoption. In addition to its value as a practice-assessment tool, this form could be also used for retrospective peer-review initiatives. Although the ABPN MOC program requires review of at least five patients as part of each PIP unit, it is important to note that larger samples will provide more accurate estimates of quality of care within a practice.

After using the PIP tool to assess the pattern of care provided to patients, the physician should determine whether specific aspects of care need to be improved. Through such practice assessment, the physician may determine that deviations from the quality indicators are clinically appropriate and justified or he or she may choose to acquire new knowledge and modify his or her practice to improve quality. For example, if patients in the physician's current psychiatric caseload are not screened for tobacco or alcohol use, then an area for improvement could involve implementation of systematic screening for alcohol and tobacco use, which are common among patients with any psychiatric disorders.

It is important to note that although these tools are intended to highlight current evidence-based assessment and treatment recommendations for patients with or at risk for developing substance use disorders, justifiable variations from recommended care are expected. Assessment and treatment recommendations provided in the practice guidelines are generally intended to be relevant to the majority of individuals (28, 29). However, patients vary widely in their clinical presentations, presence of comorbid physical and psychiatric conditions, response to treatment, and other factors that may influence clinical decision making. In addition, practice guidelines and quality indicators are often derived from findings of efficacy and effectiveness trials in which stringent enrollment criteria are used; thus individuals in clinical trials often differ in important ways from those seen in routine clinical practice (30). To this end, divergence from evidence-based recommendations can be anticipated. Finally, the PIP tools need to be updated regularly to keep pace with the growing scientific base for the assessment and treatment of substance use disorders.

The PIP tools presented in Appendices 1 and 2 provide clinicians with an opportunity for practice assessment in preparation for the new 2014 ABPN MOC program requirements. Because the evidence-based quality indicators presented here are considered core components in the care of patients with substance use problems or disorders, use of this tool can serve as a foundation in developing a systematic approach to practice improvement for the assessment and treatment of patients with substance use disorders.

ACKNOWLEDGMENT

This work was generously funded by a grant from the American Psychiatric Foundation. Authors would like to thank John A. Renner, Jr., MD, Chair, APA's Council on Addiction Psychiatry, for his review and thoughtful feedback on this manuscript.

REFERENCES

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62:593–602
2. Dawson DA, Li TK, Grant BF: A prospective study of risk drinking: at risk for what? *Drug Alcohol Depend* 2008; 95:62–72
3. Substance Abuse and Mental Health Services Administration: Results from the 2009 National Survey on Drug Use and Health: Vol. 1. Summary of National Findings. NSDUH Series H-38A, HHS Publication SMA 10-4586Findings. Rockville, MD, Office of Applied Studies
4. Schneider Institute for Health Policy: Substance Abuse: The Nation's Number One Health Problem, 2nd Ed. Princeton, NJ, The Robert Wood Johnson Foundation, 2001. <http://www.rwjf.org/files/publications/other/SubstanceAbuseChartbook.pdf>
5. Kessler RC: The epidemiology of dual diagnosis. *Biol Psychiatry* 2004; 56:730–737
6. Annual Medical Examiner Data 1990: Data from the Drug Abuse Warning Network (DAWN) Statistical Series: Series 1, Number 10-B. DHHS Publication (ADM) 91-1840. Rockville, MD, US Department of Health and Human Services, National Institute on Drug Abuse, 1991
7. Centers for Disease Control: Alcohol-related mortality and years of potential life lost: United States, 1987. *MMWR Morb Mortal Wkly Rep* 1990; 39:173–177
8. Hasin DS, Stinson FS, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2007; 64:830–842
9. Mokdad AH, Marks JS, Stroup DF, Gerberding JL: Actual causes of death in the United States, 2000 [published corrections appear in *JAMA* 2005; 293:293–294, 298]. *JAMA* 2004; 291:1238–1245
10. Swendsen J, Conway KP, Degenhardt L, Glantz M, Jin R, Merikangas KR, Sampson N, Kessler RC: Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. *Addiction* 2010; 105:1117–1128
11. Work Group on Substance Use Disorders: Treatment of patients with substance use disorders, 2nd edition. American Psychiatric Association. *Am J Psychiatry* 2006; 163(8 suppl):5–82. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_5.aspx
12. Connery HS, Kleber HD: Guideline Watch (April 2007): Practice guideline for the treatment of patients with substance use disorders, 2nd edition. *Focus* 2007; 5:163–166. <http://www.psychiatryonline.com/content.aspx?aid=149073>
13. Management of SUD Working Group. VA/DOD Clinical Practice Guideline: Management for Substance Use Disorders (SUD). Washington, DC, Department of Veteran's Affairs, Department of Defense, 2009. http://www.healthquality.va.gov/Substance_Use_Disorder_SUD.asp
14. Clinical Practice Guideline: Treating tobacco use and dependence: 2008 update. Bethesda, MD, U.S. Department of Health and Human Services, 2008. http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf
15. VA Center for Medication Safety, Tobacco Use Cessation Technical Advisory Group, Public Health Strategic Healthcare Group, VA Pharmacy Benefits Management Services, VISN Pharmacist Executives, Medical Advisory Panel: Varenicline criteria for prescribing. Updated Feb 2010. http://www.healthquality.va.gov/Management_of_Tobacco_Use_MTU.asp

16. Helping Patients Who Drink Too Much: A Clinician's Guide. NIH Publication 07-3769. Bethesda, MD, National Institute on Alcohol Abuse and Alcoholism, 2005 ed., reprinted May 2007. http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm
17. Prescribing Medications for Alcohol Dependence. NIH Publication 07-3769. Bethesda, MD, National Institute on Alcohol Abuse and Alcoholism, October 2008. Update <http://www.niaaa.nih.gov/Publications/Education-TrainingMaterials/Documents/PrescribingMeds.pdf>
18. National Institute for Health and Clinical Excellence: Drug Misuse: Opioid Detoxification. National Clinical Practice Guideline number 52. London, Alden Press, 2007. <http://guidance.nice.org.uk/CG52>
19. Wang PS, Lane M, Olsson M, Pincus HA, Wells KB, Kessler RC: Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62:629–640
20. Substance Abuse and Mental Health Services Administration: Results From the 2004. National Survey on Drug Use and Health: National Findings. DHHS Publication (SMA) 05-4062. Rockville, MD, Office of Applied Studies, 2005
21. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ: Recovery from DSM-IV alcohol dependence: United States, 2001–2002. *Addiction* 2005; 100:281–292
22. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA: The quality of health care delivered to adults in the United States. *N Engl J Med* 2003; 348:2635–2645
23. Wilk JE, West JC, Narrow WE, Marcus SC, Rubio-Stipec M, Rae DS, Pincus HA, Regier DA: Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis? *Compr Psychiatry* 2006; 47:258–264 Epub; 2006. April 19.
24. Montoya ID, Herbeck DM, Svikis DS, Pincus HA: Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. *Am J Addict* 2005; 14:441–454
25. Montoya I, Svikis D, Marcus S, Suarez A, Tanielian T, Pincus HA: Psychiatric care of patients with depression and comorbid substance abuse disorders. *J Clin Psychiatry* 2000; 61:698–705
26. American Board of Psychiatry and Neurology, Inc.: Maintenance of Certification program. Buffalo Grove, IN, American Board of Psychiatry and Neurology, Inc., 2009. http://www.abpn.com/downloads/moc/moc_web_doc.pdf
27. Work Group on Psychiatric Evaluation of Adults: Psychiatric evaluation of adults, 2nd edition. American Psychiatric Association. *Am J Psychiatry* 2006; 163(6 suppl):3–36. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_1.aspx
28. Dickey B, Sederer LI (eds): Improving Mental Health Care: Commitment to Quality. Washington, DC, American Psychiatric Publishing, Inc., 2001
29. Eddy DM: Practice policies: Where do they come from? *JAMA* 1990; 263: 1265–1269, 1272
30. Zarin DA, Young JL, West JC: Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. *Soc Psychiatry Psychiatr Epidemiol* 2005; 40:27–35
31. Fagerstrom KO, Schneider NG: Fagerstrom Test for Nicotine Dependence, in *Handbook of Psychiatric Measures*, 2nd ed. Edited by Rush AJ, First MB, and Blacker D. Rosslyn, VA, American Psychiatric Publishing Inc., 2008, pp 448–449
32. Rethinking Drinking: Alcohol and Your Health. NIH Publication 10-3770. Bethesda, MD, National Institute on Alcohol Abuse and Alcoholism, Revised April 2010. <http://rethinkingdrinking.niaaa.nih.gov/>
33. Compton WM, Thomas YF, Stinson FS, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV Drug Abuse and Dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2007; 64:566–576
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision. Washington, DC, American Psychiatric Association. 2005

NOTES

Appendix 1. Performance in Practice Physician Assessment Module for the Screening of Adults with Substance Use Disorder

Instructions: Choose five adult patients as indicated in the table below. Review the charts for these five adult patients to determine if care was consistent with the evidence-based recommendations described in each row (Yes/No). If **Yes**, check the appropriate box; if **No** or **Unknown**, leave the box unchecked.

Scoring: In the **TOTAL** column, tally the total number of check marks in each row. For any row for which the total is less than 5, examine whether clinical or other circumstances explain why practice in this area was not consistent with recommended care. If not, consider whether changes or use of any of the suggested clinical tools in your practice could strengthen the provision of evidence-based care.

To use this Module for Part IV MOC, see instructions on page 40.

I. Screening for Substance Use Disorders	Patient					TOTAL Number of Patients with Check Mark in Each Row	Recommendations and Clinical Resources		
	#1	#2	#3	#4	#5				
Select five patients you treated in your current practice (regardless of the psychiatric diagnoses).									
Within the past year, either as part of the initial assessment or subsequent evaluations . . .									
1. Was the patient screened for current or past tobacco use?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> Smoking is common among individuals with other substance use disorder and psychiatric disorders. It is essential that clinicians routinely screen for current or past tobacco use in order to provide timely and appropriate interventions (11, 13–14). Nearly all daily tobacco users are nicotine dependent. Identification and treatment of comorbid nicotine dependence may improve recovery for other substance use disorders (13). Fagerstrom Test for Nicotine Dependence (FTND) is a well-validated instrument that can be used as a screening tool for nicotine dependence as well as a severity rating scale that can inform treatment planning (11, 31) 		
2. Was the patient screened for current or past alcohol use?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> Screening for alcohol use is recommended for all patients seen in general medical and mental health settings (16). Annual screening has been recommended by the VA/DoD guideline (13). Available well-validated and guideline recommended tools include NIAAA single question screener asking about the number of heavy drinking days in the past year, CAGE questionnaire (4 items), AUDIT-C (3 items) or full AUDIT (10 items): http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm (13, 16, 27) 		
3. Has there been documentation of the number of standard drinks the patient consumes per week?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> At-risk drinking/unhealthy alcohol use among men ≤65 years of age involves: greater than 14 standard drinks/week (13, 16). At-risk drinking/unhealthy alcohol use among women and persons >65 years of age involves: greater than 7 standard drinks/week (13, 16). A standard drink is any drink that contains about 0.6 fluid ounce of pure alcohol (e.g., one 12-oz. beer or 5-oz. glass of wine contains 0.6 fluid ounce pure alcohol) (16). For a more detailed description of a standard drink go to http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide13_p_mats.htm. 		

Appendix 1. Performance in Practice Physician Assessment Module for the Screening of Adults with Substance Use Disorder (p. 2 of 2)

I. Screening for Substance Use Disorders	Patient					TOTAL Number of Patients with Check Mark in Each Row	Recommendations and Clinical Resources
	#1	#2	#3	#4	#5		
4. Has there been documentation of the highest number of drinks consumed on any single occasion within the past month/past year?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> • At-risk drinking/unhealthy alcohol use among men ≤ 65 years of age involves: 5 or more drinks on any occasion in the past month (13) or past year (16). • At-risk drinking/unhealthy alcohol use among women and persons > 65 years of age involves 4 or more drinks on any occasion in the past month (13) or past year (16).
5. Has there been documentation whether the patient engaged in unhealthy alcohol use (i.e., nondependent alcohol use problem) or meets the criteria for an alcohol use disorder?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> • Recommend lower limits or abstinence for patients when medically indicated (e.g., patients with alcohol use disorder, pregnancy, liver disease, other medical conditions potentially exacerbated by drinking, or medication regimens that interact with alcohol) (13, 16). • Consider a brief intervention for at-risk drinking (16). • Provide educational materials for clinicians (16) http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm • Provide educational materials for patients (32). http://rethinkingdrinking.niaaa.nih.gov/.
6. Has there been inquiry regarding use of other substances, including use of illicit drugs, caffeine, illicit use of over-the-counter and prescription medications, inhalants?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> • Individuals who misuse, abuse or develop dependence for a specific drug commonly misuse, abuse, or develop dependence toward other substances (8, 33).
7. If a patient was suspected, presumed, or identified as having a substance use disorder, did the patient receive a comprehensive assessment for substance use disorders in order to inform treatment planning?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> • For patients with suspected, presumed or identified substance use disorders a comprehensive assessment for substance use disorders should be conducted. • A detailed list for comprehensive evaluation can be found in APA Practice Guidelines for SUD 2006 (11, 12), APA Practice Guidelines for Psychiatric Evaluation 2006 (27), the VA/DOD Clinical Practice Guidelines for SUD 2009 (13), and the NICE Practice Guidelines for Drug Misuse 2007 (18). • Appendix B. Performance in Practice Physician Assessment Tool for the Assessment and Treatment of Adults with Substance Use Disorder provides a tool detailing components of a comprehensive assessment.

Appendix 2. Performance in Practice Physician Assessment Module for the Assessment and Treatment of Adults with Substance Use Disorder

Instructions: Choose five adult patients as indicated in the table below. Review the charts for these five adult patients to determine if care was consistent with the evidence-based recommendations described in each row (Yes/No). If Yes, check the appropriate box; if No or Unknown, leave the box unchecked.

Scoring: In the **TOTAL** column, tally the total number of check marks in each row. For any row for which the total is less than 5, examine whether clinical or other circumstances explain why practice in this area was not consistent with recommended care. If not, consider whether changes or use of any of the suggested clinical tools in your practice could strengthen the provision of evidence-based care.

To use this Module for Part IV MOC, see instructions on page 40.

II. Comprehensive Assessment for Substance Use Disorders	Patient					TOTAL Number of Patients with Check Mark in Each Row	Recommendations and Clinical Resources		
	#1	#2	#3	#4	#5				
Select five patients you treated in your current practice with suspected, presumed, or identified substance use disorders.									
Did the patient receive a comprehensive evaluation to guide treatment, including assessment of the following?									
1. Detailed history of past and present substance use, associated problems, symptoms, and types and amount of substances used (e.g., alcohol, illicit drugs, tobacco, caffeine, over-the-counter and prescription medications, inhalants), last use and history of withdrawal	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> A detailed list for comprehensive evaluation can be found in APA Practice Guidelines for SUD 2006 (11, 12), APA Practice Guidelines for Psychiatric Evaluation 2006 (27), the VA/DOD Clinical Practice Guidelines for SUD 2009 (13), and the NICE Practice Guidelines for Drug Misuse 2007 (18). With permission from the patient, consider obtaining collateral input from significant other(s) or other sources of information in order to provide complete representation of individual's substance use problems (11). The specific substance or substances used will influence the cognitive, psychological, and behavioral effects of substance use as well as the potential impact on physiological functions (e.g., vital signs; cardiac, pulmonary, renal, hepatic and other gastrointestinal effects). 		
2. Effects of substance use on cognitive functioning	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
3. Effects of substance use on psychological and behavioral functioning	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
4. Effects of substance use on physiological functioning	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
5. General medical and psychiatric history, including physical examination and necessary laboratory tests	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
6. History of psychiatric treatments and outcomes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
7. Family and social history	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
8. Risk to self and others, including aggressive, suicidal or other self-injurious behaviors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			
9. Assessment for signs and symptoms that would suggest a need for medically managed withdrawal or detoxification (e.g., tremulousness, vital sign changes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5			

Appendix 2. Performance in Practice Physician Assessment Module for the Assessment and Treatment of Adults with Substance Use Disorder (p. 2 of 3)

III. Treatment for Substance Use Disorders	Patient					TOTAL Number of Patients with Check Mark in Each Row	Recommendations and Clinical Resources		
	#1	#2	#3	#4	#5				
<ul style="list-style-type: none"> • Definition of Substance Abuse: A maladaptive pattern of substance use leading to clinically significant impairment or distress, with one or more of the following occurring within a 12-month period: failure to fulfill major roles or obligations at work, school, or home consequent of substance use; recurrent substance use when physically hazardous; recurrent substance-related legal problems; continued substance use despite having persistent social or interpersonal problems which are caused or exacerbated by the effects of the substance (34). • Definition of Substance Dependence: A maladaptive pattern of substance use, leading to clinically significant impairment or distress with three or more of the following, occurring within a 12-month period: development of tolerance and withdrawal; substance is often taken in larger amounts or over longer period of time than intended; persistent desire or unsuccessful efforts to cut down or control use; a great deal of time is spent in activities necessary to obtain the substance; giving up important social, occupational, or recreational activities because of substance use; substance is used despite knowledge of its deleterious impact on physical and psychological health (34). 									
A. Treatment Approaches for Nicotine Use Disorder									
If you have a patient with nicotine dependence N = number of patient charts reviewed with nicotine dependence Was the patient assessed for:						___/N	<ul style="list-style-type: none"> • Among patients with nicotine dependence, the APA Practice Guideline for the Treatment of Patients with SUD recommends assessing patients for readiness to quit (11). 		
1. Readiness to quit tobacco use	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N			
2. Past attempts to quit and reasons for failure	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N			
3. Preferences with respect to treatment modality	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N			
For patients <u>ready</u> to quit tobacco use:							<ul style="list-style-type: none"> • Psychosocial treatments for nicotine dependence have shown to be effective (e.g., cognitive behavioral therapy, behavioral therapies, brief intervention, motivational enhancement therapy provided in individual, group, or telephone formats) (11, 14). • Pharmacotherapy [e.g., a nicotine replacement therapy, bupropion, as first line (11, 14, 15), and varenicline as second line (15)] is recommended for individuals who prefer to use such agents or who have not achieved cessation without pharmacological treatments (11–12, 14). Refer to package inserts for all FDA-approved medications for the treatment of tobacco use in order to obtain updates on contraindications, warnings, side effects, etc. • The combination of pharmacotherapy and psychotherapy has been shown to be more effective than either alone (14). 		
4. Were evidence-based psychosocial interventions <u>AND/OR</u> pharmacotherapy offered?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N			
B. Treatment Approaches for Nondependent Alcohol Use, Alcohol Abuse, or Dependence									
If you have a patient with nondependent alcohol use problems who is an at risk drinker but does not meet diagnostic criteria for alcohol use disorder N = number of patient charts reviewed with non dependent alcohol use							<ul style="list-style-type: none"> • Provide a brief intervention for at-risk drinking (NIAAA Clinician Guide). • Additional information or interventions for at risk drinking can be found at: http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm • Provide educational materials for patients with alcohol use problems: http://rethinkingdrinking.niaaa.nih.gov/ 		
1. Was the patient advised and assisted in cutting down/quitting alcohol consumption (e.g., was there discussion about unhealthy alcohol consumption and whether patient educational materials were provided)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N			

Appendix 2. Performance in Practice Physician Assessment Module for the Assessment and Treatment of Adults with Substance Use Disorder (p. 3 of 3)

III. Treatment for Substance Use Disorders (continued)	Patient					TOTAL Number of Patients with Check Mark in Each Row	Recommendations and Clinical Resources
	#1	#2	#3	#4	#5		
If you have a patient with an alcohol use disorder N = number of patient charts reviewed with an alcohol use disorder						___/N	
1. Did the patient receive an evidence-based psychosocial intervention?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N	<ul style="list-style-type: none"> Brief intervention is recommended as the first step toward engaging the patient in a dialogue about potential alcohol use problems or disorder (16). Evidence-based psychosocial treatments include brief intervention, cognitive behavior coping skills training, motivational enhancement therapy, behavioral therapy, 12-step facilitation, interpersonal therapy, self-help manuals, behavioral self-control, case management, behavioral couples therapy, community reinforcement approach, and group therapy (11, 13, 16).
2. Was pharmacotherapy considered as a potential treatment option (e.g., naltrexone, acamprosate, disulfiram) OR Was the patient referred a psychiatrist or another physician specializing in addiction medicine?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N	<ul style="list-style-type: none"> Oral naltrexone, acamprosate, disulfiram, and extended-release injectable naltrexone are FDA-approved for the treatment of alcohol dependence (13, 16). Topiramate (oral medication for treatment of epilepsy and migraine) has shown to be effective in treating alcohol dependence, although it is not approved by the FDA for this indication (17). Extended-release injectable naltrexone is recommended when treatment adherence is a concern (11, 13). If medications are prescribed, they should be offered in combination with addiction-focused counseling (13, 16).
C. Treatment Approaches for Opioid Abuse or Dependence							
If you have a patient with an opioid use disorder N = number of patient charts reviewed with an opioid use disorder							
1. Was the patient provided, offered, or referred for pharmacotherapy for opioid dependence <u>in conjunction with</u> addiction-focused psychosocial treatment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/N	<ul style="list-style-type: none"> First-line treatment for opioid-dependent patients includes opioid agonist treatment [e.g., methadone, buprenorphine monotherapy for pregnant women, buprenorphine/naloxone, naltrexone, or extended release form of injectable naltrexone (recently FDA-approved for the treatment of opioid dependence)] under appropriate medical supervision <u>AND</u> concurrent addiction-focused psychosocial treatment (e.g., contingency management/ motivational incentive, cognitive behavior coping skill training) (13, 18).

PERFORMANCE IN PRACTICE (PIP) MODULES

1. PIP Module for the Screening of Adults with Substance Use Disorder (Appendix 1)

2. PIP Module for the Assessment and Treatment of Adults with Substance Use Disorder (Appendix 2)

Either of these PIP modules, *PIP Module for Screening of Adults with Substance Use Disorder (SUD)* and *PIP Module for Assessment and Treatment of Adults with SUD* can be used to fulfill a Maintenance of Certification (MOC) Part IV Performance in Practice (PIP) requirement. The modules are approved for MOC Part IV by the American Board of Psychiatry and Neurology (ABPN). ** The chart review data collected in Stages A and C, as well as the improvement plan, are included in this issue of Focus. The data is for your use. You do not submit the data to the ABPN. To earn credit, submit an evaluation (see page 41) to APA as you complete each of the three stages (A, B, C) of a module. You must complete Stages A, B, and C of a PIP module to qualify for a completed MOC Part IV activity. The PIP modules provide clinicians with an opportunity for practice assessment. The evidence-based quality indicators presented in these modules are core components in the screening and care of patients with substance use problems or disorders.

Instructions to Use a Module to Fulfill ABPN MOC Part IV Requirement and Earn CME credit.

STAGE A Chart Review

Through chart review, the physician uses the **Screening of Adults** or **Assessment and Treatment** forms provided to assess whether their current screening, or their current assessment and treatment is consistent with evidence-based recommendations.

Program Evaluation Stage A – complete the evaluation for Stage A and submit it to American Psychiatric Association (APA).

CME Credit for Stage A – 5 AMA PRA category 1 credits™

STAGE B Improvement Plan and Suggested Interventions

After comparing your recorded patient data to quality measures in Stage A you should initiate and document a plan for improvement. You may decide to access additional resources as part of your improvement plan. For example:

1. Use of specific recommendations and clinical resources outlined in Stage A of the module.
2. FOCUS Journal of Lifelong Learning in Psychiatry: Addiction: Current and Future Treatments. Winter 2011 9:1
3. APA Practice Guideline for the Treatment of Patients with Substance Use Disorders – Psychiatryonline.com.
4. CME Course - APA Practice Guideline for the Treatment of Patients with Substance Use Disorders – apaeducation.org
5. National Institute on Alcohol Abuse and Alcoholism (NIAAA): A Clinician's Guide (2005) at <http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/guide.pdf>

Improvement Plan Documentation

Record your improvement plan in the space below or on a separate sheet for your own use. Your improvement plan is not submitted to ABPN.

Program Evaluation Stage B – complete the evaluation for Stage B and submit it to APA.

CME Credit for Stage B – 5 AMA PRA category 1 credits™

STAGE C Repeat Chart Review

Within 24 months following your initial chart review and completion of an improvement plan, complete a second chart review using the same module. Reevaluate your performance by comparing results of Stage C with Stage A review. You may use the same or different patient charts. Document Improvement for your records.

Program Evaluation Stage C – complete the evaluation for Stage C and submit it to APA.

CME Credit for Stage C – 10 AMA PRA category 1 credits™ and Completion of Part IV MOC ABPN Clinical Module Requirements.

These performance in practice (PIP) modules were developed by identifying evidence-based assessment and treatment recommendations from the following sources: the American Psychiatric Association's (APA's) "Practice Guideline for the Treatment of Patients with Substance Use Disorders" (2006) (11); APA's "Guideline Watch: Practice Guideline for the Treatment of Patients with Substance Use Disorders" (2007) (12); the Veteran's Administration (VA)/Department of Defense (DoD) "Clinical Practice Guideline: Management of Substance Use Disorder (SUD)" (2009) (13); the VA/DoD "Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update" (2008) (14) and Varenicline criteria for prescribing (updated February 2010) (15); the National Institute on Alcohol Abuse and Alcoholism (NIAAA): A Clinician's Guide (2005) (16); the NIAAA Prescribing Medications for Alcohol Dependence (2008) (17); the National Institute for Health and Clinical Excellence, NICE Clinical Guideline: Drug Misuse—Opioid Detoxification (2007) (18); and APA's *Practice Guideline for Psychiatric Evaluation of Adults* (2006) (27). These evidence-based guidelines were developed through systematic medical literature reviews and critical evaluation of this scientific research by experts in the assessment and treatment of substance use disorders. The physician PIP Tool is based on the best available current medical research and evidence-based recommendations for the assessment and treatment of substance use disorders.

**Completion of these PIP modules does not fulfill MOC Part IV Patient and Peer feedback requirements.

EVALUATION SURVEY FOR USE WITH PERFORMANCE IN PRACTICE PHYSICIAN PRACTICE ASSESSMENT MODULES:**Check the Module and Stage you are Evaluating**

- ___ 1. Performance in Practice Module for the Screening of Adults with Substance Use Disorder. Stage A ___, B ___, or C ___.
- ___ 2. Performance in Practice Module for the Assessment and Treatment of Adults with Substance Use Disorder. Stage A ___, B ___, or C ___.
- CME credit Begin Date: February 2011 End Date: February 2013.

To earn AMA PRA category 1 credit™ for a Performance in Practice Module and to document participation in an ABPN approved MOC Part IV activity, physicians should use the assessment tools as indicated. Physicians who complete in sequence, the three stages (A-C) of a Performance In Practice module may be awarded a total of 20 credits. Participants should complete an evaluation survey for each of the three STAGES of a module. CME credit is earned for each of the three stages in sequence. Stage A = 5 credits, Stage B = 5 credits, Stage C = 10 credits. Stages are completed within a 24 month period.

Objective: After completion of this activity, physicians will have the foundation for performance improvement initiatives aimed at enhancing outcomes for patients with substance use disorders.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians. APA designates this educational activity (completion of Stages A-C) for a maximum of 20 AMA PRA category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

These Performance in Practice Modules: 1. **PIP Module for the Screening of Adults** and 2. **PIP Module for the Assessment and Treatment of Adults**, are approved by the American Board of Psychiatry and Neurology (ABPN) for MOC Part IV.

EVALUATION SURVEY FOR STAGES A AND C

		1	2	3	4	5	
1. Overall, I am satisfied with the usefulness of this PIP tool in assessing my practice patterns.	Strongly disagree	0	0	0	0	0	Strongly agree
2. The material was presented without bias.	Strongly disagree	0	0	0	0	0	Strongly agree
3. Completing this PIP tool has helped me to verify that I am providing appropriate care to my patients.	Strongly disagree	0	0	0	0	0	Strongly agree
4. By completing this PIP tool, I have identified at least one way in which I can improve my care of patients.	Strongly disagree	0	0	0	0	0	Strongly agree

EVALUATION SURVEY FOR STAGE B

		1	2	3	4	5	
1. Overall I am satisfied with the usefulness of STAGE B	Strongly disagree	0	0	0	0	0	Strongly agree
2. Based on STAGE A, I was able to identify and review quality measures assessing my practice patterns.	Strongly disagree	0	0	0	0	0	Strongly agree
3. Based on STAGE A, I accessed additional resources.	Strongly disagree	0	0	0	0	0	Strongly agree
4. Based on STAGE A, I developed an improvement plan that I will apply in practice	Strongly disagree	0	0	0	0	0	Strongly agree

American Psychiatric Association CME

1000 Wilson Blvd., Suite 1825 Arlington, VA 22209-3901

Telephone: (703) 907-8637, Fax: (703) 907-7849

To earn credit for each completed stage of a Performance in Practice Module, complete an evaluation and send this page to APA. Retain a copy of this form for your records.

Number of hours you spent on this activity _____
(understanding & using the tool; completing the survey up to 5 hrs)

Date _____

APA Member: Yes _____ No _____

Focus subscriber number _____

Last name First name Middle initial Degree

Mailing address

City State Zip code Country

Fax number: _____ E-mail address: _____

I would like to receive my certificate by:

Fax _____ E-mail _____

Performance in Practice: Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-Related Behaviors

Farifteh F. Duffy, Ph.D.
Eve K. Mościcki, Sc.D., M.P.H.
Laura J. Fochtman, M.D.
Douglas G. Jacobs, M.D.
Diana E. Clarke, M.Sc., Ph.D.
Robert Plovnick, M.D., M.S.
Robert Kunkle, M.A.

Abstract: The American Board of Medical Specialties (ABMS) and the American Board of Psychiatry and Neurology (ABPN) are implementing multifaceted *Maintenance of Certification* (MOC) requirements to enhance quality of patient care and assess and verify the competence of physicians over time (ABPN 2009). Beginning in 2013, for those applying for 2014 MOC examinations, the practice assessment component (Part 4 of MOC) will require physicians to compare their care for five or more patients with “published best practices, practice guidelines or peer-based standards of care and develop a plan to improve effectiveness and efficiency of care delivery in their clinical practice” (ABPN 2009). To this end, the evidence-based *Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors* that is presented here provides psychiatrists with the opportunity to gain experience with practice assessment, in preparation for the new ABMS and ABPN MOC requirements. Moreover, this tool can facilitate implementation of a systematic approach toward practice improvement for the assessment and treatment of patients with suicidal ideation and behavior.

Suicide-related morbidity and mortality among psychiatric patients are ongoing concerns in providing good patient care (1, 2). The vast majority of individuals who experience such morbidity or mortality will have an underlying psychiatric illness (1, 3–14). Population-based evidence has consistently demonstrated that fatal and nonfatal suicidal behaviors can be associated with mood disorders, psychotic disorders, substance use disorders, anxiety disorders, conduct disorder, and antisocial and borderline personality disorders (4, 5, 13–27). Psychiatric disorders represent potentially modifiable risk factors, and their identification and appropriate treatment are central components of efforts to reduce risk for suicide (3, 7, 28).

Suicide fatalities are the 11th leading cause of death in the United States, accounting for 1.4% of all deaths (29). In 2007, the most recent year for which final mortality data are available, the 34,598 suicide deaths in the United States represented a

rate of 11.3 deaths per 100,000 individuals (29). The 12-month prevalence of nonfatal suicidal self-

CME Disclosure

Farifteh F. Duffy, Ph.D., Eve K. Mościcki, Sc.D., M.P.H., and Diana E. Clarke, M.Sc., Ph.D., American Psychiatric Institute for Research and Education, Arlington, VA.

Laura J. Fochtman, M.D., Department of Psychiatry and Behavioral Science, Stony Brook University, Stony Brook, NY.

Douglas G. Jacobs, M.D., Screening for Mental Health, Inc., Wellesley Hills, MA.

Robert Plovnick, M.D., M.S. and Robert Kunkle, M.A., American Psychiatric Association, Arlington, VA.

All authors report no competing interests.

Address correspondence to Farifteh Duffy, Ph.D., American Psychiatric Institute for Research and Education, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209. E-mail: fduffy@psych.org.

Acknowledgment: This work was generously funded by a grant from the American Psychiatric Foundation.

injuries among U.S. adults ranges from 0.2% to 0.6% (4, 5, 14–15).

The national burden of injury associated with fatal and nonfatal suicidal behaviors is large and includes hospitalization, emergency department visits, reported events, unreported events that are not medically treated, and suicide mortality. The overall burden translates into nontrivial economic and societal costs, with 376,306 individuals treated in emergency departments and 163,489 hospitalized in 2008 (30), direct costs estimated to be approximately \$68 million (31), indirect costs estimated to be \$11.8 billion (28), and devastating emotional consequences for families and friends of decedents.

Suicidal behaviors exist along a continuum from fleeting thoughts about suicide at one end to ending one's life at the other end (28). The fundamental features that define suicidal thoughts and behaviors and that distinguish suicidal from nonsuicidal thoughts and behaviors are 1) the act must be self-inflicted, 2) the act must be intentional, and 3) the objective is death (28). A useful nomenclature proposed by O'Carroll and colleagues (2, 32) that reflects these fundamental features and defines a gradation in the continuum of suicide-related behaviors includes the following:

- *Suicide*: Self-inflicted death with explicit or implicit evidence that the person intended to die
- *Suicide attempt*: Self-injurious behavior with a nonfatal outcome accompanied by explicit or implicit evidence that the person intended to die
- *Aborted suicide attempt*: Potentially self-injurious behavior with explicit or implicit evidence that the person intended to die but stopped the attempt before physical damage occurred
- *Suicidal ideation*: Thought of serving as the agent of one's own death; seriousness may vary depending on the specificity of suicidal plans and the degree of suicidal intent
- *Suicidal intent*: Subjective expectation and desire for a self-destructive act to end in death
- *Lethality of suicidal behavior*: Objective danger to life associated with a suicide method or action. Note that lethality is distinct from, and may not always coincide with, an individual's expectation of what is medically dangerous.
- *Deliberate self-harm*: Willful self-inflicting of painful, destructive, or injurious acts without intent to die

More recent nomenclatures building on the works by O'Carroll and colleagues include the Institute of

Medicine proposed nomenclature in their review *Reducing Suicide: A National Imperative* (28), and the Columbia Classification Algorithm of Suicide Assessment (C-CASA) (33).

MAINTENANCE OF CERTIFICATION: PERFORMANCE IN PRACTICE (PIP) PHYSICIAN PRACTICE ASSESSMENT REQUIREMENTS

By 2014, the American Board of Medical Specialties (ABMS) and the American Board of Psychiatry and Neurology (ABPN) plan to implement multifaceted *Maintenance of Certification* (MOC) requirements to enhance quality of patient care and assess competence of physicians over time (34). The MOC process will include a practice assessment component, requiring physicians to compare their care for five or more patients "with published best practices, practice guidelines or peer-based standards of care." Based on the results of this practice assessment, physicians are then asked to develop a practice improvement plan to enhance effectiveness and efficiency in delivery of clinical care and reevaluate their practice within 24 months after the initial evaluation (34).

Suicide risk assessment is one of the core components of a comprehensive psychiatric evaluation (35). Given the potential for suicidal ideation and behavior across the spectrum of psychiatric disorders, timely identification and appropriate treatment of mental disorders, which are considered potentially modifiable risk factors, may reduce the probability of patients developing suicidal ideation and behaviors (3). Moreover, several evidence-based treatments are currently available to target suicide-related behaviors. The *Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors* presented in Appendix 1, has been developed in response to new ABMS and ABPN maintenance of certification requirements. This tool provides psychiatrists with an opportunity for practice improvement in a clinical area that poses a substantial burden of injury, morbidity, and mortality across multiple psychiatric diagnoses.

This PIP tool was developed by first identifying key evidence-based assessment and treatment recommendations from practice guidelines of the APA, Veterans Administration and Department of Defense (VA/DoD), and the National Institute for Health and Clinical Excellence (NICE). The APA sources included the *Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors* (2) (2003), *Practice Guideline for Psychiatric Evaluation of Adults* (35) (2006), *Practice Guide-*

line for the Treatment of Patients With Substance Use Disorders (36) (2006), *Guideline Watch: Practice Guideline for the Treatment of Patients with Substance Use Disorders* (37) (2007), *Practice Guideline for the Treatment of Patients with Major Depressive Disorder* (38) (2010), *Practice Guideline for the Treatment of Patients with Borderline Personality Disorder* (39) (2001), and the *Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder* (40) (2005). The VA/DoD sources included the *Clinical Practice Guideline: Management of Major Depressive Disorder* (41) (2009) and the *Clinical Practice Guideline: Management of Bipolar Disorder in Adults* (42) (2010). The NICE Clinical Guideline resources included *Depression: The Treatment and Management of Depression in Adults* (43) (2009) and *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care* (44) (2009).

These evidence-based practice guidelines were developed through systematic medical literature reviews and critical evaluation of scientific research by experts in the field of suicide as well as individuals with expertise in other areas of psychiatry, including depression, bipolar disorder, and schizophrenia. Thus, the PIP tool presented here is based on the best available evidence for comprehensive assessment and treatment of adults with suicidal ideation and behavior. Although several of the practice guidelines that have been referenced are more than 5 years old, core recommendations that have been highlighted in the PIP tool are still considered best practice.

The *Performance in Practice Physician Practice Assessment Tool for Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors* presented in Appendix 1 is designed to facilitate retrospective chart review of the core components of a comprehensive evaluation for risk of suicide and suicide-related behaviors, as a part of psychiatric evaluation for patients with any psychiatric diagnoses. Appendix 2 provides a general review of evidence-based treatment(s) specifically targeting suicide-related behaviors. Each of the appendices attempts to highlight aspects of care that are evidence-based and have significant public health implications where gaps in guideline adherence are common. The last column of each appendix provides guideline-supported recommendations, knowledge-base and resources to assist in practice improvement efforts. Quality improvement opportunities that arise from using this tool can generally be managed by individual psychiatrists and applied as a

part of their routine practice, rather than relying on other health care system resources.

The PIP tool has been designed to be relevant across clinical settings (e.g., inpatient and outpatient), is straightforward to complete, and is usable in a pen-and-paper format to aid adoption. In addition to its value as a self-assessment tool, this form could be also used for MOC retrospective peer-reviewed initiatives. Although the ABPN MOC program requires review of at least five patients as part of each PIP unit, larger samples will provide more accurate estimates of quality of care within a practice.

After using the PIP tool to assess the pattern of care provided to patients, the psychiatrist should determine whether specific aspects of care need to be improved. Through such practice assessment, the psychiatrist may determine that deviations from the quality indicators are clinically appropriate and justified, or he or she may choose to acquire new knowledge and modify his or her practice to improve quality. For example, if patients in the psychiatrist's current psychiatric caseload are not adequately assessed for suicide-related behaviors, then an area for improvement could involve implementation of systematic assessment for suicidal ideation and behaviors across all patients.

It is important to note, however, that although this tool is intended to highlight current evidence-based assessment and treatment recommendations for patients at risk for suicide-related behaviors, justifiable variations from recommended care are expected. Assessment and treatment recommendations provided in the practice guidelines are generally intended to be relevant to the majority of individuals (45, 46). However, practice guidelines and quality indicators are often derived from findings of efficacy and effectiveness trials where stringent enrollment criteria are used; thus individuals in clinical trials often differ in important ways from those seen in routine clinical practice (47). Moreover, patients vary widely in their clinical presentations, presence of comorbid physical and psychiatric conditions, response to treatment, and other factors, thus influencing clinical decision making.

CONCLUSION

The PIP tool presented in Appendix 1 provides clinicians with an opportunity for practice assessment in preparation for the new 2014 ABPN MOC program requirements. Because the evidence-based quality indicators presented here are considered core components in the care of patients

at risk for suicide-related behaviors, use of this tool can serve as a foundation for development and implementation of a systematic approach to practice improvement for the assessment of patients with suicidal ideation and behavior.

REFERENCES

- Mann JJ: Neurobiology of suicidal behaviour. *Nat Rev Neurosci* 2003; 4:819–828
- American Psychiatric Association: APA Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors. *Am J Psychiatry* 2003; 160(11 suppl):1–60. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_14.aspx
- Mościcki EK: Suicidal behaviors among adults, in *Oxford Handbook of Suicide and Self-Injury*. Edited by Nock MK, Ed. Oxford, UK, Oxford University Press, in press
- Kessler RC, Berglund P, Borges G, Nock M, Wang PS: Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. *JAMA* 2005; 293:2487–2495
- Joe S, Baser RE, Breeden G, Neighbors HW, Jackson JJ: Prevalence of and risk factors for lifetime suicide attempts among blacks in the United States. *JAMA* 2006; 296:2112–2123
- Lesage AD, Boyer R, Grunberg F, Vanier C, Morissette R, Ménard-Buteau C, Loyer M: Suicide and mental disorders: a case-control study of young men. *Am J Psychiatry* 1994; 151:1063–1068
- Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H: Suicide prevention strategies: a systematic review. *JAMA* 2005; 294:2064–2074
- Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED: Relationships of age and axis, I: diagnoses in victims of completed suicide: a psychological autopsy study. *Am J Psychiatry*. 1996; 153: 1001–1008
- Rich CL, Young D, Fowler RC: San Diego Suicide Study, I: young vs old subjects. *Arch Gen Psychiatry* 1986; 43:577–582
- Beautrais AL, Joyce PR, Mulder RT, Fergusson DM, Deavoll BJ, Nightingale SK: Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case-control study. *Am J Psychiatry* 1996; 153:1009–1014
- Mościcki EK, O'Carroll P, Regier DA, Rae DS, Roy A, Locke BZ: Suicide attempts in the Epidemiologic Catchment Area Study. *Yale J Biol Med* 1988; 61:259–268
- Mann JJ, Waternaux C, Haas GL, Malone KM: Toward a clinical model of suicidal behavior in psychiatric patients. *Am J Psychiatry* 1999; 156:181–189
- Miles CP: Conditions predisposing to suicide: a review. *J Nerv Ment Dis* 1977; 164:231–246
- Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee SS: Suicide and suicidal behavior. *Epidemiol Rev* 2008; 30:133–154
- Nock MK, Borges G, Bromet EK, Alonso J, Angermeyer M, Beautrais A, Bruffaerts R, Chiu WT, de Girolamo G, Gluzman S, de Graaf R, Gureje O, Haro JM, Huang Y, Karam E, Kessler RC, Lepine JP, Levinson D, Medina-Mora ME, Ono Y, Posada-Villa J, Williams D: Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. *Br J Psychiatry* 2008; 192:98–105
- Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED: Relationships of age and axis, I: diagnoses in victims of completed suicide: a psychological autopsy study. *Am J Psychiatry*. 1996; 153: 1001–1008.
- Rich CL, Young D, Fowler RC: San Diego Suicide Study, I: young vs old subjects. *Arch Gen Psychiatry* 1986; 43:577–582.
- Beautrais A: Suicides and serious suicide attempts: two populations or one? *Psychol Med* 2001; 31:837–845
- Kessler RC, Borges G, Walters EE: Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. *Arch Gen Psychiatry* 1999; 56:617–626
- Beautrais AL, Joyce PR, Mulder RT, Fergusson DM, Deavoll BJ, Nightingale SK: Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case-control study. *Am J Psychiatry* 1996;153:1009–1014.
- Petronis KR, Samuels JF, Mościcki EK, Anthony JC: An epidemiologic investigation of potential risk factors for suicide attempts. *Soc Psychiatry Psychiatr Epidemiol* 1990; 25:193–199
- Lesage AD, Boyer R, Grunberg F, Vanier C, Morissette R, Ménard-Buteau C, Loyer M: Suicide and mental disorders: a case-control study of young men. *Am J Psychiatry* 1994; 151:1063–1068.
- Gratus JL, Qin P, Lincoln AK, Miller M, Lawler E, Sørensen HT, Lash TL: Posttraumatic stress disorder and completed suicide. *Am J Epidemiol* 2010; 171:721–727
- Wilcox HC, Storr CL, Breslau N: Posttraumatic stress disorder and suicide attempts in a community sample of urban American young adults. *Arch Gen Psychiatry* 2009; 66:305–311
- Dumais A, Lesage AD, Alda M, Roleau G, Dumont M, Chawky N, Roy M, Mann JJ, Benkelfat C, Turecki G: Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. *Am J Psychiatry* 2005; 162:2116–2124
- Rich CL, Motooka MS, Fowler RC, Young D: Suicide by psychotics. *Biol Psychiatry* 1988; 23:595–601
- Robins E: Psychosis and suicide. *Biol Psychiatry* 1986; 21:665–672
- Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE: *Reducing Suicide: A National Imperative*. Washington, DC, National Academies Press, 2002
- Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B: Deaths: Final Data for 2007. *National Vital Statistics Reports Web Release*, vol 58, no 19. Hyattsville, MD, National Center for Health Statistics, 2010
- Centers for Disease Control and Prevention: Suicide Facts at a Glance, Summer 2010. http://www.cdc.gov/violenceprevention/pdf/Suicide_DataSheet-a.pdf
- Palmer CS, Revicki DA, Halpern MT, Hatzianandreu EJ: The cost of suicide and suicide attempts in the United States. *Clin Neuropharmacol* 1995; 18(suppl 3):S25–S33
- O'Carroll PW, Berman AL, Maris RW, Moscicki EK, Tanney BL, Silverman MM: Beyond the Tower of Babel: a nomenclature for suicidology. *Suicide Life Threat Behav* 1996; 26:237–252
- Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. *Am J Psychiatry* 2007; 164:1035–1043
- American Board of Psychiatry and Neurology: Maintenance of Certification, 2009. http://www.abpn.com/downloads/moc/moc_web_doc.pdf
- American Psychiatric Association: APA Practice Guideline for Psychiatric Evaluation of Adults, 2nd ed. *Am J Psychiatry* 2006; 163(6 suppl):3–36. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_1.aspx
- American Psychiatric Association: APA Practice Guideline for the Treatment of Patients with Substance Use Disorders, 2nd ed. *Am J Psychiatry* 2006;163(8 suppl):5–82. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_5.aspx
- Connery HS, Kleber HD: Guideline Watch: Practice Guideline for the Treatment of Patients with Substance Use Disorders, 2nd ed. *Focus* 2007; 5:163–166. <http://www.psychiatryonline.com/content.aspx?aid=149073>
- American Psychiatric Association: APA Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. *Am J Psychiatry* 2010; 167(10 suppl):1–118. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx
- American Psychiatric Association: APA Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. *Am J Psychiatry* 2001; 158:1–52
- Oldham JM: Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. *Focus* 2005; 3:396–400. <http://www.psychiatryonline.com/content.aspx?aid=149073>
- Management of Major Depressive Disorder Working Group: VA/DOD Clinical Practice Guideline: Management of Major Depressive Disorder. Washington, DC, Department of Veteran's Affairs, Department of Defense, 2008. http://www.healthquality.va.gov/Major_Depressive_Disorder_MDD_Clinical_Practice_Guideline.asp
- Management of Bipolar Disorder Guideline Update Working Group: VA/DOD Clinical Practice Guideline: Management of Bipolar Disorder in Adults. Washington, DC, Department of Veteran's Affairs, Department of Defense, 2010. http://www.healthquality.va.gov/Management_of_Bi.asp
- National Institute for Health and Clinical Excellence: Depression: The Treatment and Management of Depression in Adults, Update. *National Clinical Practice Guideline Number 90*. London, UK, 2009. <http://guidance.nice.org.uk/CG90>
- National Institute for Health and Clinical Excellence: Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care, Update. *National Clinical Practice Guideline Number 82*. London, UK, 2009. <http://guidance.nice.org.uk/CG82>
- Dickey B, Sederer LI (eds): *Improving Mental Health Care: Commitment to Quality*. Washington, DC, American Psychiatric Publishing, Inc., 2001
- Eddy DM: Practice policies: Where do they come from? *JAMA* 1990; 263:1265, 1269,1272

- ## NOTES

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Appendix 1: Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors (p. 1 of 4)

Instructions: Choose five adult patients as indicated in the table below. Review the charts for these adult patients to determine if care was consistent with the evidence-based recommendations described in each row (Yes/No). If Yes, check the appropriate box; if No or Unknown, leave the box unchecked.

Scoring: In the **TOTAL** column, tally the total number of checkmarks in each row. For any row for which the total is less than 5, examine whether clinical or other circumstances explain why practice in this area was not consistent with recommended care. Consider whether changes in your practice or use of any of the suggested clinical tools could strengthen the provision of evidence-based care.

I. Comprehensive Assessment for Suicide and Suicide-related Behaviors	Patient					TOTAL Number of Patients with Check Mark in Each Row	Supporting Knowledge-base Resources, and Clinical Issues for Consideration
	#1	#2	#3	#4	#5		

Definition of terms comprising suicidal ideation and behavior (2, 30)

- **Suicide:** Self-inflicted death with explicit or implicit evidence that the person intended to die
- **Suicide attempt:** Self-injurious behavior with a nonfatal outcome accompanied by explicit or implicit evidence that the person intended to die
- **Aborted suicide attempt:** Potentially self-injurious behavior with explicit or implicit evidence that the person intended to die but stopped the attempt before physical damage occurred
- **Suicidal ideation:** Thought of serving as the agent of one's own death; seriousness may vary depending on the specificity of suicidal plans and the degree of suicidal intent
- **Suicidal intent:** Subjective expectation and desire for a self-destructive act to end in death
- **Lethality of suicidal behavior:** Objective danger to life associated with a suicide methods or action. Note that lethality is distinct from and may not always coincide with an individual's expectation of what is medically dangerous.
- **Deliberate self-harm:** Willful self-inflicting of painful, destructive, or injurious acts without intent to die

Select five patients you treated in your current psychiatric caseload who present with one or more psychiatric symptoms, regardless of the psychiatric diagnoses.

Within the past year, either as part of the initial assessment or subsequent evaluations . . .

1. Has the patient received an assessment for risk of suicide and suicide-related behaviors at least once, as a part of the clinical evaluation?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> • The vast majority of individuals who experience suicide-related mortality or morbidity have an underlying psychiatric illness (3); thus psychiatric illness is a major risk factor for suicidal behaviors. To this end, patients across all psychiatric diagnostic groups should obtain a comprehensive assessment of suicide risk. Timely identification and appropriate treatment of mental disorders may reduce the possibility that patients will develop suicidal ideation and behaviors (3). • One of the potential goals of clinical management when treating patients with psychiatric disorders is to provide appropriate interventions and reduce the potential risk for suicidal behaviors (2). • The potential for suicidal behavior increases with an individual's burden of risk (3). However, even with careful assessment of suicide risk, the ability to predict suicidal behavior is poor, with potential for many false positives and false negatives (2, 38). • Available suicide risk assessment instruments that can provide clinicians with a memory aid to conduct assessment of suicide-related behaviors include: <ul style="list-style-type: none"> ➢ MacArthur Initiative on Depression and Primary Care: http://www.depression-primarycare.org/ (48) ➢ Assessment and treatment of suicidal patients (46)—recommended by the VA/DoD Practice Guideline for Depression (41). ➢ A Review of Suicide Assessment Measures for Intervention Research with Adults and Older Adults (50).
--	--------------------------	--------------------------	--------------------------	--------------------------	--------------------------	-------	---

Appendix 1. Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors (p. 2 of 4)

I. Comprehensive Assessment for Suicide and Suicide-related Behaviors						Patient	TOTAL Number of Patients with Check Mark in Each Row	Supporting Knowledge-base Resources, and Clinical Issues for Consideration				
						#1	#2	#3	#4	#5		
A comprehensive evaluation for risk of suicide and suicide-related behaviors should assess for the following components (2, 38)												
2. Was the patient assessed for current/ suicidal or self-harming thoughts, plans, and intent (regardless of patient's psychiatric diagnoses)?						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none">Assess for specific methods planned; expectation of method's lethality; any preparatory acts and access to methods and means (e.g., access to firearms by the patient).
3. Was the patient assessed for prior suicidal ideation and behaviors?						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Assess for <ul style="list-style-type: none">Previous serious suicidal ideation, including frequency and plans.Previous suicidal behaviors including suicide attempts or aborted attempts.Previous nonsuicidal self-injurious behaviors.
4. Were all current psychiatric illnesses identified?						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none">Assess for recent psychiatric diagnoses, specifically diagnosis of mood, psychosis, substance use disorder (SUD), anxiety disorders including PTSD, cluster B personality disorders—a dose-response relationship has been observed with regard to increased risk for suicidal ideation and/or attempts among persons with multiple psychiatric diagnoses (3).
5. Was the patient's prior psychiatric history assessed?						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none">Assess for previous psychiatric diagnoses and treatments, including illness onset, course, prior or recent psychiatric hospitalization, and treatment for SUD.
6. Was the patient assessed for current as well as previous psychiatric signs and symptoms?						<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Access for: <ul style="list-style-type: none">Sign and symptoms of current hopelessness, impulsivity, anhedonia, panic attacks, anxiety, psychomotor agitation, psychotic symptoms, presence of aggression and violence and long-standing tendency to lose temper or become aggressive with little provocation, global insomnia, decreased self-esteem, narcissistic vulnerability, psychic pain, nature of cognition to include loss of executive function, tunnel vision, polarized thinking, close-mindedness, poor coping and problem solving skills.Alcohol or other substance use associated with the current presentation of suicidal ideation or behaviors—approximately 25%–50% of adults who die by suicide are intoxicated at the time of death (3). The number of substances used appears to be more important than the type of substance used as contributors to risk for suicidal ideation and behavior (3).

Appendix 1. Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors (p. 3 of 4)

I. Comprehensive Assessment for Suicide and Suicide-related Behaviors	Patient					TOTAL Number of Patients with Check Mark in Each Row	Supporting Knowledge-base Resources, and Clinical Issues for Consideration
	#1	#2	#3	#4	#5		
7. Was the patient assessed for current as well as history of co-occurring medical conditions?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Assess for: <ul style="list-style-type: none"> Recent medical diagnoses, including a cardiovascular event, cancer, epilepsy, arthritis, headache and other chronic severe pain. Previous hospitalizations, surgeries, medical diagnoses and treatments.
8. Was the patient assessed for family history related to mental disorders and suicide-related behaviors?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Assess for: <ul style="list-style-type: none"> Family history of suicide and suicide attempts. Family history of mental illness, including substance use.
9. Was the patient assessed for the presence of acute as well as chronic psychosocial stressors?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Assess for acute and chronic psychosocial stressors including: <ul style="list-style-type: none"> Significant loss (e.g., loss of loved ones). Employment status. Living situation (e.g., living alone). Presence or absence of external support. Presence and quality of family relationships. History of physical or sexual abuse and other trauma.
10. Was the patient assessed for his or her strengths and vulnerabilities?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	Assess for individual strengths, resilience, and vulnerabilities including (2, 3, 51–53): <ul style="list-style-type: none"> Reasons for living and plans for the future, Coping skills, Personality traits, Past responses to stress, Self-esteem and self-efficacy, Capacity to utilize support from others, Capacity for reality testing, Ability to tolerate psychological pain and satisfy psychological needs, and Cultural and religious beliefs about death or suicide.
11. If patient was clinically judged to be at elevated risk for suicide and suicide-related behaviors, did he/she receive an ongoing assessment regarding changes in clinical status and risk for suicide?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	___/5	<ul style="list-style-type: none"> Physicians should address the modifiable risk factors (e.g., psychiatric disorder, symptom severity, difficulty sleeping, availability of social support, provision of psychosocial rehabilitative services, to address occupational or housing concerns) identified in the initial psychiatric evaluation and make ongoing assessment during the course of treatment (2). The frequency of patient monitoring should be determined based on the patient's symptom severity (specifically presence of suicidal ideation), co-occurring disorders, adherence to treatment, availability of social support, frequency and severity of side effects (38).

Appendix 1. Performance in Practice Physician Practice Assessment Tool for the Assessment and Treatment of Adults at Risk for Suicide and Suicide-related Behaviors (p. 4 of 4)

I. Comprehensive Assessment for Suicide and Suicide-related Behaviors	Patient					TOTAL Number of Patients with Check Mark in Each Row	Supporting Knowledge-base Resources, and Clinical Issues for Consideration
	#1	#2	#3	#4	#5		
							<ul style="list-style-type: none"> When pharmacotherapy is indicated for an individual with suicidal thoughts or behaviors, the choice of a medication should consider its lethality in overdose. Treatment effects may not be observed immediately and patients should be educated about possible delays in symptom relief. Close monitoring is particularly important during this early period of treatment as well as with changes in medications or dosages. The FDA has issued warnings for varenicline (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm169986.htm), anti-convulsants (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm) and, for those under age 25, antidepressants (http://www.fda.gov/drugs/drugsafetyinformationbydrugclass/ucm096273) suggesting that these agents may confer some increase in the possibility of suicidal ideas or behaviors. Accordingly, patients, patients' families and other caregivers should be trained to look for the emergence of agitation, irritability, unusual changes in behavior or suicidal ideation or behaviors and to report such symptoms immediately to health care providers.

Appendix 2. Treatment Options for Suicide-Related Behaviors

- Consider evidence-based somatic, psychotherapeutic, or combined interventions that have demonstrated efficacy in reducing the risk for suicide when treating patients at risk for suicide or suicide-related behaviors taking into account patients' prior medical and psychiatric history, co-occurring conditions, prior response to treatment, adverse effects of specific agents, and patient preferences.
- The least restrictive setting for treatment that will address patient's safety and facilitate improvement in patient's condition should be considered. However, for patients who pose serious threat of harm to self or others, hospitalization should be considered. Such high risk patients who refuse hospitalization can be admitted involuntarily if their condition meets the criteria of their local jurisdiction for involuntary admission (38).
- Factors to consider in determining the nature and intensity of treatment include (but are not limited to): the availability and adequacy of social support, access to and lethality of suicide means, the presence of co-occurring SUD, past personal and family history of suicidal behavior, and nature of doctor-patient alliance (38).

Supporting Knowledge-base and Clinical Issues for Consideration

1. For patients with bipolar disorder with reported suicidal-related behaviors, consider treatment with lithium.	<ul style="list-style-type: none"> • Long-term maintenance treatment with lithium has been shown to be associated with significant reduction in the risk of suicide-related behaviors among patients with bipolar disorder (2, 3, 42). When deciding between lithium and other first-line agents for treatment of patients with bipolar disorder, the efficacy of lithium in decreasing suicidal behavior should be taken into consideration, when weighing benefits and risks of treatments with each medication (2).
2. For patients with schizophrenia, schizoaffective disorders or patients with current psychotic symptoms with reported suicidal-related behaviors, consider treatment with clozapine.	<ul style="list-style-type: none"> • Clozapine treatment is associated with significant decreases in rates of suicide attempts for individuals with schizophrenia and schizoaffective disorder. However, benefits of clozapine need to be weighed against the risk of adverse effects, which has generally led clozapine to be reserved for use when psychotic symptoms have not responded to other antipsychotic medications (2, 3).
3. For patients with borderline personality disorder, consider providing dialectical behavior therapy.	<ul style="list-style-type: none"> • For patients with borderline personality disorder, Dialectical Behavior Therapy (DBT) has been shown to reduce the frequency of suicide attempts (3, 54).
4. For patients with severe episodes of major depression that are accompanied by suicidal thoughts or behaviors, or for patients suffering from depression and associated psychotic or catatonic features for whom a delay in treatment response is considered life threatening, consider providing ECT.	<ul style="list-style-type: none"> • ECT has established efficacy in patients with severe depressive illness, with and without psychotic features. ECT is associated with a rapid and robust antidepressant response as well as rapid diminution in associated suicidal thoughts (2). Continuation or maintenance treatment with pharmacotherapy or with ECT is recommended after an acute ECT course (2, 38, 41, 43). • If treatment with antidepressants is indicated, select an antidepressant with low risk lethality; SSRIs and other newer antidepressants pose lower risk regarding lethality (2). Antidepressant effects may not be observed for days or weeks after starting treatment; therefore, patients should be monitored closely early in treatment and educated about probable delay in symptom relief (2).
5. For patients who have attempted suicide, consider providing suicide-specific cognitive behavior therapy.	<ul style="list-style-type: none"> • Suicide-specific cognitive behavior therapy has been shown to reduce recurring suicide attempts (3, 55).
6. For patients with reported suicide-related behaviors, consider providing combined somatic and psychotherapeutic interventions.	<ul style="list-style-type: none"> • Patients with suicidal thoughts, plans, or behaviors could benefit most from a combination of somatic therapies and psychotherapeutic interventions (2, 38).

PERFORMANCE IN PRACTICE (PIP) CLINICAL MODULE

1. PIP Clinical Module for Comprehensive Assessment for Suicide and Suicide-Related Behaviors (Appendix 1)

The PIP module, *Comprehensive Assessment for Suicide and Suicide-Related Behaviors* can be used to fulfill a Maintenance of Certification (MOC) Part IV Performance in Practice (PIP) requirement. The module is approved for MOC Part IV by the American Board of Psychiatry and Neurology (ABPN). ** The chart review data collected in Stages A and C, as well as the improvement plan, are included in this issue of Focus. The data is for your use. You do not submit the data to the ABPN. To earn credit, submit an evaluation (see p. 182) to APA as you complete each of the three stages (A, B, C) of a module. You must complete Stages A, B, and C of a PIP module to qualify for a completed MOC Part IV activity. The PIP module provides clinicians with an opportunity for practice assessment. The evidence-based quality indicators presented in this module is core components in the screening and care of patients with substance use problems or disorders.

Instructions to Use a Module to Fulfill ABPN MOC Part IV Requirement and Earn CME credit.

STAGE A Chart Review

Through chart review, the physician uses the **Comprehensive Assessment** form provided to assess whether their current screening, or their current assessment and treatment is consistent with evidence-based recommendations.

Program Evaluation Stage A – complete the evaluation for Stage A and submit it to American Psychiatric Association (APA).

CME Credit for Stage A – 5 AMA PRA category 1 credits™

STAGE B Improvement Plan and Suggested Interventions

After comparing your recorded patient data to quality measures in Stage A you should initiate and document a plan for improvement. You may decide to access additional resources as part of your improvement plan. For example:

1. Use of specific recommendations and clinical resources outlined in Stage A of the module.
2. FOCUS Journal of Lifelong Learning in Psychiatry: Quality and Professionalism in Psychiatry, Jabbarpour Y, Jayaram G, Suicide Risk, Navigating the failure modes
3. APA Practice Guideline for the Treatment of Patients with Suicidal Behaviors – Psychiatryonline.com.
4. CME Course - APA Practice Guideline for the Treatment of Patients with Suicidal Behaviors – apaeducation.org

Improvement Plan Documentation

Record your improvement plan in the space below or on a separate sheet for your own use. Your improvement plan is not submitted to ABPN.

Program Evaluation Stage B – complete the evaluation for Stage B and submit it to APA.

CME Credit for Stage B – 5 AMA PRA category 1 credits™

STAGE C Repeat Chart Review

Within 24 months following your initial chart review and completion of an improvement plan, and within a reasonable time to enact and be able to see review improvements in your chart, complete a second chart review using the same module. Reevaluate your performance by comparing results of Stage C with Stage A review. You may use the same or different patient charts. Document Improvement for your records.

Program Evaluation Stage C – complete the evaluation for Stage C and submit it to APA.

CME Credit for Stage C – 10 AMA PRA category 1 credits™ and Completion of Part IV MOC ABPN Clinical Module Requirements.

The performance in practice (PIP) module was developed by identifying evidence-based assessment and treatment recommendations from the following sources: the American Psychiatric Association's (APA's) *Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors* (2003) (2); *Practice Guideline for the Psychiatric Evaluation of Adults* (2006) (353); *Practice Guideline for the Treatment of Patients With Substance Use Disorders* (2006) (36); *Guideline Watch: Practice Guideline for the Treatment of Patients with Substance Use Disorder* (2007) (37); *Practice Guideline for the Treatment of Patients with Major Depressive Disorder* (2010) (38); *Practice Guideline for the Treatment of Patients with Borderline Personality Disorder* (2001) (39); and the *Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder* (2005) (40). The VA/DoD sources included the *Clinical Practice Guideline for the Management of Major Depressive Disorder* (2009) (418) and the *Clinical Practice Guideline for the Management of Bipolar Disorder in Adults* (2010) (42). The NICE Clinical Guideline resources included *Depression: The treatment and management of depression in adults* (2009) (43); and *Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care* (2009) (41). The *Physician PIP Modules* presented here are based on the best available evidence-based recommendations to support comprehensive assessment and treatment of adults with suicidal ideation and behavior.

**Completion of this PIP module does not fulfill MOC Part IV Patient and Peer feedback requirements.

EVALUATION SURVEY FOR USE WITH PERFORMANCE IN PRACTICE PHYSICIAN PRACTICE ASSESSMENT MODULES:

Check the Module and Stage you are Evaluating

___ 1. Performance in Practice Module for the Comprehensive Assessment for Suicide and Suicide-Related Behaviors. Stage A ___, B ___, or C ___.

CME credit Begin Date: February 2011 End Date: February 2013.

To earn AMA PRA category 1 credit™ for a Performance in Practice Module and to document participation in an ABPN approved MOC Part IV activity, physicians should use the assessment tools as indicated. Physicians who complete in sequence, the three stages (A-C) of a Performance In Practice module may be awarded a total of 20 credits. Participants should complete an evaluation survey for each of the three STAGES of a module. CME credit is earned for each of the three stages in sequence. Stage A = 5 credits, Stage B = 5 credits, Stage C = 10 credits. Stages are completed within a 24 month period and within a reasonable time to make and assess improvements.

Objective: After completion of this activity, physicians will have the foundation for performance improvement initiatives aimed at enhancing outcomes for patients through evaluating and treating suicide risk and suicide-related behaviors.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians. APA designates this educational activity (completion of Stages A-C) for a maximum of 20 AMA PRA category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This Performance in Practice Module: 1. **PIP Module for Comprehensive Assessment** is approved by the American Board of Psychiatry and Neurology (ABPN) for MOC Part IV, Clinical Module.

EVALUATION SURVEY FOR STAGES A AND C

		1	2	3	4	5	
1. Overall, I am satisfied with the usefulness of this PIP tool in assessing my practice patterns.	Strongly disagree	0	0	0	0	0	Strongly agree
2. The material was presented without bias.	Strongly disagree	0	0	0	0	0	Strongly agree
3. Completing this PIP tool has helped me to verify that I am providing appropriate care to my patients.	Strongly disagree	0	0	0	0	0	Strongly agree
4. By completing this PIP tool, I have identified at least one way in which I can improve my care of patients.	Strongly disagree	0	0	0	0	0	Strongly agree

EVALUATION SURVEY FOR STAGE B

		1	2	3	4	5	
1. Overall I am satisfied with the usefulness of STAGE B	Strongly disagree	0	0	0	0	0	Strongly agree
2. Based on STAGE A, I was able to identify and review quality measures assessing my practice patterns in STAGE B.	Strongly disagree	0	0	0	0	0	Strongly agree
3. Based on STAGE A, I accessed additional resources.	Strongly disagree	0	0	0	0	0	Strongly agree
4. Based on STAGE A, I developed an improvement plan that I will apply in practice	Strongly disagree	0	0	0	0	0	Strongly agree

American Psychiatric Association CME

1000 Wilson Blvd., Suite 1825 Arlington, VA 22209-3901

Telephone: (703) 907-8637, Fax: (703) 907-7849

To earn credit for each completed stage of a Performance in Practice Module, complete an evaluation and send this page to APA. Retain a copy of this form for your records.

Date _____

APA Member: Yes _____ No _____

Focus subscriber number _____

Last name First name Middle initial Degree

Mailing address

City State Zip code Country

Fax number: _____ E-mail address: _____

I would like to receive my certificate by:

Fax _____ E-mail _____

Appendix 6

A Comprehensive Approach to Disseminate Evidence Based Care for PTSD

Running Title: PTSD/Depression Care Dissemination Project

Meeting: PTSD Expert Panel Meeting
Date: Monday, November 3, 2008
Time: 9 AM to 5PM
Location: American Psychiatric Institute for Research & Education; 1000 Wilson Blvd, Arlington, VA; 20th Floor, Room 2030
Participants: David Benedek, MD; Henry Chung, MD; Thomas Craig, MD; Matthew Friedman, MD, PhD; Charles Hoge, MD; David Katzelnick, MD; Harold Kudler, MD; Cameron Ritchie, MD, MPH; Robert Ursano, MD; Joshua Wilk, PhD
Staff: Lisa Countis; Farifteh Duffy, PhD; Eve Mościcki, ScD, MPH; William Narrow, MD, MPH; Darrel Regier, MD, MPH; Donald Rae, MS; Elizabeth Stickman, MSW, MPH; Joyce West, PhD, MPP

TIME		ACTIVITY	PRESENTER/ DISCUSSION LEADER
8:00-9:00		Breakfast	
		Welcome and Introductions	
9:00-9:15	1	APIRE's current PTSD activities and APA's DSM-V Development	Darrel Regier
9:15-9:35	2	Overview of project aims, timeline, and meeting agenda ✓ What are the key components of PTSD care? ✓ What approaches are working in DoD/VA practices? ✓ Where are opportunities for improvement? ✓ How do we measure improvement?	Farifteh Duffy
		Disease Management & Dissemination Models	
9:35-10:00	3	Application of Chronic Care Model for PTSD	David Katzelnick
10:00-10:20	4	Institute for HealthCare Improvement Breakthrough Series Model	Henry Chung
10:20-10:30		Break	
		Current Status of the Field	
10:30- 11:00	5	DSM-V: PTSD diagnosis and VA assessment and treatment	Matthew Friedman
11:00- 11:30	6	DoD: PTSD/Comorbid TBI assessment and treatment	Charles Hoge
11:30- 11:45		OPEN DISCUSSION	
11:45- 12:15	7	PTSD Screening Instruments ✓ What are the strengths and limitations of current instruments? ✓ What top 2 instruments can be recommended for use with military men and women? ✓ What other desirable features do the best instruments offer?	Eve Mościcki Open discussion
		Guidelines	
12:15-1:15 Working Lunch	8	Key assessment and treatment recommendations for PTSD derived from DoD/VA, APA, and NICE Clinical guidelines and IOM report and updates on PTSD care from Guideline Watch ✓ What are key aspects of PTSD care that can be potential targets for intervention?	Farifteh Duffy Open discussion
1:15-1:45	9	Presenting evidence-based assessment and treatment recommendations in	Thomas Craig

Appendix 8

A Comprehensive Approach to Disseminate Evidence Based Care for PTSD

Running Title: PTSD/Depression Care Dissemination Project

		a user-friendly package	
1:45-2:00		Break	
		Treatment of PTSD	
2:00-2:30	10	DoD: Promising models for acute care of PTSD w or w/o comorbidity	Robert Ursano
2:30-3:00	11	VA: Promising models for chronic care of PTSD w or w/o comorbidity	Harold Kudler
		Developing the Curriculum Framework	
3:00-4:00	12	Revisiting Meeting Aims <ul style="list-style-type: none"> ✓ What are the key components of PTSD care? ✓ What approaches are working in DoD/VA practices? ✓ Where are opportunities for improvement? ✓ How do we measure improvement? 	Farifteh Duffy Open discussion
4:00-4:30	13	Plans to recruit clinicians to participate in the PTSD/DP project <ul style="list-style-type: none"> ✓ Where should the pilot study be implemented, MTFs or VA treatment facilities? ✓ Who should be recruited—primary care providers, psychiatrists, other clinicians/gatekeepers? ✓ What “key staff” are important to include on the practice teams? ✓ What are the best approaches for recruiting? 	Joyce West Open discussion
4:30-5:00	14	Preliminary plans for workshops – Next Steps	Farifteh Duffy
5:00	15	Adjourn	

Appendix 9
Comprehensive Approach to Disseminate Evidence-Based Care for PTSD (PTSD/DP)
Post-Traumatic Stress Disorder Assessment Tools

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
1. Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD) <i>Prins, Kimerling, Cameron, Oumiette, Shaw, Thrailkill, Sheikh & Gusman, 1999</i>	Length: 4 items Mode: Self-report Time: 2-3 minutes Scoring: if any 2 items endorsed, or single hyper-arousal item endorsed, refer for further evaluation	Reliability <i>Test-retest reliability</i> $r = 0.84$ <i>Internal consistency</i> = 0.79 Validity <i>Optimal sensitivity and specificity</i> = 0.87	<ul style="list-style-type: none"> • Screening • Included on Post-Deployment Health Assessment (DD Form 2796) 	Online	Currently used in military populations. Recommended in DoD/VA Guidelines.
2. Post Traumatic Stress Disorder Brief Screen <i>Leskin & Westrup, 1999</i>	Length: 4 items Mode: Self-report Time: 2-3 minutes Scoring: If two or more items endorsed, refer for additional assessment	Overall efficiency = 0.78 Correlations lower for other mental disorders Adequate construct validity	<ul style="list-style-type: none"> • Screening 	Online	Recommended in DoD/VA Guidelines
3. Short Screening Scale for DSM-IV PTSD <i>N Breslau, EL Peterson, RC Kessler, & LR Schultz, 1999</i>	Length: 7 items Mode: Self-report Time: 5 minutes Scoring: summation of positive responses (0 to 7) Cutoff score: 4	Reliability <i>Test-retest reliability</i> = 0.84 <i>Likelihood Ratio:</i> 0.04 to 13.40 Validity <i>Sensitivity:</i> 80% <i>Specificity:</i> 97%	<ul style="list-style-type: none"> • Screening 	Online	Recommended in DoD/VA Guidelines
4. Combat Exposure Scale (CES) <i>T Keane, J Fairbank, J Caddell, R Zimering, K Taylor, & C Mora, 1989</i>	Length: 7 items Mode: Self-report Time: 5 minutes Scoring: 0 to 41 calculated by using a sum of weighted scores	Reliability <i>Test-retest reliability</i> = 0.97 <i>K</i> = 0.85 <ul style="list-style-type: none"> • Norms include military populations 	<ul style="list-style-type: none"> • Screening • Psychiatric settings. Primarily used for war-zone related stress experiences. • Male population used for psychometric evaluation. 	Online	
5. Short Post-Traumatic Stress Disorder Rating Interview (SPRINT) <i>Connor & Davidson, 2001</i>	Length: 8-item Mode: Self-report Time: 5-10 minutes Scoring: Symptoms are rated on 5 point scales from 0 (not at all) to 4 (very much). <i>Cut-off score:</i> 14 Populations with higher prevalence: 11- 13	Reliability <i>Test-retest reliability</i> = 0.778 <i>Cronbach's α</i> 0.77 at baseline and 0.88 at endpoint Validity <i>Sensitivity:</i> 0.95 <i>Specificity:</i> 0.96 <i>Convergence:</i> DTS $r = 0.73$ Responsive to symptom change over time 14-17 score: 96% accuracy with victims of trauma	<ul style="list-style-type: none"> • Screening, monitoring • Assesses the core symptoms of PTSD (intrusion, avoidance, numbing, and arousal), somatic malaise, stress vulnerability, and role and social functional impairment. 	Online	

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
6. Trauma Screening Questionnaire (TSQ) <i>CR Brewin, S Rose, B Andrews, J Green, P Tata, C McEvedy, S Turner, & EB Foa, 2002</i>	Length: 10 items Mode: Self-report Time: 5 minutes Scoring: 5 re-experiencing items; 5 arousal items Cutoff score: 6	Validity <i>Sensitivity:</i> 0.86 <i>Specificity:</i> 0.93 <ul style="list-style-type: none"> • Positive Predictive Power: 0.91 • Negative Predictive Power: 0.92 • Overall Efficiency: 0.92 • Norms include military populations 	<ul style="list-style-type: none"> • Screening: 4 weeks or more post-trauma • Based on PTSD Symptom Scale – Self Report (PSS-SR; Foa et al., 1993) • Does not assess level of fear, helplessness, or horror experienced, or information about criterion C avoidance symptoms. • Originally administered to 42 train crash survivors. 	Included in article and by request Brewin, CR 2005. <i>J of Traumatic Stress</i> , 18:53-62. Translation: Chinese, Dutch Japanese, French	Currently used in military populations
7. Trauma Questionnaire (TQ) <i>LM McIntyre, MI Butterfield, K Nanda, K Parsey, KM Stechuchak, AW McChesney, C Koons, & LA Bastian, 1999</i>	Length: 10 items Mode: Self-report Time: apprx 5 minutes	Validity <i>Construct validity:</i> good to excellent Specificity and sensitivity is good, except for questions dealing with desire for mental health referral. <ul style="list-style-type: none"> • Norms include military populations (Statistical research ongoing)	<ul style="list-style-type: none"> • Screening for women’s history of childhood and adult sexual trauma, sexual harassment and domestic violence. • Developed for use in veteran population; includes assessment of whether trauma occurred in the military • Subjects have requested mental health referral more frequently in clinical interviews than with the questionnaire. 	Online	Currently used in military populations

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
8. Impact of Event Scale (IES) <i>MJ Horowitz, N Wilner, & W Alvarez, 1979</i>	Length: 15 items Mode: Self-report Time: 5-10 minutes Scoring: Grade Level 6.0 Subscale scores for Intrusion, Avoidance, and Hyperarousal; Total score range 0 to 75	Reliability <ul style="list-style-type: none"> Intrusion subscale: Cronbach's α 0.79 to 0.92 Avoidance subscale: Cronbach's α 0.73 to 0.91 Test-retest total score 1 week interval: $r = 0.93$ Subscale correlations (pre-therapy, 4 mos after, and 12 mos after): 0.57 to 0.78 Validity Correlation: SCID <ul style="list-style-type: none"> Intrusion subscale: 0.56 Avoidance subscale: 0.29 Total score: 0.53 MSS <ul style="list-style-type: none"> Intrusion subscale: 0.56 Avoidance subscale: 0.29 Total score: 0.53 MMPI-PTSD <ul style="list-style-type: none"> Intrusion subscale: 0.33 Avoidance subscale: 0.21 Total score: 0.33 Norms include military populations IES has demonstrated sensitivity to change with psychosocial and pharmacological treatment for PTSD.	<ul style="list-style-type: none"> Screening Brief, reliable assessment of intrusion and avoidance symptoms. Caution must be used to population that may be prone to malingering due to the high face validity of the items. 	Online Copyright and permission for nonprofit research and clinical use granted by Horowitz without need for a permission request. Available on Handbook of Psychiatric Measures CD-ROM and Zilberg et al 1982 article.	
9. PTSD Checklist (PCL) <i>FW Weathers, JA Huska, TM Keane</i>	Length: 17 items Mode: Self-report Time: 5-10 minutes Scoring: 1-5 Scale Cutoff score: 50 Gender and/or time since a traumatic event may influence reporting style, resulting in different optimal cutoff	Reliability <i>Cronbach's α: 0.94 to 0.97</i> <i>Test-retest reliability: 0.96 at 2-3 days and 0.88 at 1 week</i> Validity Attention should be given to cutoff scores according to population prevalence <u>Cutoff score: 50</u> <i>Sensitivity: 0.78 to 0.82</i> <i>Specificity: 0.83 to 0.86</i> <u>Cutoff score of 44</u> <i>Sensitivity: 0.94</i> <i>Specificity: 0.86</i> • Norms include military populations	<ul style="list-style-type: none"> Screening, monitoring Lack of studies using diverse and/or mixed samples 	Online Translation: Spanish	Recommended in DoD/VA Guidelines

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
10. PTSD Checklist-Military Version (PCL-M) <i>FW Weathers, JA Huska, TM Keane</i>	Length: 17 items Mode: Self-report Time: 5-10 minutes Scoring: 1-5 Scale Cutoff score: 50 Re-experiencing and avoidance symptoms apply to military-related stressful experiences only	<i>See #9</i> Reliability <ul style="list-style-type: none"> Internal consistency coefficients: 0.97 Test-retest reliability: 0.96 (over 2-3 days) Validity Correlations <ul style="list-style-type: none"> M-PTSD: 0.93 MMPI-PK: 0.77 IES: 0.90 <i>Sensitivity:</i> 0.82 <i>Specificity:</i> 0.83 <i>K:</i> 0.64 Norms include military populations	<ul style="list-style-type: none"> Screening, monitoring 	Online	Recommended in DoD/VA Guidelines
11. PTSD Checklist – Civilian Version (PCL-C) <i>FW Weathers, JA Huska, TM Keane</i>	Length: 17 items Mode: Self-report Time: 5-10 minutes Scoring: 1-5 Scale Cutoff score: 44 Cutoffs should be used with caution as they were developed from samples with high prevalence rates of current PTSD and may not be appropriate for samples with lower rates	<i>See #9</i> <ul style="list-style-type: none"> Norms include military populations 	<ul style="list-style-type: none"> Screening, monitoring 	Online	Recommended in DoD/VA Guidelines
12. PTSD Checklist-Stressor Specific Version (PCL-S) <i>FW Weathers, JA Huska, TM Keane</i>	Length: 17 items Mode: Self-report Time: 5-10 minutes Scoring: 1-5 Scale Re-experiencing and avoidance symptoms apply to a stressful experience specified by the experimenters	<i>See #9</i> Reliability <i>Cronbach's α:</i> 0.94 Validity Correlations <ul style="list-style-type: none"> CAPS: 0.93 Sensitivity: 0.94–0.97 Specificity: 0.86 Overall efficiency: 0.90–0.94 <ul style="list-style-type: none"> Norms include military populations 	Screening, monitoring	Online	Recommended in DoD/VA Guidelines

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
13. Davidson Trauma Scale (DTS) <i>JR Davidson, 1997</i>	<p>Length: 17 items Mode: Self-report Time: 10 minutes Scoring: Dichotomous, 3-point scale, and 5-point scale from 0 to 4.</p> <p>Frequency score (0 to 68), severity score (0 to 68), and total score (0 to 136)</p> <p>Response formats vary making scale longer to complete than other 17 items scales</p>	<p>Reliability Test-retest coefficient: 0.86 (P<0.0001) repeat of the DTS one to two weeks later</p> <ul style="list-style-type: none"> • 0.93 at one to two weeks • 0.73 at six months <p>Internal Consistency:</p> <ul style="list-style-type: none"> • Overall: Cronbach's α 0.99 • Frequency scale: Cronbach's α 0.97 • Severity scale: Cronbach's α 0.98 <p>Validity Construct/ Convergent/ Discriminate: Correlations</p> <ul style="list-style-type: none"> • CAPS: 0.78 (P<0.0001) • IES: 0.64 (P<0.0001) • SCL-90-R PTSD: 0.89 initial, 0.85 repeat • AUDIT: 0.29 initial, 0.31 repeat • Ratio measure of thyroid function: total T3/free T4 (0.27 initial, 0.20 repeat) and startle response (0.18 initial, 0.26 repeat). <p>Criterion-related/ Concurrent/ Predictive: Concurrent validity with Structured Clinical Interview for DSM-III-R (SCID) scores Cut-score 40</p> <ul style="list-style-type: none"> • Efficiency= 0.83 • Sensitivity = 0.69 • Specificity = 0.95 • Positive predictive value = 0.92 • Negative predictive value = 0.79 <ul style="list-style-type: none"> • Predictive validity /Regression analysis (DTS scores = predictor; CGI scores = outcome): (p<0.005)and R2 0.10 • Total score was a significant predictor of reaction to treatment as assessed by the CGI, although the model accounted for a small proportion of the variance in scores. • Norms include military populations 	<ul style="list-style-type: none"> • Screening, monitoring of treatment effect, assessment of symptom severity • Assesses DSM-IV PTSD criteria (B–D) • Generalizability of the scale's use among children and adolescents is unknown. 	<p>Contact Mental Health Systems, Inc. The cost per administration/ copy is apprx. \$1.00, via a copyright license agreement</p> <p>Available in several language translations.</p>	

Scale & Reference	Administration	Psychometric Properties	Clinical Use	Availability	Comments
14. IES-R <i>DS Weiss & CR Marmar, 1996</i>	<p>Length: 22 items Mode: Self-report Time: 5-10 minutes Scoring: 5 point Scale</p> <p>Revised instrument includes arousal symptoms</p> <p>Total score: 0 to 88</p> <p>Subscales: Intrusion, Avoidance, and Hyperarousal</p> <p>Recommend using <i>means</i> instead of raw sums with subscales scores for comparison with SCL-90-R scores</p>	<p>Reliability</p> <ul style="list-style-type: none"> • Intrusion α: 0.87 to 0.92 • Avoidance α: 0.84 to 0.86 • Hyperarousal α: 0.79 to 0.90 <p><i>Test-Retest Correlation</i> of subscales (shorter, longer recency of event):</p> <ul style="list-style-type: none"> • Intrusion = 0.57, 0.94 • Avoidance subscale = 0.51, 0.89 • Hyperarousal subscale = 0.59, 0.92 <p>Validity <i>Criterion (or Predictive) Validity</i></p> <ul style="list-style-type: none"> • Hyperarousal subscale: good predictive validity with regard to trauma. • Intrusion and avoidance subscales: detect change in respondent's clinical status over time and detect relevant differences in the response to traumatic events of varying severity <p><i>Content Validity</i></p> <ul style="list-style-type: none"> • Intrusion and avoidance subscales: 85% <p><i>Construct Validity:</i></p> <ul style="list-style-type: none"> • Two sleep items highly correlated • Ex. item-to-subscale correlation ("I had trouble falling asleep") • hyperarousal subscale: 71% • intrusion subscale: 79% <ul style="list-style-type: none"> • Norms include military populations 	<ul style="list-style-type: none"> • Screening • DSM-IV PTSD criteria (B–D) 	Online	

Appendix 8: PTSD Care Dissemination Project - Planning Meeting Agenda February 4, 2011

Time	Section #	Activity
8:00-8:30AM		Breakfast
8:30-8:50 AM	1	Introduction, Welcome, Project Overview (Darrel Regier, Farrah Duffy)
8:50-9:20 AM	2	➤ Benefits of systematic approach for routine monitoring – theory, research, success stories (NDMLI, National College Depression Partnership Experiences, RESPECT-MIL) (Henry Chung, Charles Engel, David Katzelnick)
9:20- 9:40AM	3	➤ Review of Chronic Care Model for chronic disease management (Henry Chung)
9:40-10:15AM	4	➤ Clinical Workflow at: 1) Behavioral Health Clinic, Malcolm Grow Medical Center, Andrews Air Force Base 2) Psychiatry clinic, Walter Reed Army Medical Center <ul style="list-style-type: none"> • Current clinical workflow to support management of PTSD, depression, and alcohol problems - Site presentations (10-15 minutes each) • Q&A
10:15-10:30AM		➤ Break
10:30-11:30AM	5	➤ Clinical Workflow Analysis and AHLTA enhancement- Military success stories (Charles Motsinger, Tim Corcoran) (15 minutes) ➤ Clinical Workflow Analysis to facilitate AHLTA enhancement at Behavioral Health Clinic at Malcolm Grow Medical Center, and Psychiatry Clinic at Walter Reed Army Medical Center – What is required? (Charles Motsinger; Tim Corcoran) <ul style="list-style-type: none"> • Chart review • Site visits • High risk file/registry
11:30-12:00PM	6	➤ Review of PCL-C, PHQ-9, AUDIT and AUDIT-C as core assessment tools (Charles Engel, Henry Chung, Joyce West)
12:00-12:20 PM	7	➤ Review IHI - PDSA approach to implementing quality improvement (David Katzelnick, Henry Chung)
12:20-12:45PM		➤ Lunch
12:45-1:05PM	8	➤ Assessment tools for suicidality (Eve Mościcki, Diana Clarke)
1:05 -1:30PM	9	➤ Overview of assessment tools to assess functional impairment: WHO-DAS II, Sheehan Disability Scale (William Narrow, Farrah Duffy)
1:30-3:00PM	10	<i>Participatory group activity</i> ➤ Define patient population for tracking ➤ High risk file/registry ➤ Review and discuss proposed change concepts, measures, and goals ➤ Select feasible change concepts, measures, and goals ➤ Q&A
3:00-3:15PM		➤ Break
3:15-3:35PM	11	➤ Review performance in practice clinical tools for PTSD, Depression and SUD, a quality improvement exercise (Eve Mościcki, Farrah Duffy, Joyce West)
3:35-4:15PM	12	<i>Site-specific group activity</i> ➤ Site-specific implementation planning discussion (30 min) ➤ Q & A
4:15-5:00PM	13	➤ Way Forward – concrete steps: timeline, responsibilities, follow-up, etc. (Charles Motsinger, Farrah Duffy) ➤ Adjourn